{
    "url": "https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690d10k.htm",
    "report_type": "10-K",
    "context": [
        {
            "id": 0,
            "context": "Item\u20091.\nBusiness\nOverview We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We utilize concerted diligence efforts in search of therapies that will improve the lives of those who suffer from rare or difficult to treat diseases. With an unwavering patient focus embedded in everything we do, we are committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.",
            "type": "paragraph"
        },
        {
            "id": 1,
            "context": "Our flagship U.S. commercial product is FIRDAPSE\u00ae (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome, or LEMS, for adults and for children ages six and up. Further, on January 24, 2023, we closed our acquisition of FYCOMPA\u00ae and are now also marketing that product in the United States. FYCOMPA\u00ae (perampanel) CIII is a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Finally, on July 18, 2023, we closed our acquisition of an exclusive license for North America for vamorolone, a novel corticosteroid treatment for patients suffering from Duchenne Muscular Dystrophy (DMD). On October 26, 2023, the FDA approved AGAMREE\u00ae (vamorolone) oral suspension 40 mg/ml for the treatment of DMD. We are currently planning the commercial launch of AGAMREE\u00ae in the United States during the first quarter of 2024.",
            "type": "paragraph"
        },
        {
            "id": 2,
            "context": "FIRDAPSE\u00ae On November 28, 2018, we received approval from the FDA for our new drug application, or NDA, for FIRDAPSE\u00ae Tablets 10 mg for the treatment of adult patients (ages 17 and above) with LEMS, and in January 2019, we launched FIRDAPSE\u00ae in the United States. Further, on September 29, 2022, the FDA approved our supplemental NDA (sNDA) to expand the indicated age range for FIRDAPSE\u00ae Tablets 10 mg to include pediatric patients, six years of age and older for the treatment of LEMS.",
            "type": "paragraph"
        },
        {
            "id": 3,
            "context": "We sell FIRDAPSE\u00ae through a field force experienced in neurologic, central nervous system or rare disease products consisting at this time of approximately 35 field personnel, including sales (Regional Account Managers), thought leader liaisons, patient assistance and insurance navigation support (Patient Access Liaisons), and payor reimbursement (National Account Managers). We also have a field-based force of 10 medical science liaisons who are helping educate the medical community about scientific literature concerning LEMS and FIRDAPSE\u00ae.",
            "type": "paragraph"
        },
        {
            "id": 4,
            "context": "Additionally, for the last few years we have contracted with an experienced inside sales agency that works to generate leads through telemarketing to targeted physicians. This inside sales agency allowed our sales efforts to not only reach the neuromuscular specialists who regularly treat LEMS patients, but also the roughly 9,000 neurology and neuromuscular healthcare providers that may be treating a LEMS patient who can benefit from FIRDAPSE\u00ae. However, effective January 1, 2024 we have terminated that arrangement. We also use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient with small cell lung cancer. Further, we continue to make available at no-cost a LEMS voltage gated calcium channel antibody diagnostic testing program for use by physicians who suspect that one of their patients may have LEMS and wish to reach a definitive diagnosis.",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "Finally, we are continuing to expand our digital and social media activities to introduce our products and services to potential patients and their healthcare providers. We also work with several rare disease advocacy organizations (including the Myasthenia Gravis Foundation of America and the National Organization for Rare Disorders) to help increase awareness and level of support for patients living with LEMS and to provide education for the physicians who treat these rare diseases and the patients they treat.",
            "type": "paragraph"
        },
        {
            "id": 6,
            "context": "3\nIndex to Financial Statements We are supporting the distribution of FIRDAPSE\u00ae through Catalyst Pathways\u00ae, our personalized treatment support program for patients who enroll in it. Catalyst Pathways\u00ae is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen required to reach an effective therapeutic dose. It also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most drug products for ultra-orphan diseases are distributed and dispensed to patients. We believe that by using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general. In order to help patients with LEMS afford their medication, we, like other pharmaceutical companies which are marketing drugs for ultra-orphan conditions, have developed an array of financial assistance programs that are available to reduce patient co-pays and deductibles to a nominal affordable amount. A co-pay assistance program designed to keep out-of-pocket costs to not more than $10 per month (currently less than $2 per month) is available for all LEMS patients with commercial coverage who are prescribed FIRDAPSE\u00ae. Our FIRDAPSE\u00ae co-pay assistance program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE. Separately, we are donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to any U.S. LEMS patients in financial need. Subject to compliance with regulatory requirements, our goal is that no LEMS patient is ever denied access to their medication for financial reasons. In January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE\u00ae in the United States. The notice letters each alleged that the six patents listed in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) in connection with FIRDAPSE\u00ae are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the Federal Food, Drug and Cosmetic Act (FDCA), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions, thus triggering the stay. Further, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer, and we filed a similar lawsuit against this manufacturer in November 2023 in the U.S. District Court for the District of New Jersey. We intend to vigorously protect and defend our intellectual property for FIRDAPSE\u00ae and, although there can be no assurance, we believe that our patent estate will protect FIRDAPSE\u00ae from generic competition. On August 4, 2023, we submitted an sNDA to increase the indicated maximum daily dosage of FIRDAPSE\u00ae tablets from 80 mg to 100 mg for the treatment of LEMS. On October 13, 2023, we announced that the FDA had accepted for review our sNDA and assigned a Prescription Drug User Fee Act (PDUFA) action date of June 4, 2024. There can be no assurance that the FDA will approve our sNDA. We are advised by our sub-licensee for FIRDAPSE\u00ae in Japan, DyDo Pharma, Inc. (DyDo), that on December 18, 2023, based on a preliminary favorable interim data analysis after six months into the safety phase of its registration study to evaluate the efficacy and safety of FIRDAPSE\u00ae for the treatment of LEMS, they filed a Japan NDA with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to commercialize the product in Japan. The review period is expected to be approximately nine months from the submission date, and there can be no assurance that the NDA filing made by DyDo will be approved. Further, upon acceptance of the Japan NDA by the PMDA, which occurred on December 18, 2023, our license for FIRDAPSE\u00ae automatically expanded to include other key markets in Asia and Latin America, and we are currently initiating plans to seek opportunities to expand FIRDAPSE\u00ae\u2019s global footprint through strategic partnerships (with the current focus on the Asia Pacific and Latin American regions). FYCOMPA\u00ae On December 17, 2022, we entered into an agreement with Eisai for the acquisition of the U.S. rights to FYCOMPA\u00ae (perampanel) CIII. FYCOMPA\u00ae is a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. It was the first, and still the only, drug of its class to be approved for epilepsy. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. FYCOMPA\u00ae is a controlled substance and is approved with a box warning label. 4",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "Index to Financial Statements FYCOMPA\u00ae is used to treat certain types of focal onset seizures (seizures that involve only one part of the brain) in adults and children four years of age and older. It is also used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures (also known as a \u201cgrand mal\u201d seizure, a seizure that involves the entire body) in adults and children 12 years of age or older. Perampanel is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain. On January 24, 2023, we closed our acquisition of the U.S. rights to FYCOMPA\u00ae. In connection with the acquisition, we purchased Eisai\u2019s regulatory approvals and documentation, product records, intellectual property, inventory, and other matters relating to the U.S. rights for FYCOMPA\u00ae, in exchange for an upfront payment of $160 million in cash. We also agreed to pay Eisai an additional cash payment of $25 million if a requested patent extension for FYCOMPA\u00ae until June 8, 2026 was approved by the U.S. Patent and Trademark Office (USPTO), which did not occur. Finally, we agreed to pay Eisai royalty payments after patent protection for FYCOMPA\u00ae expires, which royalty payments will be reduced upon generic equivalents to FYCOMPA\u00ae entering the market. In conjunction with the closing of the asset purchase, we entered into two additional agreements with Eisai; a Transition Services Agreement (TSA) and a Supply Agreement. Under the TSA, a U.S. subsidiary of Eisai provided us with certain transitional services, and under the Supply Agreement, Eisai agreed to manufacture FYCOMPA\u00ae for us for at least seven years at prices listed in the Supply Agreement (to be updated on a yearly basis). The transition services provided under the TSA ended on December 31, 2023. Initially, following the closing of the acquisition, we began to market FYCOMPA\u00ae in the U.S. through Eisai under the TSA as we built our FYCOMPA\u00ae marketing and sales team, and in May 2023, we took over the marketing program for FYCOMPA\u00ae. In that regard, we have hired approximately 35 sales and marketing personnel to support FYCOMPA\u00ae, most of whom previously worked in Eisai\u2019s U.S. sales division marketing FYCOMPA\u00ae. We have also hired seven medical science liaisons to help us educate the medical community who treat epilepsy about scientific literature regarding epilepsy and FYCOMPA\u00ae. We are supporting patients using FYCOMPA\u00ae through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $10 for their FYCOMPA\u00ae co-pay (with a maximum savings of $1,300 per year). The FYCOMPA\u00ae Instant Savings Card Program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Department of Veterans Affairs (VA), Department of Defense (DoD), or TRICARE. Patent protection for FYCOMPA\u00ae is primarily from two patents listed in the Orange Book. The first, U.S. patent no. 6,949,571 (the \u2018571 patent) will expire May 23, 2025, including patent term extension. Although the Company had requested that the USPTO reconsider this expiration date in favor of a June 8, 2026 expiration date, the request for reconsideration of the agency\u2019s patent term extension calculation was denied and the Company has exhausted its reasonable avenues for an extension of that patent term. The Company will update the Orange Book to reflect the May 23, 2025 expiration date at the appropriate time. The second FYCOMPA\u00ae patent in the Orange Book is U.S. Patent No. 8,772,497 (the \u2018497 patent), which expires on July 1, 2026. The \u2018497 patent has been the subject of previous Paragraph IV certifications from three NDA filers. On February 20, 2023, we received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA\u00ae. The same company sent a similar letter to us later in February with a similar certification for the tablet formulation for FYCOMPA\u00ae, the fourth such certification for this formulation. Both of these letters were Paragraph IV Certifications of non-infringement, non-validity, and unenforceability of the \u2018497 patent for FYCOMPA\u00ae but each application, like the previous Paragraph IV notices from ANDA filers, does not challenge the \u2018571 patent. Accordingly, the FDA may not approve any ANDA prior to expiration of the \u2018571 patent, including patent term extension. Similar to the actions with the FIRDAPSE\u00ae Paragraph IV Certifications described above, after due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions for both FYCOMPA\u00ae formulations, thus triggering the 30 month stay for each application. AGAMREE\u00ae On June 19, 2023, we entered into a License and Collaboration Agreement (AGAMREE\u00ae License Agreement) and an Investment Agreement (Investment Agreement) with Santhera Pharmaceuticals Holding, Inc. (Santhera). Under the AGAMREE\u00ae License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera\u2019s investigational product candidate, AGAMREE\u00ae (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera. Both transactions closed on July 18, 2023. Under the AGAMREE\u00ae License Agreement, upon closing, we made a $75 million payment to Santhera in return for the exclusive North American license for AGAMREE\u00ae. Additionally, following approval of the NDA for the drug, on October 26, 2023, we became obligated to make a milestone payment of $36 million to Santhera, $26 million of which Santhera has advised us was used to make milestone payments that they owe to third parties. The $36 million payment was made during the fourth quarter of 2023. We may also be obligated to pay future regulatory and commercial milestone payments to Santhera tied to calendar year sales of AGAMREE\u00ae, as well as commercial royalties. In addition to the rights to commercialize the product in North America, the AGAMREE\u00ae License Agreement provides us with the right of first negotiation for AGAMREE\u00ae in Europe and Japan should Santhera pursue partnership opportunities in those territories. Additionally, we will hold the North American rights to any future approved indications for AGAMREE\u00ae. 5",
            "type": "paragraph"
        },
        {
            "id": 8,
            "context": "Index to Financial Statements Concurrent with the closing of the AGAMREE\u00ae License Agreement, we made a strategic investment into Santhera in which we acquired 1,414,688 of Santhera\u2019s post-reverse split ordinary shares (representing approximately 11.26% of Santhera\u2019s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume weighted average price prior to signing), with the approximately $15.7 million USD in equity investment proceeds, inclusive of the approximately $13.5 million USD fair value of the investment in Santhera and approximately $2.2 million USD of transaction costs included in acquired in-process research and development, to be used by Santhera for Phase IV studies of AGAMREE\u00ae in DMD and future development of additional indications for AGAMREE\u00ae. At February 26, 2024, the closing price of Santhera\u2019s common shares on the SIX Swiss Exchange was CHF 11.36 per share. DMD, the most common form of muscular dystrophy, is a rare and life-threatening neuromuscular disorder characterized by progressive muscle dysfunction, ultimately leading to loss of ambulation, respiratory failure, and fatality. Current standard treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 patients in the U.S. are affected by DMD, with approximately 70% of patients currently receiving a corticosteroid treatment. Steroids are expected to remain the backbone of therapy for DMD patients and dosed concomitantly with other therapies. AGAMREE\u00ae\u2019s unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid with dissociative properties in maintaining efficacy that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In the pivotal VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting, and vitamin D deficiency. Adverse events were generally of mild to moderate severity. On October 13, 2023, Santhera announced that the European Union\u2019s Committee for Medicinal Products for Human Use (CHMP) adopted a positive position in favor of AGAMREE\u00ae for the treatment of DMD patients aged four and older. In its recommendation for approval, CHMP acknowledged that there was a positive benefit-risk profile of AGAMREE\u00ae in such patient population, including certain safety benefits of AGAMREE\u00ae compared to standard of care corticosteroids in the treatment of DMD. On October 26, 2023, the U.S. FDA approved Santhera\u2019s NDA for AGAMREE\u00ae for use in treating DMD in patients aged two years and older. As part of the previously described transaction, Santhera has transferred the approved New Drug Application to us. Further, on December 18, 2023, the European Commission (EC) granted to Santhera marketing authorization for AGAMREE\u00ae for the treatment of DMD in patents ages four years and older and on January 12, 2024, Santhera announced that AGAMREE\u00ae had received approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. On January 15, 2024, Santhera announced that AGAMREE\u00ae was commercially launched in Germany. We currently expect to launch AGAMREE\u00ae in the U.S. during the first quarter of 2024. We are incurring substantial commercialization expenses, including sales, marketing, analytical infrastructure, patient services, patient advocacy, and other commercialization related expenses, in preparation for the launch of the product in the U.S. We incurred a portion of such commercialization expenses during the fourth quarter of 2023 and we are incurring additional expenses during the first quarter of 2024. We anticipate minimal sales and marketing personnel expansion to market AGAMREE\u00ae, with approximately 10 additional commercial team members required, due to the synergy of this product within our existing neuromuscular franchise. We will support the distribution of AGAMREE\u00ae through our Catalyst Pathways\u00ae patient services program to ensure that patients have access to a dedicated, personalized support team that assists families through the AGAMREE\u00ae patient journey, from answering questions to coordinating financial assistance programs for eligible patients. We have established a joint steering committee with Santhera that will oversee the lifecycle management and development of AGAMREE\u00ae for additional indications beyond DMD. Under our AGAMREE\u00ae License Agreement with Santhera, we have agreed to purchase commercial supply of AGAMREE\u00ae from Santhera at agreed upon rates. To support the approval of AGAMREE\u00ae, a randomized, double-blind, placebo and prednisone-controlled multinational trial of vamorolone was carried out in 121 patients with DMD. The study included patients ages four to less than seven years of age at time of enrollment in the study who were corticosteroid na\u00efve and ambulatory. The trial met the primary (time to stand velocity after 24 weeks for vamorolone, 6 mg/kg per day vs placebo) and several sequential secondary motor function endpoints. Study participants receiving vamorolone, 2 mg/kg per day, and vamorolone, 6 mg/kg per day, showed improvements in multiple functional endpoints over the 24-week treatment period as compared to placebo. The statistical thresholds for the primary outcome and several secondary outcomes for vamorolone treatment were met, and vamorolone demonstrated efficacy across both dose ranges. The differences in time to stand from supine velocity (TTSTAND) were clinically meaningful. The differences in 6-minute walk test (6MWT) were also clinically meaningful. 6",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "Index to Financial Statements\n\n| \u2022 | Continue to commercialize FIRDAPSE\u00ae for the treatment of LEMS and improve disease awareness. We are currently commercializing FIRDAPSE\u00ae in the United States and through a sublicense to KYE Pharmaceuticals in Canada. We are working to expand awareness of the disease, including to physicians treating LEMS patients who have small-cell lung cancer, and helping health care providers and their patients understand the benefits of FIRDAPSE\u00ae. A cornerstone of our U.S. strategy is our continuing development of Catalyst Pathways\u00ae, our personalized treatment support program, and our development of the patient assistance programs that are required to further our goal that no LEMS patient be denied access to FIRDAPSE\u00ae for financial reasons within existing legal restrictions. |\n| \u2022 | Continue to commercialize FYCOMPA\u00ae. In the first quarter of 2023, we acquired the U.S. rights to the epilepsy drug FYCOMPA\u00ae. We are currently successfully distributing and marketing FYCOMPA\u00ae. We believe that having a second marketed product adds substantially to our business franchise. |\n| \u2022 | Successfully launch AGAMREE\u00ae in the United States. In the third quarter of 2023, we acquired an exclusive license from Santhera Pharmaceuticals. Under the AGAMREE\u00ae License Agreement, we obtained an exclusive North America license for AGAMREE\u00ae for the treatment of DMD and as a treatment for other diseases. We also made a strategic investment into Santhera, the funds of which will be used to further the development of the product. We believe that this transaction not only added a third product to our portfolio, but also leverages the sales infrastructure that we have developed to market FIRDAPSE\u00ae. We currently plan to launch this product before the end of the first quarter of 2024. |",
            "type": "table"
        },
        {
            "id": 10,
            "context": "Index to Financial Statements\nIndex to Financial Statements\nIndex to Financial Statements\n\n| \u2022 | $30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022 and $10 million was paid on the first anniversary of the closing of the settlement. We will be obligated to pay the remaining balance on the second anniversary of closing; |\n| \u2022 | An annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst\u2019s FIRDAPSE\u00ae patents in the United States, 2.5% (with a minimum annual royalty of $5 million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and |\n| \u2022 | If Catalyst were to receive a priority review voucher for FIRDAPSE\u00ae or RUZURGI\u00ae in the future, 50% of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. |",
            "type": "table"
        },
        {
            "id": 11,
            "context": "Index to Financial Statements Compassionate Use Programs We continue to make FIRDAPSE\u00ae available to a limited number of patients diagnosed with Congenital Myasthenic Syndromes, or Downbeat Nystagmus (DN) through investigator-sponsored compassionate use programs. Further, when we acquired the U.S. rights to RUZURGI\u00ae, we agreed to continue to supply RUZURGI\u00ae to these patients with neuromuscular conditions other than LEMS who are without access to an approved drug and were being treated with RUZURGI\u00ae under investigator-sponsored INDs at the time of our settlement with Jacobus. We will continue to supply this RUZURGI\u00ae research drug to these IND holders for as long as this research amifampridine drug product is available. We currently estimate that current stocks of this research drug will last for approximately 12 to 18 months. The active ingredient used to make this product is no longer available. As a result, we do not anticipate being able to continue to supply this drug once we have exhausted the existing research drug supplies. Sales, Marketing and Distribution Launch of FIRDAPSE\u00ae in January 2019 In January 2019, we launched FIRDAPSE\u00ae in the United States through a field force of approximately 20 personnel who are experienced in neurologic, central nervous system or rare diseases in sales, patient support and payer reimbursement. The sales representatives (Regional Account Managers) who were part of the field force targeted approximately 1,250 physicians who are either neuromuscular specialists or general neurologists with a known adult LEMS patient or specific training in neuromuscular diseases. We also utilized field force Patient Access Liaisons who work with the patients and provider offices to help navigate the insurance landscape, as well as National Account Managers who work directly with the payors to ensure comprehensive coverage for FIRDAPSE\u00ae across the commercial and governmental plans in the United States. We also at that time had a field-based force of seven medical science liaisons who help educate the medical communities about LEMS and about our company\u2019s ongoing clinical trial activities. Further, we work closely with several rare disease advocacy organizations (including the National Organization for Rare Disorders (NORD) and the Myasthenia Gravis Foundation of America) to help increase awareness and the level of support for patients living with LEMS and other neuromuscular diseases, and to provide education for the physicians who treat these rare diseases and the patients they treat. In early 2020, we expanded our field sales group by almost one hundred percent and established a partnership with an experienced inside sales agency generating leads through telemarketing to targeted physicians. Through this expansion of our sales team, we were working to expand our sales efforts beyond the neuromuscular specialists who regularly treat LEMS patients to reach roughly 9,000 neurology and neuromuscular healthcare providers that might be treating an adult LEMS patient who can benefit from FIRDAPSE\u00ae. However, we terminated the inside sales agency effective January 1, 2024. We also use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might treat a LEMS patient with small cell lung cancer. Finally, we make available a no-cost LEMS voltage gated calcium channel (VGCC) antibody testing program for physicians who suspect their patient may have LEMS and wish to reach a definitive diagnosis. We are supporting the distribution of FIRDAPSE\u00ae through \u201cCatalyst Pathways\u00ae\u201d, our personalized treatment support program. \u201cCatalyst Pathways\u00ae\u201d is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen to an effective therapeutic dose. It also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most pharmaceutical products for ultra-orphan diseases are distributed and dispensed to patients. By using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general. In addition, \u201cCatalyst Pathways\u00ae\u201d is the gateway for our free bridge medication for patients while they are waiting for a coverage determination or, later on, for patients whose access is threatened by the bureaucratic complications arising from a change of insurer. The \u201cCatalyst Pathways\u00ae\u201d program is also the access point for our Patient Assistance Program, which provides longer-term free medication for those who are uninsured or functionally uninsured with respect to FIRDAPSE\u00ae because they may be unable to obtain coverage from their payor despite having health insurance. We are continuing efforts on the challenging process to identify patients and their physicians who have been diagnosed with LEMS, but have not had access, awareness or understanding of this treatment for their rare disease. These patients often do not see their physician frequently, have many questions about changing treatment(s), and may not perceive the need to change to a new therapy. Further, we have begun to focus our commercial efforts to locate misdiagnosed and undiagnosed LEMS patients and provide educational and sales activities to help improve the diagnosis, understanding of the treatment, and information on the prescribing process. We plan to continue to support LEMS and rare disease patient organizational groups\u2019 efforts to generate awareness and educate patients and physicians on the diagnosis of LEMS, the impact of the disease, and the support services and treatments available. Access to FIRDAPSE\u00ae In order to help patients afford their medication, we, like other pharmaceutical companies who are marketing drugs for ultra-orphan conditions, have developed an array of financial assistance programs that are available to reduce patient co-pays and deductibles to a nominal affordable amount. For eligible patients with commercial coverage who are prescribed FIRDAPSE\u00ae for LEMS, a co-pay assistance program is available, which is designed to keep out-of-pocket costs to $10 or less per month (currently less than $2 per month). Our FIRDAPSE\u00ae co-pay assistance program is not available to patients enrolling in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or Tricare. Secondly, we are donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to LEMS patients in financial need. Our goal is to ensure that no LEMS patient is ever denied access to their medication for financial reasons. 11",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "Index to Financial Statements To date, FIRDAPSE\u00ae has been widely covered and reimbursed by private and public payors for the indicated small population of adult LEMS patients. sNDA to increase the maximum daily dose for FIRDAPSE\u00ae On August 4, 2023, we submitted an sNDA to increase the indicated maximum daily dosage of FIRDAPSE\u00ae tablets from 80 mg to 100 mg for the treatment of LEMS. On October 13, 2023, we announced that the FDA had accepted for review our sNDA and assigned a Prescription Drug User Fee Act (PDUFA) action date of June 4, 2024. There can be no assurance that the FDA will approve our sNDA. Canadian Market Our New Drug Submission filing for FIRDAPSE\u00ae for the symptomatic treatment of LEMS was approved when Health Canada issued a Notice of Compliance, or NOC, on July 31, 2020. In August 2020, we entered into a license agreement with KYE Pharmaceuticals, or KYE, pursuant to which we licensed to KYE the Canadian rights for FIRDAPSE\u00ae for the treatment of LEMS. On August 10, 2020, Health Canada issued a NOC to Medunik (Jacobus\u2019 licensee in Canada for RUZURGI\u00ae) for the treatment of LEMS. Shortly thereafter, we initiated a legal proceeding in Canada seeking judicial review of Health Canada\u2019s decision to issue the NOC for RUZURGI\u00ae as incorrect and unreasonable under Canadian law. Data protection, per Health Canada regulations, is supposed to prevent Health Canada from issuing an NOC to a drug that directly or indirectly references an innovative drug\u2019s data, for eight years from the date of the innovative drug\u2019s approval. The RUZURGI\u00ae Product Monograph clearly references pivotal nonclinical carcinogenicity and reproductive toxicity data for amifampridine phosphate developed by us. As such, we believe that our data was relied upon to establish the nonclinical safety profile of RUZURGI\u00ae needed to meet the standards of the Canadian Food and Drugs Act. On June 3, 2021, we announced a positive decision in this proceeding that quashed the NOC previously issued for RUZURGI\u00ae and remanded the matter to the Minister of Health to redetermine its decision to grant marketing authorization to RUZURGI\u00ae despite FIRDAPSE\u00ae\u2019s data protection rights. However, on June 28, 2021, we announced that Health Canada had re-issued an NOC for RUZURGI\u00ae, once again allowing the product to be marketed in Canada for patients with LEMS. As a result, in July 2021 we, along with our partner in Canada, KYE, filed a second suit against Health Canada to overturn this decision. On March 11, 2022, we announced that we had received a favorable decision from the Canadian court setting aside, for the second time, the decision of Health Canada approving RUZURGI\u00ae for the treatment of LEMS patients. In its ruling, the court determined that the Minister of Health\u2019s approach to evaluating whether FIRDAPSE\u00ae\u2019s data deserved protection based on FIRDAPSE\u00ae\u2019s status as an innovative drug, which protects by regulation the use of such data as part of a submission seeking an NOC for eight years from approval of the innovative drug, was legally flawed and not supported by the evidence. The Minister of Health appealed that decision, and, in January 2023, the Canadian Appellate Court overturned the trial court\u2019s decision. Thereafter, the Minister of Health reissued an NOC for RUZURGI\u00ae in Canada and, as a result, RUZURGI\u00ae is once again approved for sale in Canada. While there can be no assurance, we do not expect that the reissuance of the NOC for RUZURGI\u00ae in Canada will have a material adverse effect on our results of operations. Japanese Market In May 2019, we entered into an amendment to our license agreement for FIRDAPSE\u00ae. Under the amendment, we expanded our commercial territory for FIRDAPSE\u00ae, which originally was comprised of North America, to include Japan. We have also reached an agreement with Japanese regulatory authorities as to the scope of the clinical trial that will be required to be completed before an application can be submitted to Japanese regulatory authorities to commercialize FIRDAPSE\u00ae for the treatment of LEMS in Japan. Finally, we have been granted orphan drug designation in Japan for FIRDAPSE\u00ae for the symptomatic treatment of LEMS. On June 28, 2021, we entered into a sub-license agreement with DyDo Pharma, Inc., or DyDo, pursuant to which we sub-licensed to DyDo the Japanese rights for FIRDAPSE\u00ae for the treatment of LEMS. Under the terms of the agreement, DyDo has the exclusive rights to commercialize the product in Japan. DyDo is responsible for funding all clinical, regulatory, marketing and commercialization activities in Japan. We are responsible for clinical and commercial supply, as well as providing support to DyDo in its efforts to obtain regulatory approval for the product from the Japanese regulatory authorities. Subject to the satisfaction of terms and conditions as set forth in the agreement, we have earned an upfront payment and are eligible to receive further development and sales milestones for FIRDAPSE\u00ae, as well as revenue on sales to DyDo of product that we supply to them. 12",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "Index to Financial Statements In December 2021, we announced that DyDo had initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of FIRDAPSE\u00ae for the treatment of LEMS. On December 18, 2023, DyDo submitted a Japan NDA for FIRDAPSE\u00ae to the PMDA. There can be no assurance that the application will be approved. Future Markets for FIRDAPSE\u00ae Under the amendment to our FIRDAPSE\u00ae license agreement that added Japan to our territory, upon the acceptance of DyDo\u2019s NDA by the PMDA (Japanese regulatory agency), which occurred on December 18, 2023, our territory in which we have the right to seek to commercialize FIRDAPSE\u00ae has automatically expanded to include several countries in Asia and Latin America, and we have begun taking steps seeking to expand our FIRDAPSE\u00ae activities into some of these other countries. Intellectual property and regulatory exclusivity protections for FIRDAPSE\u00ae The bulk of our patent rights related to FIRDAPSE\u00ae are derived from our license agreement with BioMarin, which was transferred to SERB in 2020. In August 2020, the United States Patent and Trademark Office (USPTO) allowed Patent No. 10,793,893 (the \u2019893 patent) to our licensor and thereby to us, and the patent issued on October 6, 2020. The patent is directed to the use of suitable doses of amifampridine to treat patients, regardless of the therapeutic indication, that are slow metabolizers of amifampridine. Any drug product containing amifampridine with a label that states the patented dosing regimens and doses in the Dosing and Administration section prior to April 7, 2034, the expiration date of the patent, could possibly infringe this patent. Generic drug product labels would necessarily have to do this, and we intend to take all appropriate actions to protect our intellectual property. In April 2021, the USPTO also allowed Patent No. 11,060,128 (the \u2019128 patent) to our licensor and thereby to us, and this second patent issued on July 13, 2021. The patent is directed to the use of suitable doses of amifampridine to treat patients suffering with LEMS that are slow metabolizers of amifampridine. Any drug product containing amifampridine with a label for the treatment of LEMS, that states the patented dosing regimens and doses in the Dosing and Administration section of a product label, including generic drug product labels, could possibly infringe this patent prior to this patent\u2019s expiration date. On December 24, 2021, January 3, 2022 and January 7, 2022, the USPTO allowed various continuing applications that matured into U.S. Patent Nos. 11,268,128, 11,274,332 and 11,274,331, respectively. These patents were timely listed in the Orange Book and cover, among other things, methods of treating LEMS in subjects who are fast metabolizers of amifampridine. As part of our transaction with Jacobus Pharmaceuticals, Catalyst also acquired two patents. One of these patents, 10,626,088 issued by the USPTO on April 21, 2020, was suitable for listing in the Orange Book and has now been listed in further support of FIRDAPSE\u00ae. The other patent, 9,783,497 issued by the USPTO on October 10, 2017, is not considered listable in the Orange Book, but, to the extent that it is necessary, Catalyst intends to enforce that patent against infringement as it would any of the Orange Book patents. On December 19, 2023 and January 6, 2024, the USPTO issued Patent Nos. 11,845,977 and 11,873,525, respectively. These new patents cover methods of treating LEMS with FIRDAPSE\u00ae under fasting and fed conditions of dosing. We are also pursuing additional patent applications for FIRDAPSE\u00ae in an effort to further protect our drug product. There can be no assurance that any additional patents will be issued that provide additional intellectual property protection for our drug product. There can be no assurance that we do not or will not infringe on patents held by third parties or that third parties in the future will not claim that we have infringed on their patents. In the event that our products or technologies infringe or violate the patent or other proprietary rights of third parties, we may be prevented from pursuing product development, manufacturing or commercialization of our products that utilize such technologies. For example, there may be patents or patent applications held by others that contain claims that our products or operations might be determined to infringe or that may be broader than we believe them to be. Given the complexities and uncertainties of patent laws, there can be no assurance as to the impact that future patent claims against us may have on our business, financial condition, results of operations, or prospects. Until FIRDAPSE\u00ae was approved in November 2018, no drug product containing amifampridine for any indication had been approved by the FDA such that we received five-year \u201cnew chemical entity\u201d exclusivity from the FDA. New chemical entity exclusivity provides a five-year period of marketing exclusivity for all indications and in the absence of an Orange Book listed patent, precludes a generic from submitting an ANDA until that five-year period has expired. Further, when FIRDAPSE\u00ae was approved for the treatment of LEMS patients, we received seven-year orphan drug exclusivity (ODE) for our product for the treatment of LEMS, precluding a generic filer from receiving final FDA approval until the ODE exclusivity period has expired. Because we have Orange Book listed patents for FIRDAPSE\u00ae, potential generic filers were permitted to submit ANDA filings to the FDA starting on the \u201cNCE-1\u201d date (November 28, 2022). 13",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "Index to Financial Statements In January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers advising us that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE\u00ae in the United States. The notice letters each allege that our six patents listed in the FDA Orange Book in connection with FIRDAPSE\u00ae are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDAs until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first, and in that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions. Further, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer, and we filed a similar lawsuit against this manufacturer in November 2023 in the U.S. District Court for the District of New Jersey. We intend to vigorously protect and defend our intellectual property for FIRDAPSE\u00ae and, although there can be no assurance, we believe that our patents will protect FIRDAPSE\u00ae from generic competition. We have also in-licensed the FIRDAPSE\u00ae trademark from our licensor, SERB S.A., and the trademark was registered in the United States in March 2015. Protection of our intellectual property and regulatory exclusivities is a strategic priority for our business. Our ability to protect and use our intellectual property rights and regulatory exclusivity in the future development and commercialization of our products, operate without infringing the proprietary rights of others, and prevent others from infringing our proprietary rights, is crucial to our future success. See Item 1A. \u201cRisk Factors \u2013 Risks Related to Our Intellectual Property.\u201d FYCOMPA\u00ae Product Overview Epilepsy is a serious neurological condition that affects approximately 50 million individuals worldwide, 80% of whom live in developing countries. An estimated 1.7% of U.S. adults have been diagnosed with the condition. The FDA approved FYCOMPA\u00ae in October 2012 as an adjunctive agent for the treatment of focal onset seizures with or without secondary generalization in patients with epilepsy at least four years of age. In June 2015, the agency approved a second indication for primary generalized tonic-clonic seizures in patients with epilepsy who are at least 12 years of age. FYCOMPA\u00ae is a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor. In the nervous system, glutamate is known to be a major excitatory neurotransmitter, but the exact antiepileptic mechanism of perampanel in humans is unknown. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. In addition, AMPA receptor antagonists may prevent neuronal death. At the time of its approval, the FDA included specific significant warnings for FYCOMPA\u00ae that it required to be included prominently in all communications about the product. Such warnings are known as \u201cblack box\u201d warnings because they are traditionally surrounded by a black box to emphasize their significance. For FYCOMPA\u00ae, the warning addresses rare but serious behavioral changes that occur in some patients using FYCOMPA\u00ae including aggression (up to and including homicidal behavior), hostility, anger, distrust and other extreme behavioral changes; visual and auditory hallucinations; and difficulty with memory. In addition, FYCOMPA\u00ae was classified as a Schedule III controlled substance under the Federal Controlled Substances Act (CSA) prior to its approval due to evidence of prolonged use creating a physical dependence in some patients and the potential for abuse. Epilepsy Epilepsy is a long-term (chronic) disease that causes repeated seizures due to abnormal electrical signals produced by damaged brain cells. A burst of uncontrolled electrical activity within brain cells causes a seizure. Epilepsy is generally diagnosed after an individual suffers two seizures within a 24-hour period. Generally, cells in the brain send messages to and receive messages from all areas of the body. These messages are transmitted via a continuous electrical impulse that travels from cell to cell. Epilepsy disrupts this rhythmic electrical impulse pattern. Instead, there are bursts of electrical energy \u2014 like an unpredictable lightning storm \u2014 between cells in one or more areas of your brain. This electrical disruption causes changes in awareness (including loss of consciousness), sensations, emotions and muscle movements. In the U.S., about 3.47 million people have epilepsy. Of this number, approximately 3 million are adults and 470,000 are children. There are 150,000 new cases of epilepsy in the U.S. each year. Worldwide, approximately 50 million people have epilepsy. 14",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "Index to Financial Statements\n\n| \u2022 | Motor: A simple focal seizure with motor symptoms will affect muscle activity, causing jerking movements of a foot, the face, an arm or another part of the body. Physicians can diagnose which side of the brain is affected by observing which side of the body experiences symptoms, since the left brain controls the right side of the body and the right brain controls the left. |\n| \u2022 | Sensory: A simple focal seizure may cause sensory symptoms affecting the senses, such as: hearing problems, hallucinations and olfactory or other distortions. |\n| \u2022 | Autonomic: A simple focal seizure with autonomic symptoms affects the part of the brain responsible for involuntary functions. These seizures may cause changes in blood pressure, heart rhythm, or bowel or bladder function. |\n| \u2022 | Psychic: Some simple focal seizures strike parts of the brain that trigger emotions or memories of previous experiences, causing feelings of fear, anxiety, or d\u00e9j\u00e0 vu (the illusory feeling that something has been experienced before). |",
            "type": "table"
        },
        {
            "id": 16,
            "context": "Index to Financial Statements\nIndex to Financial Statements Intellectual Property Protections for FYCOMPA\u00ae Patent protection for FYCOMPA\u00ae is primarily from two patents listed in the Orange Book. The first, U.S. patent no. 6,949,571 (the \u2018571 patent) will expire May 23, 2025, including patent term extension. Although the Company had requested that the USPTO reconsider this expiration date in favor of a June 8, 2026 expiration date, the request for reconsideration of the agency\u2019s patent term extension calculation was denied and the Company has exhausted its reasonable avenues for an extension of that patent term. The Company will update the Orange Book to reflect the May 23, 2025 expiration date at the appropriate time. The second FYCOMPA\u00ae patent in the Orange Book is U.S. Patent No. 8,772,497 (the \u2018497 patent). This patent claims the commercial crystalline form of perampanel for FYCOMPA\u00ae and expires on July 1, 2026. The \u2018497 patent has been the subject of previous Paragraph IV certifications from three ANDA filers. U.S. Patent No. 8,304,548, which is not Orange Book listable, claims the commercial process used to produce perampanel for FYCOMPA\u00ae and has an expiration date of October 14, 2027. On February 20, 2023, we received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA\u00ae. The same company sent a similar letter to us later in February with a similar certification for the tablet formulation for FYCOMPA\u00ae, the fourth such certification for this formulation. Both of these letters were paragraph IV certifications of non-infringement, non-validity, and unenforceability of the \u2018497 patent for FYCOMPA\u00ae but each application, like the previous Paragraph IV notices from ANDA filers, does not challenge the \u2018571 patent. Similar to the actions with the FIRDAPSE\u00ae Paragraph IV Certifications described above, after due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions for both FYCOMPA\u00ae formulations, thus triggering the 30 month stay for each application. AGAMREE\u00ae Product Overview AGAMREE\u00ae is a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with DMD. In clinical studies, AGAMREE\u00ae showed evidence of inhibition of pro-inflammatory NF-kB (nuclear factor kappa light chain enhancer of activated B cells) pathways, which are, a family of highly conserved transcription factors that regulate many important cellular behaviors, in particular, inflammatory responses and cellular growth. This inhibition is achieved through high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties. It is hoped that AGAMREE\u00ae will demonstrate similar efficacy to traditional corticosteroids with reduced negative downstream impacts or side effects. The FDA approved AGAMREE\u00ae for the treatment of DMD in patients aged two and older on October 26, 2023. Clinical Trials Supporting the Approval of AGAMREE\u00ae To support the approval of AGAMREE\u00ae, a randomized, double-blind, placebo and prednisone-controlled multinational trial of vamorolone was carried out in 121 male patients with DMD. The study included patients 4 to less than 7 years of age at time of enrollment in the study who were corticosteroid na\u00efve and ambulatory. The trial met the primary (time to stand velocity after 24 weeks for vamorolone, 6 mg/kg per day vs placebo) and several sequential secondary motor function endpoints. Study participants receiving vamorolone, 2 mg/kg per day, and vamorolone, 6 mg/kg per day, showed improvements in multiple functional endpoints over the 24-week treatment period as compared to placebo. The statistical thresholds for the primary outcome and several secondary outcomes for vamorolone treatment were met, and vamorolone demonstrated efficacy across both dose ranges. The differences in time to stand from supine velocity (TTSTAND) were clinically meaningful. The differences in 6-minute walk test (6MWT) were also clinically meaningful. Access to AGAMREE\u00ae We plan to support AGAMREE\u00ae through our Catalyst Pathway Program\u00ae, which includes a dedicated, personalized support team that assists families through the AGAMREE\u00ae treatment journey, from answering questions to coordinating financial assistance programs for eligible patients. Acquisition of AGAMREE\u00ae On June 19, 2023, we entered into the AGAMREE\u00ae License Agreement and the Investment Agreement with Santhera. Under the AGAMREE\u00ae License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera\u2019s investigational product candidate, AGAMREE\u00ae (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera. 17",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "Index to Financial Statements\n\n| U.S. Patent No. | Indication | Expiration Date |\n| 10,857,161 | Non-hormonal steroid modulators of NF-kB for treatment of disease | May 28, 2029 |\n| 8,334,279 | Non-hormonal steroid modulators of NF-.kappa.B for treatment of disease | May 28, 2029 |\n| 11,471,471 | Aqueous oral pharmaceutical suspension compositions | March 17, 2040 |\n| 11,382,922 | Aqueous oral pharmaceutical suspension compositions | July 16, 2040 |\n| 11,690,853 | Non-hormonal steroid modulators of NF-kb for treatment of disease | March 7, 2033 |\n| 11,833,159 | Non-hormonal steroid modulators of NF-kb for treatment of disease | May 28, 2029 |\n| \u2022 | Progressive muscle weakness and atrophy that begins in the legs and pelvis, occurring less severely in the arms, neck, and other areas of the body. |\n| \u2022 | Calf muscle hypertrophy (increase in muscle size). |",
            "type": "table"
        },
        {
            "id": 18,
            "context": "Index to Financial Statements\n\n| \u2022 | Difficulty climbing up stairs. |\n| \u2022 | Difficulty walking that gets worse over time. |\n| \u2022 | Frequent falls. |\n| \u2022 | Waddling gait (walk). |\n| \u2022 | Toe walking. |\n| \u2022 | Fatigue. |\n| \u2022 | Cardiomyopathy. |\n| \u2022 | Breathing difficulties and shortness of breath. |\n| \u2022 | Cognitive impairment and learning difficulty. |\n| \u2022 | Delayed speech and language development. |\n| \u2022 | Developmental delay. |\n| \u2022 | Scoliosis. |\n| \u2022 | Short stature. |",
            "type": "table"
        },
        {
            "id": 19,
            "context": "Index to Financial Statements FIRDAPSE\u00ae We have entered into agreements with a supplier of the active pharmaceutical ingredient (API) contained in FIRDAPSE\u00ae for future requirements and we have contracted with third-party contract manufacturers who manufacture FIRDAPSE\u00ae tablets for us. FYCOMPA\u00ae Under our Supply Agreement with Eisai, Eisai has agreed to manufacture and supply to us finished bulk FYCOMPA\u00ae tablets for a seven year period that will run through at least the end of 2029. In addition, Eisai has assigned to us third-party manufacturing contracts related to final packaging of bulk FYCOMPA\u00ae tablets and also the manufacture of the oral solution formulation. AGAMREE\u00ae Under our License and Collaboration Agreement with Santhera, we have agreed to purchase supplies of AGAMREE\u00ae from Santhera until January 1, 2026, after which we have the right, but not an obligation, to contract with outside, third-party manufacturers for the manufacture and supply of AGAMREE\u00ae. Manufacturing Changes Any significant change that we make for any of our drug products must be approved by the FDA in an sNDA. If the manufacturing plan and data are insufficient, any sNDA we submit will not be approved. Before an sNDA can be approved, our manufacturers must also demonstrate compliance with FDA\u2019s cGMP regulations and policies. Further, even if we receive approval of any sNDAs for our drug product(s), if our manufacturers do not follow cGMPs in the manufacture of our products, it may delay product launches or shipments and adversely affect our business. Since we contract with third parties to manufacture our products, our contract manufacturers are required to comply with all applicable environmental laws and regulations that affect the manufacturing process. As a result, we do not believe that we will have any significant direct exposure to environmental issues. Competition The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by us would likely compete with currently marketed and potentially new drugs and therapies. There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations that compete with us in developing various approaches to the treatment of orphan diseases. Many of these organizations have substantially greater financial, technical, marketing and manufacturing resources than we have. FIRDAPSE\u00ae Before the approval of FIRDAPSE\u00ae, LEMS was generally treated with unapproved drugs and therapies including steroids, azathioprine, other immunosuppressants and intravenous immunoglobulin, which work by suppressing the immune system, and pyridostigmine. Plasma exchange has also been used in an attempt to remove antibodies from the body. Further, one other product, guanidine HCl tablets, was approved many years ago (during a period when drugs were not required to be reviewed by the FDA for both safety and effectiveness) for use in the treatment of LEMS. However, this drug has significant side effects and is not currently viewed as an effective treatment for LEMS. Notwithstanding, drugs may be prescribed by physicians for the treatment of LEMS whether or not they are considered effective. Finally, we are aware that amifampridine has been available from compounding pharmacies for many years and likely remains available, even though we have obtained FDA approval of FIRDAPSE\u00ae and federal law, as discussed below, generally prohibits compounding \u201cessentially copies\u201d of commercially available drugs unless those drugs are on the FDA\u2019s published drug shortages list. Compounded amifampridine is likely to be substantially less expensive than FIRDAPSE\u00ae. The Food and Drug Administration Modernization Act of 1997 included a new section, which clarified the status of pharmacy compounding under Federal law. Under Section 503A, drug products that are lawfully compounded by a pharmacist or physician for an individual patient may be entitled to exemptions from three key provisions of the FDCA: (1) the adulteration provision of section 501(a)(2)(B) (concerning FDA\u2019s cGMP regulations); (2) the misbranding provision of section 502(f)(1) (concerning the labeling of drugs with adequate directions for use); and (3) the new drug provision of section 505 (concerning the approval of drugs under NDAs or ANDAs). 20",
            "type": "paragraph"
        },
        {
            "id": 20,
            "context": "Index to Financial Statements To qualify for these statutory exemptions, a compounded drug product must satisfy several legal requirements. One of these requirements restricts the universe of bulk drug substances that a compounder may use. Specifically, every bulk drug substance used in compounding: (1) must comply with an applicable and current USP or NF drug monograph, if one exists, as well as the current USP chapters on pharmacy compounding; (2) if such a monograph does not exist, the bulk drug substance must be a component of an FDA-approved drug; or (3) if a monograph does not exist and the bulk drug substance is not a component of an FDA-approved drug, it must appear on a list of bulk drug substances that may be used in compounding (i.e., the \u201cSection 503A bulk substances list 1\u201d). While the advertising provisions in Section 503A were ruled unconstitutional in part in the United States by the Supreme Court in 2002, the FDA, since 2013, has aggressively regulated and exercised oversight over the practice of pharmacy compounding following the compounding incident at the New England Compounding Center in Massachusetts that sickened hundreds and killed over 60 individuals. In 2013, Congress removed the unconstitutional advertising provisions in Section 503A when it passed the Drug Quality and Security Act of 2013 (DQSA), Title I (The Compounding Quality Act), rendering Section 503A enforceable in all states. The DQSA also created \u201coutsourcing facilities\u201d under Section 503B of the FDCA, which are drug compounders that voluntarily register with FDA and may produce compounded formulations for office use (at least one of which must be sterile), but must comply with FDA\u2019s cGMP regulations and other requirements set forth in Section 503B. Section 503B outsourcing facilities may also only compound from bulk substances if the product is on FDA\u2019s drug shortage list, or the substance is on FDA\u2019s Section 503B interim and final 2013 list of bulk substances that may be used in compounding (i.e., the Section 503B bulk substances list 1). The active pharmaceutical ingredient in FIRDAPSE\u00ae is not currently included in the FDA\u2019s interim or final Section 503B list of bulk substances that may be used in compounding, nor has it been nominated for its inclusion. While the FDA has been enforcing Section 503A since its re-enactment, compounders may still compound \u201cnear copies\u201d (but not \u201cessentially copies\u201d) of approved drug products, under Section 503A, so long as the prescriber makes a change to the compounded formulation that produces for that patient a significant difference between the commercially available drug and the compounded version. Section 503A compounders may also copy commercially available products if they do not do so in \u201cregular or inordinate amounts.\u201d In January 2018, FDA published a Final Guidance document titled, \u201cCompounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act.\u201d This Final Guidance sets forth FDA\u2019s enforcement policy concerning those compounders that make essentially copies of commercially available drug products. FDA has defined the term \u201cregular or inordinate\u201d in the Final Guidance to mean: \u201ca drug product that is essentially a copy of a commercially available drug product is compounded regularly or in inordinate amounts if it is compounded more frequently than needed to address unanticipated, emergency circumstances, or in more than the small quantities needed to address unanticipated, emergency circumstances.\u201d FDA has further stated it will not take enforcement action, considering all the facts and circumstances, against a compounder that compounds less than four \u201cessentially copies\u201d of a commercially available drug product in a calendar month. FYCOMPA\u00ae FYCOMPA\u00ae is the first and only AED that targets a specific receptor in the brain called \u201cAMPA\u201d. The receptor plays a role in allowing seizures to occur. Seizures have historically been treated with benzodiazepines such as clonazepam (Klonopin) and lorazepam (Ativan), GABA inhibitors such as gabapentin (Neurontin), phenobarbital (Luminal), and pregabalin (Lyrica), and sodium channel blockers such as carbamazepine (Tegretol) and lacosamide (Vimpat). Additionally, surgical options such as deep brain stimulation have been used in patients who have failed polypharmacy. Finally, there are multiple compounds that have been recently approved or are in late-stage development for focal epilepsy. AGAMREE\u00ae The market for DMD treatment is highly competitive, with multiple lines of treatment and medications, both name brand and generic. The first-line treatment has long been corticosteroids. On February 9, 2017, the FDA approved Emflaza (deflazacort), a corticosteroid marketed by PTC Therapeutics for the treatment of DMD in patients 5 years old and older. Glucocorticoids are also used, with such drugs being seen as delaying the development of scoliosis and reducing the need for surgery. In September 2016, the FDA granted accelerated approval of Eteplirsen, an \u201cexon skipping\u201d drug that targets a section of DNA called exon 51. Alaluren is an orally administered drug being developed for the treatment of genetic defects caused by what are known as \u201cnonsense mutation\u201d, a condition suffered by 10-15% of DMD patients and is currently approved in the United Kingdom and European Union. In December 2019, Vyondys 53, an \u201cexon skipping\u201d drug that targets a section of DNA called exon 53, and in August 2020, Viltespo, also an \u201cexon skipping\u201d drug that targets a section of DNA called exon 53, was also approved. Exon 53 skipping may help up to 8% of DMD patients. In addition, there are many companies who have announced plans for pre-clinical candidates and clinical development for the treatment of DMD, including gene transfer or gene editing therapies. The status of clinical development is unknown for many of these compounds, but as other companies continue to pursue development and approval of products for the treatment of DMD, their products may or may not prove to be safer and/or more efficacious than AGAMREE\u00ae. 21",
            "type": "paragraph"
        },
        {
            "id": 21,
            "context": "Index to Financial Statements\n\n| \u2022 | our ability to complete clinical development and obtain regulatory approvals for our drug candidates; |\n| \u2022 | the demonstrated efficacy, safety and reliability of our drug candidates; |\n| \u2022 | the timing and scope of regulatory approvals; |\n| \u2022 | product acceptance by physicians and other health care providers; |\n| \u2022 | the willingness of payors to cover and reimburse for our product; |\n| \u2022 | protection of our proprietary rights and the level of generic competition; |\n| \u2022 | the speed at which we develop drug candidates; |\n| \u2022 | our ability to supply commercial quantities of a product to the market; |\n| \u2022 | our ability to obtain reimbursement from private and/or public insurance entities for product use in approved indications; |\n| \u2022 | our ability to recruit and retain skilled employees; and |\n| \u2022 | the availability of capital resources to fund our development and commercialization activities, including the availability of funding from the federal government. |",
            "type": "table"
        },
        {
            "id": 22,
            "context": "Index to Financial Statements\n\n| \u2022 | submission of an investigational new drug application (IND) which must become effective before human clinical trials may begin and which must include approval by an institutional review board, or IRB, at each clinical site before the trials are initiated; |\n| \u2022 | performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use conducted in compliance with federal regulations and good clinical practice (GCP), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; |\n| \u2022 | submission to, and acceptance by, the FDA of an NDA; |\n| \u2022 | satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (cGMP) regulations to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity; |\n| \u2022 | potential FDA audit of the non-clinical and clinical trial sites that generated the data in support of the NDA; and |\n| \u2022 | FDA review and approval of the NDA. |\n| \u2022 | Phase 1 clinical trials involve the initial introduction of the drug into human subjects. These studies are designed to determine the safety of usually single doses of the compound and determine any dose limiting intolerance, as well as evidence of the metabolism and pharmacokinetics of the drug in humans. |\n| \u2022 | Phase 2 clinical trials usually involve studies in a limited patient population to evaluate the safety and efficacy of the drug for specific, targeted indications, to determine dosage tolerance and optimal dosage, and to identify possible adverse effects and safety risks. |\n| \u2022 | In Phase 3, if a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 (or occasionally Phase 1) studies, the Phase 3 studies will be conducted to further confirm clinical efficacy, optimal dosage and safety within an expanded population which may involve geographically diverse clinical trial sites. Generally, but not always, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. |\n| \u2022 | Phase 4 clinical trials are studies required of or agreed to by a sponsor that are conducted after the FDA has approved a product for marketing. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials where necessary could result in withdrawal of approval for products approved under accelerated approval regulations. |",
            "type": "table"
        },
        {
            "id": 23,
            "context": "Index to Financial Statements While Phase 1, Phase 2, and Phase 3 tests are generally required for approval of an NDA, certain drugs may not require one or more steps in the process depending on other testing and the situation involved. Additionally, the FDA, an IRB, or the sponsor may stop testing at any time if results show patients being exposed to unnecessary health risks or overly dangerous side effects. In addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other requirements, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. United States Review and Approval Process FDA approval of an NDA is required before marketing of the product may begin in the United States. The NDA must include the results of product development, pre-clinical studies and clinical studies, together with other detailed information, including information on the chemistry, manufacture and composition of the product. The FDA has 60 days from its receipt of the NDA to review the application to ensure that it is sufficiently complete for substantive review before filing it. The FDA may request additional information rather than file an NDA. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review. The submission of an NDA is also subject to the payment of a substantial application fee (for FDA fiscal year 2024 this fee is $4,048,695), although a waiver of such fee may be obtained under certain limited circumstances, including when the drug that is subject of the application has received Orphan Drug Designation for the indication sought. Further, the sponsor of an approved NDA is subject to an annual program fee, which for FDA fiscal year 2024 is $416,734 per prescription drug product. User fees typically increase annually. The approval process is lengthy and difficult, and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured to determine whether its manufacturing is cGMP\u2013compliant to assure and preserve the product\u2019s identity, strength, quality, purity and stability. If the FDA\u2019s evaluation of the NDA submission or manufacturing facilities is not favorable, the FDA will issue a complete response letter. The complete response letter outlines the deficiencies in the submission and often requires additional testing or information in order for the FDA to reconsider the application. Even after submitting this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. With limited exceptions, the FDA may withhold approval of an NDA regardless of prior advice it may have provided or commitments it may have made to the sponsor. Once an NDA is approved, changes to the conditions of approval, including additional indications, are made by the submission of a supplement to the NDA. The supplemental NDA (sNDA) must contain all of the information necessary to support the change. In the case of a new indication, that information usually consists of at least one clinical trial, and often more. Like an NDA, FDA determines whether the sNDA is sufficiently complete to permit review before it files the sNDA. FDA then reviews the sNDA. Like an NDA, FDA can either approve the sNDA or issue a complete response letter outlining the deficiencies in the sNDA. Post-approval Requirements Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. As a condition of NDA approval, the FDA may also require a risk evaluation and mitigation strategy (REMS), to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for the healthcare professionals, and other Elements To Assure Safe Use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. 24",
            "type": "paragraph"
        },
        {
            "id": 24,
            "context": "Index to Financial Statements Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or sNDA before the change can be implemented. An sNDA for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. Controlled Substance Regulations Drugs and other substances are subject to scheduling as a controlled substance under the Controlled Substances Act (CSA) depending on the drug\u2019s potential for abuse. The CSA and regulations promulgated by the Drug Enforcement Administration (DEA) impose certain requirements on controlled substances that are pharmaceutical products approved by FDA related to manufacturing, import, export, distribution and dispensing of such substances. These include registration, security, recordkeeping and reporting requirements. The CSA and regulations classify controlled substances into five schedules. Schedule I substances by definition have a high potential for abuse, have no currently \u201caccepted medical use\u201d in the U.S., lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. may classified in Schedule II, III, IV or V, depending on the potential for abuse and psychological or physical dependence. Schedule II substances are defined as having the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse. FYCOMPA\u00ae is a Schedule III drug (DEA Controlled Substance Code 2261), which means that the DEA has determined that (i) it has a potential for abuse less than the drugs or other substances in Schedules I and II, (ii) it has a currently accepted medical use in treatment in the United States, and (iii) abuse may lead to moderate or low physical dependence or high psychological dependence. Manufacturing, distributing and dispensing of Schedule III drugs are subject to specific regulatory requirements including limits on amounts that may be imported. In addition to federal regulations, the states have established separate regulations and requirements for controlled substances relating to manufacturing, storage, distribution and physician prescription procedures, including in some cases limitations on prescription refills. In addition, the third parties who perform our clinical and commercial manufacturing, distribution, and dispensing for FYCOMPA\u00ae are required to maintain necessary DEA registrations and state licenses and comply with the regulatory requirements. The DEA and the relevant state agencies periodically inspect facilities for compliance with its rules and regulations. The Hatch-Waxman Amendments Orange Book Listing In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims covering the applicant\u2019s product or approved methods of using the product. Upon approval of a drug, each of the patents listed in the application for the drug are then published in the FDA\u2019s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an Abbreviated New Drug Application (ANDA). An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as \u201cgeneric equivalents\u201d to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug. The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA\u2019s Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. 25",
            "type": "paragraph"
        },
        {
            "id": 25,
            "context": "Index to Financial Statements A certification that the new product will not infringe the already approved product\u2019s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired. Exclusivity Upon NDA approval of a new chemical entity (NCE), which is a drug product that contains an active moiety that has never been approved by FDA in any other NDA, that drug receives five years of marketing exclusivity during which FDA cannot receive any ANDA seeking approval of a generic version of that drug. A drug may obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for the previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. During this period of exclusivity, FDA cannot approve an ANDA for a generic drug that includes the change. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV notification is filed. If there is no listed patent in the Orange Book, there cannot be a Paragraph IV certification, and, thus, no ANDA can be filed before the expiration of the exclusivity period. Section 505(b)(2) NDAs Most drug products obtain FDA marketing approval pursuant to an NDA or an ANDA. A third alternative is a special type of NDA, commonly referred to as a Section 505(b)(2), or 505(b)(2), NDA, which enables the applicant to rely, in part, on FDA\u2019s previous approval of a similar product, or published literature, in support of its application. 505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA\u2019s prior findings of safety and effectiveness or published literature is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or some, of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. To the extent that the Section 505(b)(2) applicant is relying on studies conducted on previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications with respect to any patents for the approved product on which the application relies that are listed in the FDA\u2019s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. Specifically, the applicant must certify for each listed patent that either: (1) the required patent information has not been filed; or (2) the listed patent has expired; or (3) the listed patent has not expired but will expire on a particular date, and approval is not sought until after patent expiration; or (4) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product\u2019s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification. If the applicant does not challenge one or more listed patents through a Paragraph IV certification, the FDA will not approve the Section 505(b)(2) NDA application until all the listed patents claiming the referenced product have expired. Further, the FDA also will not approve, as applicable, a Section 505(b)(2) NDA application until any non-patent exclusivity has expired, for example: five-year exclusivity period for obtaining approval of an NCE; or three-year exclusivity period for an approval based on new clinical trials; or pediatric exclusivity, listed in the Orange Book for the referenced product. A section 505(b)(2) NDA applicant must send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. If the relevant patent holder elects to initiate litigation, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its product, only to be subject to significant delay and patent litigation before its product may be commercialized. Alternatively, if the NDA applicant or relevant patent holder does not file a patent infringement lawsuit within the specified 45 day period, the FDA may approve the Section 505(b)(2) application at any time. 26",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "Index to Financial Statements ANDAs Generic drugs may enter the market after the approval of an ANDA. The ANDA development process typically does not require new pre-clinical or clinical studies, but it does typically require one or more bioequivalence studies to show that the ANDA drug is bioequivalent to the previously approved brand name reference listed drug. Bioequivalence studies compare the bioavailability of the proposed drug product with that of the approved listed product containing the same active ingredient. Bioavailability is a measure of the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. A demonstration of bioequivalence means that the rate and extent of absorption of the ANDA drug is not significantly different from the rate and extent of absorption of the brand name reference listed drug when administered at the same molar dose under similar experimental conditions. As noted above, generic drug products are generally introduced to the marketplace at the expiration of patent protection and non-patent market exclusivity for the reference listed drug. However, if an ANDA applicant is the first ANDA applicant to submit an ANDA containing a Paragraph IV certification, that ANDA may be eligible for a period of generic marketing exclusivity on approval. This exclusivity, which under certain circumstances must be shared with other ANDA applicants with Paragraph IV certifications, lasts for 180 days, during which the FDA cannot grant final approval to other ANDA sponsors of an application for a generic equivalent to the same reference drug. Under certain circumstances, eligibility for 180-day exclusivity may be forfeited. Various types of changes to an approved ANDA must be requested in a prior approval supplement. In addition, some changes may only be approved after new bioequivalence studies are conducted or other requirements are satisfied. In addition, the ANDA applicant must demonstrate that manufacturing procedures and operations conform to FDA cGMP requirements. Facilities, procedures, operations, and/or testing of products are subject to periodic inspection by the FDA and other authorities. In addition, the FDA conducts pre-approval and post-approval reviews and inspections to determine whether the systems and processes are in compliance with cGMP and other FDA regulations. There are also user fees for ANDA applicants, sponsors, and manufacturers. For fiscal year 2024, the application fees are $252,453 per ANDA application. In addition, there are facility fees based on the location of the finished dosage form facility and active pharmaceutical ingredient facility, and an annual program fee based on the size of the generic drug applicant. These user fees typically increase each fiscal year. Other Regulatory Requirements In addition to regulation by the FDA and certain state regulatory agencies, we are also subject to a variety of foreign regulations governing clinical trials and the marketing of other products. Outside of the United States, our ability to market a product depends upon receiving a marketing authorization from the appropriate regulatory agencies. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. In any country, however, we will only be permitted to commercialize our products if the appropriate regulatory agency is satisfied that we have presented adequate evidence of safety, quality and efficacy. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing of the product in those countries. The regulatory approval and oversight process in other countries includes all of the risks associated with regulation by the FDA and certain state regulatory agencies as described above. Under the European Union regulatory system, applications for drug approval may be submitted either in a centralized or decentralized manner. Under the centralized procedure, a single application to the European Medicines Agency leads to an approval granted by the European Commission which permits marketing of the product throughout the European Union. The decentralized procedure provides for mutual recognition of nationally approved decisions and is used for products that do not comply with requirements for the centralized procedure. Under the decentralized procedure, the holders of national marketing authorization in one of the countries within the European Union may submit further applications to other countries within the European Union, who will be requested to recognize the original authorization based on an assessment report provided by the country in which marketing authorization is held. Pharmaceutical pricing and reimbursement In both United States and foreign markets, our ability to commercialize our products successfully, and to attract commercialization partners for our products, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party payors, including, in the United States, governmental payors such as Medicare and Medicaid, managed care organizations, private commercial health insurers and pharmacy benefit managers (PBMs). Third-party payors are increasingly challenging the prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic or other studies in order to further demonstrate the value of our products. Even with the availability of such studies, our products may be considered less safe, less effective or less cost-effective than alternative products, and third-party payors may not provide coverage and reimbursement for our drug candidates, in whole or in part. 27",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "Index to Financial Statements\n\n| \u2022 | public transparency on qualifying prices of newly launched drugs, price increases and/or discounting to better inform purchasers; |\n| \u2022 | additional controls on government-funded reimbursement for drugs; |\n| \u2022 | controls on healthcare providers; |\n| \u2022 | challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means; |\n| \u2022 | reform of drug importation laws; |\n| \u2022 | entering into contractual agreements with payors; and |\n| \u2022 | expansion of use of managed-care systems in which healthcare providers contract to provide comprehensive healthcare for a fixed cost per person. |",
            "type": "table"
        },
        {
            "id": 28,
            "context": "Index to Financial Statements\n\n| \u2022 | providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the non-clinical and clinical data necessary for approval is as efficient as possible; |\n| \u2022 | taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment; |\n| \u2022 | assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the cross-discipline members of the review team (i.e., clinical, pharmacology-toxicology, chemistry, manufacturing and control (CMC), compliance) for coordinated internal interactions and communications with the sponsor through the review division\u2019s Regulatory Health Project Manager; and |\n| \u2022 | involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review. |",
            "type": "table"
        },
        {
            "id": 29,
            "context": "Index to Financial Statements In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by FDA. The Food and Drug Omnibus Reform Act (FDORA) was recently enacted, which included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. FDORA enables the FDA to initiate enforcement action for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. In addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections of a fast track drug\u2019s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA\u2019s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. Priority Review Under FDA policies, a drug candidate is eligible for priority review, or review within a six to eight-month time frame from the time a complete NDA is submitted, if the drug candidate is intended for the treatment, diagnosis, or prevention of a serious or life-threatening condition, demonstrates the potential to address an unmet medical need, or provides a significant improvement compared to marketed drugs. Disclosure of Clinical Trial Information Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the clinical trial. Competitors may use this publicly-available information to gain knowledge regarding the progress of development programs. Anti-Kickback, False Claims Laws & the Prescription Drug Marketing Act In addition to FDA restrictions on marketing of drug products, other state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and patients, prescribers, purchasers and formulary managers on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Additionally, a violation of the federal anti-kickback statute can serve as a basis for liability under the federal civil false claims act. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. 30",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "Index to Financial Statements Other federal statutes pertaining to healthcare fraud and abuse include the Civil Monetary Penalties Law statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payor knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and the additional federal criminal health care fraud statute created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations impose obligations on certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, as well as their business associates and their subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates, their covered subcontractors and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney\u2019s fees and costs associated with pursuing federal civil actions. Pursuant to the Physician Payment Sunshine Act, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that requires certain manufacturers of approved prescription drugs that are reimbursable under Medicare, Medicaid, or the Children\u2019s Health Insurance Program, with certain exceptions, to collect and report information on payments or transfers of value to physicians, defined to include doctors, dentists, optometrists, podiatrists and chiropractors, certain other health care professionals such as physician assistants, and certain types of advanced practice nurses, and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The information reported each year is made publicly available on a searchable website. Failure to submit required information may result in civil monetary penalties. In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products, to report gifts and payments to individual physicians in these states or to report certain pricing information, including price increases and the price of newly launched drugs. Other states prohibit various other marketing-related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, several states, including California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Additionally, we may also be subject to state laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the California Consumer Privacy Act of 2018 (CCPA) imposes obligations on businesses to which it applies, including, but not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data, although it exempts some data processed in the context of clinical trials. In addition, the California Privacy Rights Act of 2020 (CPRA), which went into effect on January 1, 2023, imposes additional obligations on companies covered by the legislation and significantly modifies the CCPA, including by expanding consumers\u2019 rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that is vested with authority to implement and enforce the CCPA and CPRA. Virginia\u2019s Consumer Data Protection Act, which took effect on January 1, 2023, requires businesses subject to the legislation to conduct data protection assessments in certain circumstances and requires opt-in consent from consumers to acquire and process their sensitive personal information, which includes information revealing a consumer\u2019s physical and mental health diagnosis and genetic and biometric information that can identify a consumer. In addition, Colorado enacted the Colorado Privacy Act, and Connecticut enacted the Connecticut Data Privacy Act, each of which took effect on July 1, 2023, and Utah enacted the Consumer Privacy Act, which became effective on December 31, 2023, and each of these laws may increase the complexity, variation in requirements, restrictions and potential legal risks, and could require increased compliance costs and changes in business practices and policies. Other states have also enacted, proposed, or are considering proposing, data privacy laws, which could further complicate compliance efforts, increase our potential liability and adversely affect our business. Prescription drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the United States Prescription Drug Marketing Act (PDMA), a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act (DSCSA), has imposed new \u201ctrack and trace\u201d requirements on the distribution of prescription drug products by manufacturers, distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization) on prescription drug products in order to eventually establish an electronic interoperable prescription product to system to identify and trace certain prescription drugs distributed in the United States and preempts existing state drug pedigree laws and regulations on this topic. The DSCSA also establishes new requirements for the licensing of wholesale distributors and third-party logistic providers, although FDA regulations addressing wholesale distributors and third-party logistics providers have not yet been promulgated. We serialize our product at both the package and homogeneous case level, pass serialization and required transaction information to our customers, and believe that we comply with all such requirements. 31",
            "type": "paragraph"
        },
        {
            "id": 31,
            "context": "Index to Financial Statements Government Programs for Marketed Drugs Medicaid, the 340B Drug Pricing Program, and Medicare Federal law requires that a pharmaceutical manufacturer, as a condition of having its products receive federal reimbursement under Medicaid and Medicare Part B, must pay rebates to state Medicaid programs for all units of its covered outpatient drugs dispensed to Medicaid beneficiaries and paid for by a state Medicaid program under either a fee-for-service arrangement or through a managed care organization. This federal requirement is effectuated through a Medicaid drug rebate agreement between the manufacturer and the Secretary of Health and Human Services (HHS). CMS administers the Medicaid drug rebate agreements, which provide, among other things, that the drug manufacturer will pay rebates to each state Medicaid agency on a quarterly basis and report certain price information on a monthly and quarterly basis. The rebates are based on prices reported to CMS by manufacturers for their covered outpatient drugs. For innovator products, that is, drugs that are marketed under approved NDAs, the basic rebate amount is the greater of 23.1% of the average manufacturer price (AMP) for the quarter or the difference between such AMP and the best price for that same quarter. The AMP is the weighted average of prices paid to the manufacturer (1) directly by retail community pharmacies and (2) by wholesalers for drugs distributed to retail community pharmacies. The best price is essentially the lowest price available to non-governmental entities. Innovator products are also subject to an additional rebate that is based on the amount, if any, by which the product\u2019s current AMP has increased over the baseline AMP, which is the AMP for the first full quarter after launch, adjusted for inflation. The rebate amount for a drug has been capped at 100% of the AMP; however, effective January 1, 2024, this cap is eliminated, which means that a manufacturer could pay a rebate amount on a unit of the drug that is greater than the average price the manufacturer receives for the drug. For non-innovator products, generally generic drugs marketed under approved ANDAs, the basic rebate amount is 13% of the AMP for the quarter. Non-innovator products are also subject to an additional rebate. The additional rebate is similar to that discussed above for innovator products, except that the baseline AMP quarter is the fifth full quarter after launch (for non- innovator multiple source drugs launched on April 1, 2013 or later) or the third quarter of 2014 (for those launched before April 1, 2013). The terms of participation in the Medicaid drug rebate program impose an obligation to correct the prices reported in previous quarters, as may be necessary. Any such corrections could result in additional or lesser rebate liability, depending on the direction of the correction. In addition to retroactive rebates, if a manufacturer were found to have knowingly submitted false information to the government, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information. A manufacturer must also participate in a federal program known as the 340B drug pricing program in order for federal funds to be available to pay for the manufacturer\u2019s drugs under Medicaid and Medicare Part B. Under this program, the participating manufacturer agrees to charge certain federally funded clinics and safety net hospitals no more than an established discounted price for its covered outpatient drugs. The formula for determining the discounted price is defined by statute and is based on the AMP and the unit rebate amount as calculated under the Medicaid drug rebate program, discussed above. Manufacturers are required to report pricing information to the Health Resources and Services Administration (HRSA) on a quarterly basis. HRSA has also issued regulations relating to the calculation of the ceiling price as well as imposition of civil monetary penalties for each instance of knowingly and intentionally overcharging a 340B covered entity. Federal law also requires that manufacturers report data on a quarterly basis to CMS regarding the pricing of drugs that are separately reimbursable under Medicare Part B. These are generally drugs, such as injectable products, that are administered \u201cincident to\u201d a physician service and are not generally self-administered. The pricing information submitted by manufacturers is the basis for reimbursement to physicians and suppliers for drugs covered under Medicare Part B. As with the Medicaid drug rebate program, federal law provides for civil monetary penalties for failing to provide required information, late submission of required information, and false information. Medicare Part D provides prescription drug benefits for seniors and people with disabilities. Medicare Part D enrollees once had a gap in their coverage (between the initial coverage limit and the point at which catastrophic coverage begins) where Medicare did not cover their prescription drug costs, known as the coverage gap. However, beginning in 2019, Medicare Part D enrollees paid 25% of brand drug costs after they reach the initial coverage limit\u2014the same percentage they were responsible for before they reached that limit\u2014thereby closing the coverage gap. Most of the cost of closing the coverage gap is being borne by innovator companies and the government through subsidies. Each manufacturer of a drug approved under an NDA is required to enter into a Medicare Part D coverage gap discount agreement and provide a 70% discount on those drugs dispensed to Medicare enrollees in the coverage gap, in order for its drugs to be reimbursed by Medicare Part D. Beginning in 2025, the IRA eliminates the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees\u2019 prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. Although these discounts represent a lower percentage of enrollees\u2019 costs than the current discounts required below the out-of-pocket maximum (that is, in the coverage gap phase of Part D coverage), the new manufacturer contribution required above the out-of-pocket maximum could be considerable for very high-cost patients and the total contributions by manufacturers to a Part D enrollee\u2019s drug expenses may exceed those currently provided. 32",
            "type": "paragraph"
        },
        {
            "id": 32,
            "context": "Index to Financial Statements The IRA also allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D, although only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) are eligible to be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products begin in 2024 with the negotiated price taking effect in 2026, and negotiations for Medicare Part B products will begin in 2026 with the negotiated price taking effect in 2028. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the IRA\u2019s price negotiations requirements, but will lose that exclusion if it receives designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations. HHS will announce the negotiated maximum fair prices by September 1, 2024, and this price cap, which cannot exceed a statutory ceiling price, will come into effect on January 1, 2026, and will represent a significant discount from average prices to wholesalers and direct purchasers. The IRA also imposes rebates on Medicare Part D and Part B drugs whose prices have increased at a rate greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, some significant, including civil monetary penalties. These provisions may be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and our business. Federal Contracting/Pricing Requirements Manufacturers are also required to make their covered drugs, which are generally drugs approved under NDAs, available to authorized users of the Federal Supply Schedule (FSS) of the General Services Administration. The law also requires manufacturers to offer deeply discounted FSS contract pricing for purchases of their covered drugs by the VA, DoD, the Coast Guard, and the Public Health Service (including the Indian Health Service) in order for federal funding to be available for reimbursement or purchase of the manufacturer\u2019s drugs under certain federal programs. FSS pricing to those four federal agencies for covered drugs must be no more than the Federal Ceiling Price (FCP), which is at least 24% below the Non-Federal Average Manufacturer Price (Non-FAMP) for the prior year. The Non-FAMP is the average price for covered drugs sold to wholesalers or other middlemen, net of any price reductions. The accuracy of a manufacturer\u2019s reported Non-FAMPs, FCPs, or FSS contract prices may be audited by the government. Among the remedies available to the government for inaccuracies is recoupment of any overcharges to the four specified federal agencies based on those inaccuracies. If a manufacturer were found to have knowingly reported false prices, in addition to other penalties available to the government, the law provides for civil monetary penalties of $100,000 per incorrect item. Finally, manufacturers are required to disclose in FSS contract proposals all commercial pricing that is equal to or less than the proposed FSS pricing, and subsequent to award of an FSS contract, manufacturers are required to monitor certain commercial price reductions and extend commensurate price reductions to the government, under the terms of the FSS contract Price Reductions Clause. Among the remedies available to the government for any failure to properly disclose commercial pricing and/or to extend FSS contract price reductions is recoupment of any FSS overcharges that may result from such omissions. Tricare Retail Pharmacy Network Program The DoD provides pharmacy benefits to current and retired military service members and their families through the Tricare healthcare program. When a Tricare beneficiary obtains a prescription drug through a retail pharmacy, the DoD reimburses the pharmacy at the retail price for the drug rather than procuring it from the manufacturer at the discounted FCP discussed above. In order for the DoD to realize discounted prices for covered drugs, generally drugs approved under NDAs or biologics approved biologics license applications (BLAs), federal law requires manufacturers to pay refunds on utilization of their covered drugs sold to Tricare beneficiaries through retail pharmacies in DoD\u2019s Tricare network. These refunds are generally the difference between the Non-FAMP and the FCP and are due on a quarterly basis. Absent an agreement from the manufacturer to provide such refunds, DoD will designate the manufacturer\u2019s products as Tier 3 (non-formulary) and require that beneficiaries obtain prior authorization in order for the products to be dispensed at a Tricare retail network pharmacy. However, refunds are due whether or not the manufacturer has entered into such an agreement. 33",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "Index to Financial Statements\nItem\u20091A.\nRisk Factors\nRisk Factors Summary We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the full risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from our recent results or from our anticipated future results.",
            "type": "paragraph"
        },
        {
            "id": 34,
            "context": "34\nIndex to Financial Statements\n\n| \u2022 | Our success depends on the successful commercialization of our products. To the extent that our drug products are not commercially successful, our business, financial condition and results of operations will be materially harmed. |\n| \u2022 | Our drug products may fail to receive the degree of market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would negatively impact our business. |\n| \u2022 | Our strategy of seeking to acquire or in-license innovative technical platforms or earlier stage drug development programs outside of the neuromuscular disease space may not be successful. |\n| \u2022 | Our business may require additional capital. |\n| \u2022 | Because the target patient populations for FIRDAPSE\u00ae and AGAMREE\u00ae are small, we must achieve significant market share and obtain relatively high per-patient prices for our products to achieve meaningful gross margins. |\n| \u2022 | Because of risks associated with taking FYCOMPA\u00ae, potential patients may be reluctant to start treatment with FYCOMPA\u00ae or may discontinue use. |\n| \u2022 | Failure can occur at any stage of our drug development efforts. |\n| \u2022 | We rely on third parties to conduct our pre-clinical studies and clinical studies and trials, and if they do not perform their obligations to us we may not be able to obtain approval for additional indications. |\n| \u2022 | We will need to continue to develop and maintain distribution and production capabilities or relationships to be successful. |\n| \u2022 | We could be impacted by the viability of our suppliers. |\n| \u2022 | We may encounter difficulties in managing our growth, which would adversely affect our results of operations. |\n| \u2022 | Pressure on drug product third-party payor coverage, reimbursement and pricing may impair our ability to be reimbursed at prices or on terms sufficient to provide a viable financial outcome. |\n| \u2022 | Our internal computer systems, or those of our contract research organizations and other key vendors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. |\n| \u2022 | Our employees, sales agents and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. |\n| \u2022 | The regulatory approval process is lengthy, and we may not be able to obtain all of the regulatory approvals required to manufacture and commercialize our drug products in which we are licensed to them. |\n| \u2022 | If our pre-clinical studies or our clinical studies and trials are unsuccessful or significantly delayed, our ability to commercialize our products will be impaired. |\n| \u2022 | We may face significant delays in our clinical studies and trials due to an inability to recruit patients for our clinical studies and trials or to retain patients in the clinical studies and trials we may perform. |\n| \u2022 | If our third-party suppliers or contract manufacturers do not maintain appropriate standards of manufacturing in accordance with cGMP and other manufacturing regulations, our development and commercialization activities could suffer significant interruptions or delays. |\n| \u2022 | Our drug products are subject to continuing regulatory review. If we fail to comply with continuing United States and applicable foreign regulations, we could lose those approvals, and our business would be severely harmed. |\n| \u2022 | Enacted and future legislation or judicial action may increase the difficulty and cost for us to market our approved products or commercialize any other drug candidates we may acquire or license and affect the prices we may obtain. |",
            "type": "table"
        },
        {
            "id": 35,
            "context": "Index to Financial Statements\n\n| \u2022 | If we fail to obtain or subsequently maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE\u00ae and any other orphan drug candidates we may acquire or license, our competitors may sell products to treat the same conditions at greatly reduced prices, and our revenues would be significantly adversely affected. |\n| \u2022 | Changes to the ODA or successful legal challenges to the FDA\u2019s interpretation of the ODA may affect our ability to obtain or subsequently maintain orphan drug exclusivity or may affect the scope orphan drug exclusivity for our products. |\n| \u2022 | Our operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors are subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. |\n| \u2022 | If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. |\n| \u2022 | Whether we will be successful in our litigation to enforce our patents against Paragraph IV challengers who have filed relating to FIRDAPSE\u00ae and FYCOMPA\u00ae. |\n| \u2022 | There is a risk that our patents may not protect our products from generic competition. |\n| \u2022 | Our success will depend significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. |\n| \u2022 | We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. |\n| \u2022 | successfully establishing and maintaining effective sales, marketing, and distribution systems in jurisdictions in which our drug products are approved for sale; |\n| \u2022 | successfully establishing and maintaining commercial third-party manufacturers and having adequate commercial quantities of our drug products manufactured at acceptable cost and quality levels, including maintaining current good manufacturing practice (cGMP) and quality systems regulation standards required by various regulatory agencies; |\n| \u2022 | broad acceptance of our drug products by physicians, patients and the healthcare community; |\n| \u2022 | the acceptance of pricing and placement of our drug products on payors\u2019 formularies and the associated tiers; |",
            "type": "table"
        },
        {
            "id": 36,
            "context": "Index to Financial Statements\n\n| \u2022 | effectively competing with other approved or used medicines and future compounds in development; |\n| \u2022 | continued demonstration of safety and efficacy of our drug products in comparison to competing products; and |\n| \u2022 | obtaining, maintaining, enforcing, and defending intellectual property rights and claims. |\n| \u2022 | the efficacy and potential advantages compared to alternative treatments, including the convenience and ease, or duration of administration; |\n| \u2022 | the prevalence and severity of any side effects; |\n| \u2022 | the acceptability of the price of our drug products relative to other treatments; |\n| \u2022 | the content of the approved product labels and our ability to make compelling product claims; |\n| \u2022 | the effectiveness and adequacy of our and our collaboration partner\u2019s sales and marketing efforts; |\n| \u2022 | the patients\u2019 out-of-pocket costs in relation to alternative treatments; |\n| \u2022 | the breadth and cost of distribution support; |\n| \u2022 | the effectiveness of our patient assistance and support programs; |\n| \u2022 | the availability of third-party payor coverage and adequate reimbursement; and |\n| \u2022 | any restrictions on the use of our drug products together with other medications. |",
            "type": "table"
        },
        {
            "id": 37,
            "context": "Index to Financial Statements\n\n| \u2022 | exposure to known and unknown liabilities, including possible intellectual property infringement claims, violations of laws, tax liabilities and commercial disputes; |\n| \u2022 | incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions; |\n| \u2022 | higher than expected acquisition and integration costs; |\n| \u2022 | difficulty in combining the operations and personnel of any acquired businesses with our operations and personnel; |\n| \u2022 | inability to maintain uniform standards, controls, procedures and policies; |\n| \u2022 | restructuring charges related to eliminating redundancies or disposing of assets as part of any such combination; |\n| \u2022 | large write-offs and difficulties in assessing the relative percentages of in-process research and development expense that can be immediately written off as compared to the amount that must be amortized over the appropriate life of the asset; |\n| \u2022 | increased amortization expenses or, in the event that we write down the value of acquired assets, impairment losses; |\n| \u2022 | potential failure of the due diligence process to identify significant problems, liabilities or other shortcomings or challenges of an acquired or licensed product candidate or technology, including problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, partner disputes or issues and other legal and financial contingencies and known and unknown liabilities; and |\n| \u2022 | entry into therapeutic modalities, indications or markets in which we have no or limited direct prior development or commercial experience and where competitors in such markets have stronger market positions. |",
            "type": "table"
        },
        {
            "id": 38,
            "context": "Index to Financial Statements\n\n| \u2022 | regulators or Institutional Review Boards (IRBs) may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site; |\n| \u2022 | conditions may be imposed upon us by the FDA regarding the scope or design of our clinical trials, or we may be required to resubmit our clinical trial protocols to IRBs for review due to changes in the regulatory environment; |\n| \u2022 | the number of subjects required for our clinical trials may be larger, patient enrollment may take longer, or patients may drop out of our clinical trials at a higher rate than we anticipate; |\n| \u2022 | we may have to suspend or terminate one or more of our clinical trials if we, regulators, or IRBs determine that the participants are being subjected to unreasonable health risks; |\n| \u2022 | our third-party contractors, clinical investigators or contractual collaborators may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner; |\n| \u2022 | the FDA may not accept clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially different from the United States; |\n| \u2022 | our tests may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional testing; and |\n| \u2022 | the costs of our pre-clinical and/or clinical trials may be greater than we anticipate. |",
            "type": "table"
        },
        {
            "id": 39,
            "context": "Index to Financial Statements We will need to continue to develop and maintain distribution and production capabilities or relationships to be successful. We are licensed in Florida as a virtual drug manufacturer, which means we have no in-house manufacturing capacity and we will be obligated to rely on contract manufacturers and packagers. We cannot be sure that we will successfully manufacture any product, either independently or under manufacturing arrangements, if any, with third-party manufacturers. Moreover, if any manufacturer should cease doing business with us or experience delays, shortages of supply or excessive demands on their capacity, we may not be able to obtain adequate quantities of product in a timely manner, or at all. Manufacturers, and in certain situations their suppliers, are required to comply with current NDA commitments and current good manufacturing practices (cGMP) requirements enforced by the FDA, and similar requirements of other countries. The failure by a manufacturer to comply with these requirements could affect its ability to provide us with product. Although we intend to rely on third-party contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP. In addition, if, during a preapproval inspection or other inspection of our third-party manufacturers\u2019 facility or facilities, the FDA determines that the facility is not in compliance with cGMP, any of our marketing applications that lists such facility as a manufacturer may not be approved or approval may be delayed until the facility comes into compliance with cGMP and completes a successful re-inspection by the FDA. Any manufacturing problem, natural disaster, or epidemic, affecting manufacturing facilities, or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally, we will be reliant on third parties to supply the raw materials needed to manufacture our products. Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to future contract manufacture caused by problems at suppliers could delay shipment of products, increase our cost of sales and result in lost sales. If our suppliers were to be unable to supply us with adequate supply of our drugs, it could have a material adverse effect on our ability to successfully commercialize our drug candidates. We could be impacted by the viability of our suppliers. We source FIRDAPSE\u00ae from more than one supplier, and we have entered into contracts with our suppliers that contractually obligate them to meet our requirements. However, if our suppliers cannot or will not meet our requirements (for whatever reason), our business could be adversely impacted. We are dependent on our licensing partners for supplies of FYCOMPA\u00ae and AGAMREE\u00ae Through our agreements with Eisai for FYCOMPA\u00ae and Santhera for AGAMREE\u00ae, we have agreed to purchase our supplies of each product through such companies. If either company were unable to supply sufficient supplies of drug product, our business would be adversely impacted, whether we would be required to work with these companies to resume supplies or whether we would be required to search for a sufficient third-party supplier. We may encounter difficulties in managing our growth, which would adversely affect our results of operations. To manage future growth, we will likely need to hire, train, and manage additional employees. Concurrent with expanding our operational and marketing capabilities, we will also need to increase our product development activities. We may not be able to support, financially or otherwise, future growth, or hire, train, motivate, and manage the required personnel. Our failure to manage growth effectively could limit our ability to achieve our goals. Our success in managing our growth will depend in part on the ability of our executive officers to continue to implement and improve our operational, management, information and financial control systems, and to expand, train and manage our employee base, and particularly to expand, train and manage a specially-trained sales force to market our products. We may not be able to attract and retain personnel on acceptable terms given the intense competition for such personnel among biotechnology, pharmaceutical and healthcare companies, universities and non-profit research institutions. Our inability to manage growth effectively could cause our operating costs to grow at a faster pace than we currently anticipate and could have a material adverse effect on our business, financial condition, results of operations and prospects. Pressure on drug product third-party payor coverage, reimbursement and pricing may impair our ability to be reimbursed at prices or on terms sufficient to provide a viable financial outcome. The commercial success of our drug products will depend substantially on the extent to which the cost of those products will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities (such as Medicare and Medicaid), private health coverage insurers and other third-party payors. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services (CMS). CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. If reimbursement is not available, or is available only to limited levels, we may not be able to continue to successfully commercialize our products. Even if coverage is provided, the approved reimbursement amount may not be high enough to establish and maintain pricing sufficient to realize a meaningful return on our investment. 40",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "Index to Financial Statements The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products as cost-effective, and coverage and reimbursement may not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. There have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. For example, in December 2020, CMS issued a final rule implementing significant manufacturer price reporting changes under the Medicaid Drug Rebate Program, including an alternative rebate calculation for line extensions that is tied to the price increases of the original drug, and Best Price reporting related to certain value-based purchasing arrangements. Additionally, under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs on a unit of drug is eliminated. Elimination of this cap may, in some cases, require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of products. Additionally, the Budget Control Act which, subject to certain temporary suspension periods, imposed 2% reductions in Medicare payments to providers per fiscal year starting April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031, unless additional Congressional action is taken. Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. These cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues. If the prices for our products decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer. There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services. In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. The pricing of pharmaceutical products, in general, and of specialty drugs, in particular, has been a topic of concern in the United States Congress, where hearings have been held on the topic, and several bills have been introduced proposing a variety of actions to restrain the prices of drugs. Several healthcare reform proposals recently culminated in the enactment of the IRA, which will eliminate, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees\u2019 prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. The IRA also allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for single-source biologics) are eligible to be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products take place in 2024 with the negotiated price taking effect in 2026, and negotiations for Medicare Part B products will begin in 2026 with the negotiated price taking effect in 2028. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations. HHS will announce the negotiated maximum fair prices by September 1, 2024, and this price cap, which cannot exceed a statutory ceiling price, will go into effect on January 1, 2026. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the IRA\u2019s price negotiation requirements, but will lose that exclusion if it receives designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. The IRA also imposes rebates on Medicare Part D and Part B drugs whose prices have increased at a rate greater than the rate of inflation. Manufacturers that fail to comply with the IRA may be subject to various penalties, including significant civil monetary penalties. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. These provisions may be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of our products and product candidates. It is unclear to what extent other statutory, regulatory, and administrative initiatives will be enacted and implemented in the future and to what extent these or any future legislation or regulations will have on our business, including market acceptance, and sales, of our products and product candidates. 41",
            "type": "paragraph"
        },
        {
            "id": 41,
            "context": "Index to Financial Statements We cannot predict how any such laws or regulations, or new laws or regulations that have yet to be proposed, will affect the pricing of our product, of orphan drugs generally, or of pharmaceutical products generally. At the state level in the United States, legislatures are increasingly enacting laws and implementing regulations designed to control pharmaceutical and biologic product pricing, including price constraints, restrictions on certain product access, reporting on price increases and the introduction of high-cost drugs. In some states, laws have been enacted to encourage importation of lower cost drugs from other countries and bulk purchasing. For example, the FDA released a final rule in September 2020 providing guidance for states to build and submit importation plans for drugs from Canada, and FDA authorized the first such plan in Florida in January 2024. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drug products that we successfully commercialize or put pressure on our product pricing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or access could have a material adverse effect on our business, operations and financial condition. Our internal computer systems, or those of our contract research organizations and other key vendors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. Our internal computer systems and those of our contract research organizations and other key vendors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our drug candidates could be delayed. Our employees, sales agents and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. We are exposed to the risk of fraud or other misconduct by our employees, sales agents or consultants. Misconduct could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Risks Related to Government Regulation The regulatory approval process is lengthy, and we may not be able to obtain all of the regulatory approvals required to manufacture and commercialize our drug products in which we are licensed to them. We will not be able to commercialize our products in other countries or for additional indications until we have obtained the requisite regulatory approvals from applicable governmental authorities. To obtain regulatory approval of a drug candidate for an indication, we must demonstrate to the satisfaction of the applicable regulatory agency that such drug candidate is safe and effective for that indication. The type and magnitude of the testing required for regulatory approval varies depending on the drug candidate and the disease or condition for which it is being developed. In addition, in the United States we must show that the facilities used to manufacture our drug candidates are in compliance with cGMP requirements. We will also have to meet similar regulations in any foreign country where we may seek to commercialize our drug candidates. In general, these requirements mandate that manufacturers follow elaborate design, testing, control, documentation, and other quality assurance procedures throughout the entire manufacturing process. The process of obtaining regulatory approvals typically takes several years and requires the expenditure of substantial capital and other resources. Despite the time, expense and resources invested by us in the approval process, we may not be able to demonstrate that our drug candidate is safe and effective for such indications, in which event we would not receive the regulatory approval required to market it. 42",
            "type": "paragraph"
        },
        {
            "id": 42,
            "context": "Index to Financial Statements\n\n| \u2022 | reliance on the third-party for regulatory compliance and quality assurance; |\n| \u2022 | reliance on the continued financial viability of the third parties; |\n| \u2022 | limitations on supply availability resulting from capacity and scheduling constraints of the third parties; |\n| \u2022 | impact on our reputation in the marketplace if manufacturers of our products fail to meet the demands of our customers; |\n| \u2022 | the possible breach of the manufacturing agreement by the third-party because of factors beyond our control; and |\n| \u2022 | the possible termination or nonrenewal of the agreement by the third-party, based on its own business priorities, at a time that is costly or inconvenient for us. |",
            "type": "table"
        },
        {
            "id": 43,
            "context": "Index to Financial Statements If any of our contract manufacturers fail to achieve and maintain appropriate manufacturing standards, patients using our products could be injured or die, resulting in product liability claims. Even absent patient injury, we may be subject to product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns, or other problems that could seriously harm our business or profitability. Our drug products are subject to continuing regulatory review. If we fail to comply with continuing United States and applicable foreign regulations, we could lose those approvals, and our business would be severely harmed. We are and will continue to be subject to continuing regulatory review for our approved products, including the review of our required nonclinical and clinical post-marketing studies, and other clinical results which are reported after our drug candidates become commercially available approved drugs. As greater numbers of patients use a drug following its approval, side effects and other problems may be observed after approval that were not seen or anticipated during preapproval clinical studies and trials. In addition, the manufacturer, and the manufacturing facilities we use to make any approved drugs, will also be subject to periodic review and inspection by the FDA. The subsequent discovery of previously unknown problems with the drug, manufacturer or facility may result in restrictions on the drug, manufacturer or facility, including withdrawal of the drug from the market. If we fail to comply with applicable continuing regulatory requirements, we may be subject to fines, suspension, or withdrawal of regulatory approval, product recalls and seizures, operating restrictions, and criminal prosecutions. Our product promotion and advertising are also subject to regulatory requirements and continuing regulatory review. In particular, the marketing claims we will be permitted to make in labeling or advertising regarding our marketed products will be limited by the terms and conditions of the FDA-approved labeling and available scientific data. We must submit copies of our advertisements and promotional labeling to the FDA at the time of initial publication or dissemination. If the FDA believes these materials or statements promote our products for unapproved indications, or with unsubstantiated claims, or if we fail to provide appropriate safety related information, the FDA could allege that our promotional activities misbrand our products. Specifically, the FDA could issue an untitled letter or warning letter, which may demand, among other things, that we cease such promotional activities and issue corrective advertisements and labeling to all recipients of the misbranded materials. The FDA also could take enforcement action including seizure of allegedly misbranded product, injunction, or criminal prosecution against us and our officers or employees. If we repeatedly or deliberately fail to submit such advertisements and labeling to the agency, the FDA could withdraw our approvals. Moreover, the Department of Justice can bring civil or criminal actions against companies and executives that promote drugs or biologics for unapproved uses, based on the FDCA, the False Claims Act, and other federal laws governing the marketing and reimbursement for such products under federally supported healthcare programs such as Medicare and Medicaid. Monetary penalties in such cases have often been substantial, and civil penalties can include costly mandatory compliance programs and potential exclusion of a company\u2019s products from federal healthcare programs. Enacted and future legislation or judicial action may increase the difficulty and cost for us to commercialize FIRDAPSE\u00ae or any other drug candidates we may acquire or license and affect the prices we may obtain. In the United States, there have been a number of court cases, legislative and regulatory changes, and other potential changes relating to the healthcare system that restrict or regulate post-approval activities, which may affect our ability to profitably sell FIRDAPSE\u00ae or any other drug candidates for which we obtain marketing approval. Legislative and regulatory proposals have been made to expand post-approval requirements, restrict sales and promotional activities for pharmaceutical products, and with respect to orphan drug designation and exclusivity. In addition, increased scrutiny by the United States Congress of the FDA\u2019s approval process may subject us to more stringent product labeling and post-marketing testing and other requirements. Delays in feedback from the FDA may affect our ability to quickly update or adjust the conditions of use reflected in our label. We cannot predict whether other legislative changes will be adopted or how such changes would affect the pharmaceutical industry generally and specifically the commercialization of FIRDAPSE\u00ae and any other products we develop. If we fail to obtain or subsequently maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE\u00ae and any other orphan drug candidates we may acquire or in-license, our competitors may sell products to treat the same conditions at greatly reduced prices, and our revenues would be significantly adversely affected. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user fee waivers. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated disease or condition for a period of seven years, with an additional six months of exclusivity if the product also qualifies for pediatric exclusivity. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective, a subsequent product is deemed clinically superior, or if the manufacturer is unable to deliver sufficient quantity of the drug. Because the extent and scope of patent protection for some of our drug products may be particularly limited, orphan drug designation \u2013 and ultimately, orphan drug exclusivity \u2013 is especially important for our products that are eligible for orphan drug designation. For eligible drugs, we plan to rely on the orphan exclusivity period to maintain a competitive position. However, if we do not obtain orphan drug exclusivity for our drug candidates or we cannot maintain orphan exclusivity for our drug candidates, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced. Also, without strong patent protection, competitors may sell a generic version upon the expiration of orphan exclusivity if our patent position is not upheld. 44",
            "type": "paragraph"
        },
        {
            "id": 44,
            "context": "Index to Financial Statements\nIndex to Financial Statements\n\n| \u2022 | the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be imposed through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; |\n| \u2022 | HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; |\n| \u2022 | HIPAA, as amended by HITECH, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; |\n| \u2022 | the federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children\u2019s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced care practice nurses and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website; |\n| \u2022 | the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; |\n| \u2022 | analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and |\n| \u2022 | certain state and local laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures; require manufacturers to report price increases that exceed a statutory threshold, as well as information on the reasons for the price increase; require manufacturers to report the introduction into the market of costly drugs; require the registration of pharmaceutical sales representatives; and govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. |",
            "type": "table"
        },
        {
            "id": 45,
            "context": "Index to Financial Statements Risks Related to Our Intellectual Property If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to our drug development programs, products, and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our drug candidates. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The patent applications that we own or have licensed may fail to result in issued patents with claims that protect our drug products in the U.S. or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover our drug products, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If the patent applications we hold or have in-licensed with respect to our development programs, products, and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future drug products or candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a materially adverse effect on our business. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, many countries restrict the patentability of methods of treatment of the human body. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (USPTO) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. 47",
            "type": "paragraph"
        },
        {
            "id": 46,
            "context": "Index to Financial Statements Our success will depend significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our products, product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our products or product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our products or product candidates may infringe. In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our products or product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such products or product candidates unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable products or product candidates unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys\u2019 fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our products or product candidates, and we may do so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our products or product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties. We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third-party may also cause the third-party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, enablement, written description, or patentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. 48",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "Index to Financial Statements Third parties may also raise similar validity claims before the USPTO in post-grant proceedings, such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third-party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our products, or current or future product candidates. Such a loss of patent protection could harm our business. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares. Risks associated with our pending Paragraph IV litigation As noted throughout this report, we are presently litigating several Paragraph IV challenges relating to two of our products, FIRDAPSE\u00ae and FYCOMPA\u00ae. If we are not successful in our litigation to enforce our patents against these Paragraph IV challengers, it could have a material adverse effect on our business and financial condition. General Risk Factors Our business may require additional capital. We may need to raise additional capital in the future in order to fund our business (particularly to fund potential company or product acquisitions that are intended to expand our product offerings). If necessary, we would likely raise additional funds in the future through public or private equity offerings, debt financings, corporate collaborations, or other means. We may also seek governmental grants to support our clinical and pre-clinical trials. However, there is no assurance that any such funding will be available, and, even if it is available, whether it will be available on terms that are favorable to us. We may also seek to raise additional capital to fund additional product development efforts, even if we have sufficient funds for our planned operations. Any sale by us of additional equity or debt securities convertible into additional equity could result in dilution to our stockholders. Further, to the extent that we raise funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that are not favorable to us. If we are not able to secure funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs, which could have an adverse effect on our business. The obligations incident to being a public company place significant demands on our management. As a public reporting company, we are required to comply with the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC, including periodic reports, disclosures and more complex accounting rules. As directed by Section 404 of the Sarbanes-Oxley Act, the SEC adopted rules requiring public companies to include a report of management on a company\u2019s internal control over financial reporting in their Annual Report on Form 10-K. Based on current rules, we are required to annually report under Section 404(a) of the Sarbanes-Oxley Act regarding our management\u2019s assessment as to the effectiveness of our internal control over financial reporting. Further, under Section 404(b) of the Sarbanes-Oxley Act, our auditors are required to report on their assessment as to the effectiveness of our internal control over financial reporting. If we or our auditors are unable to conclude that we have effective internal control over our financial reporting, investors could lose confidence in the reliability of our consolidated financial statements, which could result in a decrease in the value of our common stock. 49",
            "type": "paragraph"
        },
        {
            "id": 48,
            "context": "Index to Financial Statements Our business and operations could suffer in the event of system failures or security or data breaches due to cyber-attacks, or cyber intrusions, including ransomware, phishing attacks and other malicious intrusions. In recent years, cybersecurity threats have become a greater risk and focus for companies. In particular, ransomware attacks, where a hacker locks and threatens to delete or disclose the victim\u2019s data unless a ransom is paid, has become a major risk. We and our third-party service providers are at risk of cyber-attacks or cyber intrusions via the Internet, computer viruses, break-ins, malware, ransomware, phishing attacks, hacking, denial-of-service attacks or other attacks and similar disruptions from the unauthorized use of, or access to, computer systems (including from internal and external sources). These types of incidents continue to be prevalent and pervasive across industries, including in our industry. In addition, we expect information security risks to continue to increase due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state actors. We are increasingly dependent on information technology (IT) systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, process, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. The size and complexity of our IT systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware, phishing, and other cyber-attacks. Our information security systems and those of our third-party vendors are subject to laws and regulations, or may become subject to new laws and regulations, requiring that we enact certain measures to protect the privacy and security of certain information we collect or use in our business. A security breach or privacy violation that leads to disclosure or modification of, or prevents access to, personal information or other protected information, whether caused by internal or external parties, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to notification requirements under certain agreements with third parties, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal information, resulting in increased costs or loss of revenue. Similarly, the loss or unauthorized disclosure of clinical trial data from completed, ongoing or planned clinical trials could prevent us from obtaining regulatory approval or delay our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer negative impact to our reputation, financial loss and be subject to regulatory fines and penalties. In addition, breaches and other unauthorized data access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the reliance on remote working technologies by our employees and third-party partners due to COVID-19 and related public health safety measures and the prevalent use of mobile devices that access confidential and personal information increases the risk of data security breaches, which could lead to the loss of confidential information, personal information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and IT systems, such measures may not prevent such events. Significant disruptions of our IT systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations. We are highly dependent on our small number of key personnel and advisors. We are highly dependent on our executive officers and key employees, and on our Board of Directors. The loss of the services of one or more of these individuals could significantly impede the achievement of our scientific and business objectives. We have no employment or retention agreements with any of our other officers or key employees. If we lose the services of any of our existing executive officers or key employees, or if we were unable to recruit qualified replacements on a timely basis for persons who leave our employ, our efforts to develop our drug candidates might be significantly delayed. We do not carry key-man insurance on any of our personnel. We face a risk of product liability claims and may not be able to obtain adequate insurance. Our business exposes us to potential liability risks that may arise from the clinical testing, manufacture, and/or sale of our pharmaceutical products. Patients have received substantial damage awards in some jurisdictions against pharmaceutical companies based on claims for injuries allegedly caused by the use of pharmaceutical products used in clinical trials or after FDA approval. Liability claims may be expensive to defend and may result in large judgments against us. We currently carry liability insurance that we believe to be adequate. Our insurance may not reimburse us for certain claims or the coverage may not be sufficient to cover claims made against us. We cannot predict all of the possible harms or side effects that may result from the use of our current drug candidates, or any potential future products we may acquire and use in clinical trials or after FDA approval and, therefore, the amount of insurance coverage we currently hold may not be adequate to cover all liabilities we might incur. If we are sued for any injury allegedly caused by our products, our liability could exceed our ability to pay the liability. Whether or not we are ultimately successful in any adverse litigation, such litigation could consume substantial amounts of our financial and managerial resources, all of which could have a material adverse effect on our business, financial condition, results of operations, prospects and stock price. 50",
            "type": "paragraph"
        },
        {
            "id": 49,
            "context": "Index to Financial Statements\n\n| \u2022 | developments concerning our clinical studies and trials and our pre-clinical studies; |\n| \u2022 | status of regulatory requirements for approval of our drug candidates; |\n| \u2022 | adverse publicity regarding the pricing our drug products; |\n| \u2022 | announcements of product development successes and failures by us or our competitors; |\n| \u2022 | new products introduced or announced by us or our competitors; |\n| \u2022 | adverse changes in the abilities of our third-party manufacturers to provide drug or product in a timely manner or to meet FDA requirements; |\n| \u2022 | challenges to our intellectual property which could affect our products, such as the currently pending litigation involving Paragraph IV challenges to FIRDAPSE\u00ae and FYCOMPA\u00ae; |\n| \u2022 | changes in reimbursement levels; |\n| \u2022 | changes in financial estimates by securities analysts; |\n| \u2022 | actual or unanticipated variations in operating results; |\n| \u2022 | changes in laws regarding FDA approval; |\n| \u2022 | expiration or termination of licenses (particularly our FIRDAPSE\u00ae License Agreement), research contracts, or other collaboration agreements; |\n| \u2022 | conditions or trends in the regulatory climate and the biotechnology and pharmaceutical industries; |\n| \u2022 | intellectual property, product liability or other litigation against us; |\n| \u2022 | changes in the market valuations of similar companies; |\n| \u2022 | changes in pharmaceutical company regulations or reimbursements for pharmaceutical products as a result of healthcare reform or other legislation; |\n| \u2022 | changes in economic conditions; and |\n| \u2022 | sales of shares of our common stock, particularly sales by our officers, directors and significant stockholders, or the perception that such sales may occur. |",
            "type": "table"
        },
        {
            "id": 50,
            "context": "Index to Financial Statements\n\n| \u2022 | the ability of our Board of Directors to issue preferred stock with voting or other rights or preferences; |\n| \u2022 | limitations on the ability of stockholders to amend our charter documents, including stockholder supermajority voting requirements; |\n| \u2022 | the inability of stockholders to act by written consent or to call special meetings; |\n| \u2022 | requirements that special meetings of our stockholders may only be called by the Board of Directors; and |\n| \u2022 | advance notice procedures our stockholders must comply with in order to nominate candidates for election to our Board of Directors or to place stockholders\u2019 proposals on the agenda for consideration at meetings of stockholders. |",
            "type": "table"
        },
        {
            "id": 51,
            "context": "Index to Financial Statements\nItem\u20091B.\nUnresolved Staff Comments\nNone.\n\nItem\u20092.\nProperties\nWe currently operate our business in 10,700 square feet of leased office space in Coral Gables, Florida. Our current annual rent is approximately $0.5 million.\n54\nIndex to Financial Statements\nItem\u20093.\nLegal Proceedings\nParagraph IV Patent Litigation In January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE\u00ae in the United States. The notice letters each alleged that the six patents listed in the FDA Orange Book in connection with FIRDAPSE\u00ae are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDAs until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions, thus triggering the stay. Further, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer, and we filed a similar lawsuit against the manufacturer in November 2023.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "We intend to vigorously protect and defend our intellectual property for FIRDAPSE\u00ae and, although there can be no assurance, we believe that our patent estate will protect FIRDAPSE\u00ae from generic competition. On February 20, 2023, we received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA\u00ae. The same company sent a similar letter to us later in February with a similar certification for the tablet formulation for FYCOMPA\u00ae, the fourth such certification for this formulation. Both of these letters were Paragraph IV certifications of non-infringement, non-validity, and unenforceability to the \u2018497 patent for FYCOMPA\u00ae but each application, like the previous Paragraph IV notices from ANDA filers, for FYCOMPA\u00ae tablets does not challenge the \u2018571 patent. Accordingly, the FDA may not approved any ANDA prior to expiration of the \u2018571 patent, including patent term extension. Similar to the actions with the FIRDAPSE\u00ae Paragraph IV Certifications described above, after due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions for both FYCOMPA\u00ae formulations, thus triggering the 30 month stay for each application.",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "Other Litigation From time to time we may become involved in legal proceedings arising in the ordinary course of business. Other than as set forth above, we believe that there is no litigation pending at this time that could have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or cash flows.",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "Item\u20094.\nMine Safety Disclosure\nNot applicable.\n55\nIndex to Financial Statements\nItem\u20095.\nMarket for Registrant\u2019s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities\nPerformance Graph The graph below matches Catalyst Pharmaceuticals, Inc.\u2019s cumulative 5-Year total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite index, the Russell MicroCap index, and the NASDAQ Biotechnology index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from 12/31/2018 to 12/31/2023.",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "| 12/18 | 12/19 | 12/20 | 12/21 | 12/22 | 12/23 |\n| Catalyst Pharmaceuticals, Inc. | 100.00 | 195.31 | 173.96 | 352.60 | 968.75 | 875.52 |\n| NASDAQ Composite | 100.00 | 136.69 | 198.10 | 242.03 | 163.28 | 236.17 |\n| Russell MicroCap | 100.00 | 122.43 | 148.10 | 176.73 | 137.93 | 150.80 |\n| NASDAQ Biotechnology | 100.00 | 125.11 | 158.17 | 158.20 | 142.19 | 148.72 |",
            "type": "table"
        },
        {
            "id": 56,
            "context": "The stock price performance included in this graph is not necessarily indicative of future stock price performance.\n56\nIndex to Financial Statements\n\n| Equity Compensation Plan Information |\n| Plan Category | Number of securities tobe issued upon exerciseof outstanding options,warrants, and rights | Weighted-averageexercise price ofoutstanding options,warrants, and rights | Number of securitiesremaining availablefor equitycompensation plans |\n| Equity compensation plans approved by security holders (1) | 14,177,488 | $ | 7.73 | 1,801,949 | (2) |\n| Equity compensation plans not approved by security holders | \u2014 | \u2014 | \u2014 |\n| Total | 14,177,488 | $ | 7.73 | 1,801,949 |\n| (1) | Includes our 2014 Stock Incentive Plan and our 2018 Stock Incentive Plan |\n| (2) | Remaining shares are only under our 2018 Stock Incentive Plan |",
            "type": "table"
        },
        {
            "id": 57,
            "context": "Index to Financial Statements\nItem\u20096.\nSelected Financial Data\nNot applicable.\n\nItem\u20097.\nManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction our consolidated financial statements and related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption \u201cRisk Factors\u201d in Item 1A of this report.",
            "type": "paragraph"
        },
        {
            "id": 58,
            "context": "Introduction\nManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide an understanding of our financial condition, changes in financial condition and results of operations. The discussion and analysis is organized as follows:\n\n\n\n\n\n\nOverview We are a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. We utilize concerted diligence efforts in search of therapies that will improve the lives of those who suffer from rare or difficult to treat diseases. With an unwavering patient focus embedded in everything we do, we are committed to providing innovative, best-in-class medications with the hope of making a meaningful impact on those affected by these conditions.",
            "type": "paragraph"
        },
        {
            "id": 59,
            "context": "Our flagship U.S. commercial product is FIRDAPSE\u00ae (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome, or LEMS, for adults and for children ages six and up. Further, on January 24, 2023, we closed our acquisition of FYCOMPA\u00ae and are now also marketing that product in the United States. FYCOMPA\u00ae (perampanel) CIII is a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Finally, on July 18, 2023, we closed our acquisition of an exclusive license for North America for vamorolone, a novel corticosteroid treatment for patients suffering from Duchenne Muscular Dystrophy (DMD). On October 26, 2023, the FDA approved AGAMREE\u00ae (vamorolone) oral suspension 40 mg/ml for the treatment of DMD. We are currently planning the commercial launch of AGAMREE\u00ae in the United States during the first quarter of 2024.",
            "type": "paragraph"
        },
        {
            "id": 60,
            "context": "FIRDAPSE\u00ae On November 28, 2018, we received approval from the FDA for our new drug application, or NDA, for FIRDAPSE\u00ae Tablets 10 mg for the treatment of adult patients (ages 17 and above) with LEMS, and in January 2019, we launched FIRDAPSE\u00ae in the United States. Further, on September 29, 2022, the FDA approved our supplemental NDA (sNDA) to expand the indicated age range for FIRDAPSE\u00ae Tablets 10 mg to include pediatric patients, six years of age and older for the treatment of LEMS.",
            "type": "paragraph"
        },
        {
            "id": 61,
            "context": "58\nIndex to Financial Statements We sell FIRDAPSE\u00ae through a field force experienced in neurologic, central nervous system or rare disease products consisting at this time of approximately 35 field personnel, including sales (Regional Account Managers), thought leader liaisons, patient assistance and insurance navigation support (Patient Access Liaisons), and payor reimbursement (National Account Managers). We also have a field-based force of 10 medical science liaisons who are helping educate the medical community about scientific literature concerning LEMS and FIRDAPSE\u00ae. Additionally, for the last few years we have contracted with an experienced inside sales agency that works to generate leads through telemarketing to targeted physicians. This inside sales agency allowed our sales efforts to not only reach the neuromuscular specialists who regularly treat LEMS patients, but also the roughly 9,000 neurology and neuromuscular healthcare providers that may be treating a LEMS patient who can benefit from FIRDAPSE\u00ae. However, effective January 1, 2024 we have terminated that arrangement. We also use non-personal promotion to reach the 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient with small cell lung cancer. Further, we continue to make available at no-cost a LEMS voltage gated calcium channel antibody diagnostic testing program for use by physicians who suspect that one of their patients may have LEMS and wish to reach a definitive diagnosis. Finally, we are continuing to expand our digital and social media activities to introduce our products and services to potential patients and their healthcare providers. We also work with several rare disease advocacy organizations (including the Myasthenia Gravis Foundation of America and the National Organization for Rare Disorders) to help increase awareness and level of support for patients living with LEMS and to provide education for the physicians who treat these rare diseases and the patients they treat. We are supporting the distribution of FIRDAPSE\u00ae through Catalyst Pathways\u00ae, our personalized treatment support program for patients who enroll in it. Catalyst Pathways\u00ae is a single source for personalized treatment support, education and guidance through the challenging dosing and titration regimen required to reach an effective therapeutic dose. It also includes distributing the drug through a very small group of exclusive specialty pharmacies (primarily AnovoRx), which is consistent with the way that most drug products for ultra-orphan diseases are distributed and dispensed to patients. We believe that by using specialty pharmacies in this way, the difficult task of navigating the health care system is far better for the patient needing treatment for their rare disease and the health care community in general. In order to help patients with LEMS afford their medication, we, like other pharmaceutical companies which are marketing drugs for ultra-orphan conditions, have developed an array of financial assistance programs that are available to reduce patient co-pays and deductibles to a nominal affordable amount. A co-pay assistance program designed to keep out-of-pocket costs to not more than $10 per month (currently less than $2 per month) is available for all LEMS patients with commercial coverage who are prescribed FIRDAPSE\u00ae. Our FIRDAPSE\u00ae co-pay assistance program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE. Separately, we are donating, and committing to continue to donate, money to qualified, independent charitable foundations dedicated to providing assistance to any U.S. LEMS patients in financial need. Subject to compliance with regulatory requirements, our goal is that no LEMS patient is ever denied access to their medication for financial reasons. In January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers advising that they had each submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE\u00ae in the United States. The notice letters each alleged that the six patents listed in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) in connection with FIRDAPSE\u00ae are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in these ANDA submissions. Under the Federal Food, Drug and Cosmetic Act (FDCA), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, we had 45 days from receipt of the notice letters to determine if there were grounds to bring a lawsuit and, if so, to commence patent infringement lawsuits against these generic drug manufacturers in a federal district court, which would trigger a statutory stay precluding the FDA from final approval of the subject ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first. In that regard, after conducting the necessary due diligence, we filed lawsuits on March 1, 2023 in the U.S. District Court for the District of New Jersey against each of the three generic drug manufacturers who notified us of their ANDA submissions, thus triggering the stay. Further, in October 2023, we received a Paragraph IV Certification Notice Letter from a fourth generic drug manufacturer, and we filed a similar lawsuit against this manufacturer in November 2023 in the U.S. District Court for the District of New Jersey. We intend to vigorously protect and defend our intellectual property for FIRDAPSE\u00ae and, although there can be no assurance, we believe that our patent estate will protect FIRDAPSE\u00ae from generic competition. On August 4, 2023, we submitted an sNDA to increase the indicated maximum daily dosage of FIRDAPSE\u00ae tablets from 80 mg to 100 mg for the treatment of LEMS. On October 13, 2023, we announced that the FDA had accepted for review our sNDA and assigned a Prescription Drug User Fee Act (PDUFA) action date of June 4, 2024. There can be no assurance that the FDA will approve our sNDA. 59",
            "type": "paragraph"
        },
        {
            "id": 62,
            "context": "Index to Financial Statements We are advised by our sub-licensee for FIRDAPSE\u00ae in Japan, DyDo Pharma, Inc. (DyDo), that on December 18, 2023, based on a preliminary favorable interim data analysis after six months into the safety phase of its registration study to evaluate the efficacy and safety of FIRDAPSE\u00ae for the treatment of LEMS, they filed a Japan NDA with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to commercialize the product in Japan. The review period is expected to be approximately nine months from the submission date, and there can be no assurance that the NDA filing made by DyDo will be approved. Further, upon acceptance of the Japan NDA by the PMDA, which occurred on December 18, 2023, our license for FIRDAPSE\u00ae automatically expanded to include other key markets in Asia and Latin America, and we are currently initiating plans to seek opportunities to expand FIRDAPSE\u00ae\u2019s global footprint through strategic partnerships (with the current focus on the Asia Pacific and Latin American regions). FYCOMPA\u00ae On December 17, 2022, we entered into an agreement with Eisai for the acquisition of the U.S. rights to FYCOMPA\u00ae (perampanel) CIII. FYCOMPA\u00ae is a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. It was the first, and still the only, drug of its class to be approved for epilepsy. Studies suggest that AMPA receptor antagonism can lead to reduced overstimulation and anticonvulsant effects, as well as inhibiting seizure generation and spread. FYCOMPA\u00ae is a controlled substance and is approved with a box warning label. FYCOMPA\u00ae is used to treat certain types of focal onset seizures (seizures that involve only one part of the brain) in adults and children four years of age and older. It is also used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures (also known as a \u201cgrand mal\u201d seizure, a seizure that involves the entire body) in adults and children 12 years of age or older. Perampanel is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain. On January 24, 2023, we closed our acquisition of the U.S. rights to FYCOMPA\u00ae. In connection with the acquisition, we purchased Eisai\u2019s regulatory approvals and documentation, product records, intellectual property, inventory, and other matters relating to the U.S. rights for FYCOMPA\u00ae, in exchange for an upfront payment of $160 million in cash. We also agreed to pay Eisai an additional cash payment of $25 million if a requested patent extension for FYCOMPA\u00ae until June 8, 2026 was approved by the U.S. Patent and Trademark Office (USPTO), which did not occur. Finally, we agreed to pay Eisai royalty payments after patent protection for FYCOMPA\u00ae expires, which royalty payments will be reduced upon generic equivalents to FYCOMPA\u00ae entering the market. In conjunction with the closing of the asset purchase, we entered into two additional agreements with Eisai; a TSA and a Supply Agreement. Under the TSA, a U.S. subsidiary of Eisai provided us with certain transitional services, and under the Supply Agreement, Eisai agreed to manufacture FYCOMPA\u00ae for us for at least seven years at prices listed in the Supply Agreement (to be updated on a yearly basis). As of December 31, 2023, the transition services under the TSA have been completed. Initially, following the closing of the acquisition, we began to market FYCOMPA\u00ae in the U.S. through Eisai under the TSA as we built our FYCOMPA\u00ae marketing and sales team, and in May 2023, we took over the marketing program for FYCOMPA\u00ae. In that regard, we have hired approximately 35 sales and marketing personnel to support FYCOMPA\u00ae, most of whom previously worked in Eisai\u2019s U.S. sales division marketing FYCOMPA\u00ae. We have also hired seven medical science liaisons to help us educate the medical community who treat epilepsy about scientific literature regarding epilepsy and FYCOMPA\u00ae. We are supporting patients using FYCOMPA\u00ae through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $10 for their FYCOMPA\u00ae co-pay (with a maximum savings of $1,300 per year). The FYCOMPA\u00ae instant savings card program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE. Patent protection for FYCOMPA\u00ae is primarily from two patents listed in the Orange Book. The first, U.S. patent no. 6,949,571 (the \u2018571 patent) will expire May 23, 2025, including patent term extension. Although the Company had requested that the USPTO reconsider this expiration date in favor of a June 8, 2026 expiration date, the request for reconsideration of the agency\u2019s patent term extension calculation was denied and the Company has exhausted its reasonable avenues for an extension of that patent term. The Company will update the Orange Book to reflect the May 23, 2025 expiration date at the appropriate time. The second FYCOMPA\u00ae patent in the Orange Book is U.S. Patent No. 8,772,497 (the \u2018497 patent), which expires on July 1, 2026. The \u2018497 patent has been the subject of previous Paragraph IV certifications from three NDA filers. 60",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "Index to Financial Statements On February 20, 2023, we received a Paragraph IV Certification Notice Letter from a company that appears to have filed the first ANDA for the oral suspension formulation for FYCOMPA\u00ae. The same company sent a similar letter to us later in February with a similar certification for the tablet formulation for FYCOMPA\u00ae, the fourth such certification for this formulation. Both of these letters were paragraph IV certifications of non-infringement, non-validity, and unenforceability of the \u2018497 patent for FYCOMPA\u00ae but each application, like the previous Paragraph IV notices from ANDA filers, does not challenge the \u2018571 patent. Accordingly, the FDA may not approve any ANDA prior to expiration of the \u2018571 patent, including patent term extension. Similar to the actions with the FIRDAPSE\u00ae Paragraph IV Certifications described above, after due diligence we filed lawsuits on April 5, 2023 in the U.S. District Court for the District of New Jersey against the drug manufacturer who notified us of their ANDA submissions for both FYCOMPA\u00ae formulations, thus triggering the 30 month stay for each application. AGAMREE\u00ae On June 19, 2023, we entered into the AGAMREE\u00ae License Agreement and the Investment Agreement with Santhera. Under the AGAMREE\u00ae License Agreement, we contracted to obtain an exclusive North America license, manufacturing and supply agreement for Santhera\u2019s investigational product candidate, AGAMREE\u00ae (vamorolone), a novel corticosteroid for the treatment of DMD. Under the Investment Agreement, we agreed to make a strategic investment into Santhera. Both transactions closed on July 18, 2023. Under the AGAMREE\u00ae License Agreement, upon closing, we made a $75 million payment to Santhera in return for the exclusive North American license for AGAMREE\u00ae. Additionally, following approval of the NDA for the drug, on October 26, 2023, we became obligated to make a milestone payment of $36 million to Santhera, $26 million of which Santhera has advised us was used to make milestone payments that they owe to third parties. The $36 million payment was made during the fourth quarter of 2023. We may also be obligated to pay future regulatory and commercial milestone payments to Santhera tied to calendar year sales of AGAMREE\u00ae, as well as commercial royalties. In addition to the rights to commercialize the product in North America, the AGAMREE\u00ae License Agreement provides us with the right of first negotiation for AGAMREE\u00ae in Europe and Japan should Santhera pursue partnership opportunities in those territories. Additionally, we will hold the North American rights to any future approved indications for AGAMREE\u00ae. Concurrent with the closing of the AGAMREE\u00ae License Agreement, we made a strategic investment into Santhera in which we acquired 1,414,688 of Santhera\u2019s post-reverse split ordinary shares (representing approximately 11.26% of Santhera\u2019s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume weighted average price prior to signing), with the approximately $15.7 million USD in equity investment proceeds, inclusive of the approximately $13.5 million USD fair value of the investment in Santhera and approximately $2.2 million USD of transaction costs included in acquired in-process research and development, to be used by Santhera for Phase IV studies of AGAMREE\u00ae in DMD and future development of additional indications for AGAMREE\u00ae. At February 26, 2024, the closing price of Santhera\u2019s common shares on the SIX Swiss Exchange was CHF 11.36 per share. DMD, the most common form of muscular dystrophy, is a rare and life-threatening neuromuscular disorder characterized by progressive muscle dysfunction, ultimately leading to loss of ambulation, respiratory failure, and fatality. Current standard treatment for DMD involves corticosteroids, which often come with significant side effects. It is estimated that between 11,000 and 13,000 patients in the U.S. are affected by DMD, with approximately 70% of patients currently receiving a corticosteroid treatment. Steroids are expected to remain the backbone of therapy for DMD patients and dosed concomitantly with other therapies. AGAMREE\u00ae\u2019s unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. As such, it is considered a novel corticosteroid with dissociative properties in maintaining efficacy that we hope has the potential to demonstrate comparable efficacy to corticosteroids, with the potential for a better-tolerated side effect profile. This mechanism of action may allow vamorolone to emerge as an effective alternative to the current standard of care corticosteroids in children, adolescents, and adult patients with DMD. In the pivotal VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting, and vitamin D deficiency. Adverse events were generally of mild to moderate severity. On October 13, 2023, Santhera announced that the European Union\u2019s Committee for Medicinal Products for Human Use (CHMP) adopted a positive position in favor of AGAMREE\u00ae for the treatment of DMD patients aged four and older. In its recommendation for approval, CHMP acknowledged that there was a positive benefit-risk profile of AGAMREE\u00ae in such patient population, including certain safety benefits of AGAMREE\u00ae compared to standard of care corticosteroids in the treatment of DMD. On October 26, 2023, the U.S. FDA approved Santhera\u2019s NDA for AGAMREE\u00ae for use in treating DMD in patients aged two years and older. As part of the previously described transaction, Santhera has transferred the approved New Drug Application to us. Further, on December 18, 2023, the European Commission (EC) granted to Santhera marketing authorization for AGAMREE\u00ae for the treatment of DMD in patents ages four years and older and on January 12, 2024, Santhera announced that AGAMREE\u00ae had received approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. On January 15, 2024, Santhera announced that AGAMREE\u00ae was commercially launched in Germany. We currently expect to launch AGAMREE\u00ae in the U.S. during the first quarter of 2024. We are incurring substantial commercialization expenses, including sales, marketing, analytical infrastructure, patient services, patient advocacy, and other commercialization related expenses, in preparation for the launch of the product in the U.S. We incurred a portion of such commercialization expenses during the fourth quarter of 2023 and we are incurring additional expenses during the first quarter of 2024. We anticipate minimal sales and marketing personnel expansion to market AGAMREE\u00ae, with approximately 10 additional commercial team members required, due to the synergy of this product within our existing neuromuscular franchise. We will support the distribution of AGAMREE\u00ae through our Catalyst Pathways\u00ae patient services program to ensure that patients have access to a dedicated, personalized support team that assists families through the AGAMREE\u00ae patient journey, from answering questions to coordinating financial assistance programs for eligible patients. 61",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "Index to Financial Statements We have established a joint steering committee with Santhera that will oversee the lifecycle management and development of AGAMREE\u00ae for additional indications beyond DMD. Under our AGAMREE\u00ae License Agreement with Santhera, we have agreed to purchase commercial supply of AGAMREE\u00ae from Santhera at agreed upon rates. To support the approval of AGAMREE\u00ae, a randomized, double-blind, placebo and prednisone-controlled multinational trial of vamorolone was carried out in 121 patients with DMD. The study included patients ages four to less than seven years of age at time of enrollment in the study who were corticosteroid na\u00efve and ambulatory. The trial met the primary (time to stand velocity after 24 weeks for vamorolone, 6 mg/kg per day vs placebo) and several sequential secondary motor function endpoints. Study participants receiving vamorolone, 2 mg/kg per day, and vamorolone, 6 mg/kg per day, showed improvements in multiple functional endpoints over the 24-week treatment period as compared to placebo. The statistical thresholds for the primary outcome and several secondary outcomes for vamorolone treatment were met, and vamorolone demonstrated efficacy across both dose ranges. The differences in time to stand from supine velocity (TTSTAND) were clinically meaningful. The differences in 6-minute walk test (6MWT) were also clinically meaningful. AGAMREE\u00ae has New Chemical Entity exclusivity that expires in October 2028. AGAMREE\u00ae also enjoys Orphan Drug Exclusivity expiring in October 2030. AGAMREE\u00ae is further protected by six Orange Book listed patents expiring as early as May 28, 2029 and as late as July 16, 2040. The Company has also requested Patent Term Extension and will update the relevant expiration date in the Orange Book upon a final determination by the USPTO. The earliest a generic could file an ANDA is October 26, 2027. If we were to pursue a patent infringement action if any such ANDA challenges any of AGAMREE\u00ae\u2019s Orange Book patents, then the automatic statutory 30-month stay would prevent FDA approval of the ANDA until April 26, 2031. Business Development We continue to advance our strategic initiatives and portfolio expansion efforts, focusing on broadening and diversifying our rare (orphan) Neurology product portfolio with innovative therapies that address critical unmet medical needs and expanding the geographical footprint of our existing products. In that regard, we are currently exploring clinically differentiated and adequately de-risked opportunities, with a keen focus on products to treat rare (orphan) central nervous system (CNS) and adjacent rare (orphan) diseases. These prospects include evaluating companies with existing commercial drug products or drugs in development, for potential partnerships, licensing, geographical expansion opportunities with our existing products, and/or asset acquisitions. We continue to employ a disciplined, comprehensive, and exhaustive approach to identifying and evaluating opportunities that we believe will add significant value to our company over the near, mid, and long term. However, no additional definitive agreements have been entered into to date, and there can be no assurance that these initiatives will be successful. Capital Resources At December 31, 2023, we had cash and cash equivalents of approximately $137.6 million. Further, on January 9, 2024, we completed a public offering of 10 million shares of our common stock, raising net proceeds of approximately $140.1 million. The proceeds from this offering will be used to potentially acquire new products and for general corporate purposes. Based on our current financial condition and forecasts of available cash, we believe that we have sufficient funds to support our operations for at least the next 12 months. There can be no assurance that we will continue to be successful in commercializing FIRDAPSE\u00ae and FYCOMPA\u00ae, that our commercialization of AGAMREE\u00ae will be successful, or that we will continue to be profitable and cash flow positive. Further, there can be no assurance that if we need additional funding in the future, whether such funding will be available to us on acceptable terms. Basis of Presentation Revenues. During the fiscal year ended December 31, 2023, we generated revenues from product sales of FIRDAPSE\u00ae primarily in the U.S. and FYCOMPA\u00ae in the U.S. We expect these revenues to fluctuate in future periods based on our sales of FIRDAPSE\u00ae and FYCOMPA\u00ae. We received approval from Health Canada on July 31, 2020, for FIRDAPSE\u00ae for the symptomatic treatment of LEMS and as of December 31, 2020, our sub-licensee KYE Pharmaceuticals launched FIRDAPSE\u00ae in Canada. During the fiscal year ended December 31, 2023, revenues generated under our collaboration agreement with KYE Pharmaceuticals were immaterial. We expect our revenues from the KYE collaboration agreement to fluctuate in future periods based on our collaborator\u2019s ability to sell FIRDAPSE\u00ae in Canada. 62",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "Index to Financial Statements For the fiscal year ended December 31, 2023, we did not generate revenues under our collaborative agreement with Endo. We do not expect to generate revenue in future periods as a result of Endo informing us in the fourth quarter of 2023 that they are discontinuing work on the collaboration for development and commercialization of vigabatrin and that they wish to terminate the arrangement. For the fiscal year ended December 31, 2023, we generated $1.9 million in revenues from our collaborative agreement with DyDo. We expect our revenue from the DyDo license agreement to fluctuate in future periods based on DyDo\u2019s ability to meet various regulatory milestones set forth in such agreement. Cost of Sales. Cost of sales consists of third-party manufacturing costs, freight, royalties, and indirect overhead costs associated with sales of our products. Cost of sales may also include period costs related to certain inventory manufacturing services, inventory adjustments charges, unabsorbed manufacturing and overhead costs and manufacturing variances. Research and Development Expenses. Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as support for selected investigator-sponsored research. The major components of research and development costs include acquired IPR&D, preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials, consulting, and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials, and allocations of various overhead costs related to our product development efforts. Prior to January 2023, all of our research and development resources have been devoted to the development of FIRDAPSE\u00ae, CPP-109 (our version of vigabatrin), and formerly CPP-115, and until we acquire or license new products we currently expect that our future development costs will be attributable principally to the continued development of FIRDAPSE\u00ae, FYCOMPA\u00ae and AGAMREE\u00ae. Our cost accruals for clinical studies and trials are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical study and trial sites and clinical research organizations (CROs). In the normal course of our business we contract with third parties to perform various clinical study and trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar conditions. The objective of our accrual policy is to match the recording of expenses in our consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to preclinical and clinical studies or trials are recognized based on our estimate of the degree of completion of the event or events specified in the specific study or trial contract. We monitor service provider activities to the extent possible; however, if we underestimate activity levels associated with various studies or trials at a given point in time, we could be required to record significant additional research and development expenses in future periods. Preclinical and clinical study and trial activities require significant up-front expenditures. We anticipate paying significant portions of a study or trial\u2019s cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones. Selling, General and Administrative Expenses. During 2019, we actively committed funds to developing our commercialization program for FIRDAPSE\u00ae and we have continued to incur substantial commercialization expenses, including sales, marketing, patient services, patient advocacy and other commercialization related expenses as we have continued our sales program for FIRDAPSE\u00ae. We are also now incurring substantial commercialization expenses for FYCOMPA\u00ae and substantial commercialization expenses for AGAMREE\u00ae, as we prepare for the planned launch of AGAMREE\u00ae during the first quarter of 2024. Our general and administrative expenses consist primarily of salaries and personnel expenses for accounting, corporate, compliance, and administrative functions. Other costs include administrative facility costs, regulatory fees, insurance, and professional fees for legal including litigation cost, IT, accounting, and consulting services. Amortization of Intangible Assets. Amortization of intangible assets consists of the amortization of the FYCOMPA\u00ae product rights, which are amortized using the straight-line method over its estimated useful life of 5 years, and the RUZURGI\u00ae product rights, which are amortized using the straight-line method over its estimated useful life of 14.5 years. We also capitalized the $36 million of milestone payment paid to Santhera during the fourth quarter of 2023 which is being amortized over the product\u2019s estimated useful life of 10.5 years. 63",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "Index to Financial Statements Stock-Based Compensation. We recognize expense for the fair value of all stock-based awards to employees, directors, and consultants in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP). For stock options, we use the Black-Scholes option valuation model in calculating the fair value of the awards. Income Taxes. Our effective income tax rate is the ratio of income tax expense over our income before income taxes. As of December 31, 2023, 2022 and 2021, we had no federal net operating loss carry-forwards. Additionally, we had state net operating loss carry-forwards of approximately $0, $0 and $28 million, respectively, available to reduce future Florida taxable income for the years ended December 31, 2023, 2022 and 2021. Recently Issued Accounting Standards. For discussion of recently issued accounting standards, please see Note 2, \u201cBasis of Presentation and Significant Accounting Policies,\u201d in the consolidated financial statements included in this report. Critical Accounting Policies and Estimates Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, our expected course of development, historical experience and other factors we believe are reasonable based on the circumstances, the results of which form our management\u2019s basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The amounts of assets and liabilities reported in our consolidated balance sheets and the amounts reported in our consolidated statements of comprehensive income are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, valuation of intangible assets, leases, preclinical study and clinical trial expenses, stock-based compensation and valuation allowance for deferred tax assets. The accounting policies described below are not intended to be a comprehensive list of all of our accounting policies but represent the accounting estimates which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. GAAP. There are also areas in which our management\u2019s judgment in selecting any available alternative would not produce a materially different result. Our consolidated financial statements and the notes thereto included elsewhere in this report contain accounting policies and other disclosures as required by U.S. GAAP. Revenue Recognition. Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts with our customer, payors, and other indirect customers relating to the sale of our products. These reserves are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). These estimates take into consideration a range of possible outcomes which are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the respective underlying contracts. The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Our analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates as of December 31, 2023, 2022 and 2021 and, therefore, the transaction price was not reduced further during the years ended December 31, 2023, 2022 and 2021. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Refer to Note 2, \u201cBasis of Presentation and Significant Accounting Policies,\u201d in the consolidated financial statements included in this report for further details on revenue recognition. 64",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "Index to Financial Statements Valuation of Intangible Assets. We have acquired and continue to acquire significant intangible assets that we record at fair value at the acquisition date. Transactions involving the purchase or sale of intangible assets are usually based on a discounted cash flow analysis. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, cost of capital and market participants. Each of these factors can significantly affect the value of the intangible asset. We engage independent valuation experts who review our critical assumptions and calculations for acquisitions of significant intangibles. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are deemed not recoverable, we would estimate the fair value of the assets and record an impairment loss. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest group level for which cash flows are identifiable. Stock-Based Compensation. We recognize stock-based compensation for the fair value of all share-based payments, including grants of stock options and restricted stock units. For stock options, we use the Black-Scholes option valuation model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of our common stock. The estimated expected option life is based upon the simplified method. Under this method, the expected option life is presumed to be the mid-point between the vesting date and the end of the contractual term. We will continue to use the simplified method until we have sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the expected life of our stock option awards. For the years ended December 31, 2023 and 2022, the assumptions used were an estimated annual volatility of 68.0% to 71.0% and 68.4% to 69.5%, expected holding periods of 4.5 to 5.2 years and 4.5 years, and risk-free interest rates of 3.55% to 4.92% and 1.27% to 4.07%, respectively. Results of Operations Years Ended December 31, 2023 and 2022 Revenues. For the fiscal year ended December 31, 2023, we recognized total revenues of $398.2 million which included $396.5 million in net revenue from product sales primarily in the U.S. compared to $214.2 million in total revenues, which included $213.9 million in net revenues from product sales for the fiscal year ended December 31, 2022. FIRDAPSE\u00ae net sales were approximately $258.4 million for the fiscal year ended December 31, 2023 and FYCOMPA\u00ae net sales were approximately $138.1 million for the period between January 24, 2023 (date of acquisition) and December 31, 2023. All net revenue from product sales during the fiscal year ended December 31, 2022 were from sales of FIRDAPSE\u00ae. The increase of approximately $182.6 million in net product revenues when comparing the fiscal year ended December 31, 2023 and 2022 was primarily due to the acquisition of FYCOMPA\u00ae during January 2023, and related product sales, and increases in FIRDAPSE\u00ae sales volumes of approximately 12% (which included patients who were transferred to FIRDAPSE\u00ae in the first and second quarter of 2022 when RUZURGI\u00ae was removed from the market) and net price increases. Net revenues from product sales of FIRDAPSE\u00ae increased by 20.8% from 2022 to 2023. Product revenue for FYCOMPA\u00ae in 2024 will be affected by differences in variable consideration (gross-to-net) compared to 2023, when revenues were booked under Eisai\u2019s cost arrangements with distributors and government authorities. Starting on January 1, 2024, all such costs are tied to arrangements between us and those distributors and government agencies, which costs are likely to be higher than Eisai\u2019s costs, thereby increasing the gross-to-net deductions for FYCOMPA\u00ae and correspondingly decreasing FYCOMPA\u00ae net product revenue. 65",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "Index to Financial Statements\n\n| For the year ended December 31, | Change |\n| 2023 | 2022 | $ | % |\n| Research and development expenses | $ | 10,156 | $ | 18,060 | (7,904 | ) | (43.8 | ) |\n| Acquired in-process research and development | 81,513 | \u2014 | 81,513 | \u2014 |\n| Employee stock-based compensation | 1,481 | 1,729 | (248 | ) | (14.3 | ) |\n| Total research and development expenses | $ | 93,150 | $ | 19,789 | 73,361 | 370.7 |",
            "type": "table"
        },
        {
            "id": 69,
            "context": "Index to Financial Statements\n\n| For the year ended December 31, | Change |\n| 2023 | 2022 | $ | % |\n| Selling | $ | 86,689 | $ | 29,469 | 57,220 | 194.2 |\n| General and administrative | 34,252 | 21,438 | 12,814 | 59.8 |\n| Employee stock-based compensation | 12,769 | 6,178 | 6,591 | 106.7 |\n| Total selling, general and administrative expenses | $ | 133,710 | $ | 57,085 | 76,625 | 134.2 |\n| For the year ended December 31, |\n| 2023 | 2022 |\n| Interest income (expense), net | $ | 4,675 | $ | 3,550 |\n| Dividend income | \u2014 | 93 |\n| Realized gains (losses) from the sale of available-for-sale securities | \u2014 | (762 | ) |\n| Net gains (losses) recognized during the period on equity securities | 3,024 | \u2014 |\n| Total other income, net | $ | 7,699 | $ | 2,881 |",
            "type": "table"
        },
        {
            "id": 70,
            "context": "Index to Financial Statements\n\n| \u2022 | the cost of diligence in seeking potential acquisitions and of the completion of such acquisitions, if any future acquisitions occur; |\n| \u2022 | future clinical trial results; |\n| \u2022 | the scope, rate of progress and cost of our clinical trials and other product development activities; |\n| \u2022 | the terms and timing of any collaborative, licensing and other arrangements that we may establish; |\n| \u2022 | the cost and timing of regulatory approvals; |\n| \u2022 | the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products; |\n| \u2022 | the amount of net revenues that we report from sales of FIRDAPSE\u00ae, FYCOMPA\u00ae and AGAMREE\u00ae; |\n| \u2022 | the effect of competition and market developments; |\n| \u2022 | the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights; and |\n| \u2022 | the extent to which we acquire or invest in other products. |",
            "type": "table"
        },
        {
            "id": 71,
            "context": "Index to Financial Statements\n\n| \u2022 | Payments due under our license agreement for FIRDAPSE\u00ae. We currently pay the following royalties under our license agreement: |\n| \u2022 | Royalties to our licensor for seven years from the first commercial sale of FIRDAPSE\u00ae equal to 7% of net sales (as defined in the FIRDAPSE\u00ae License Agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and |\n| \u2022 | Royalties to the third-party licensor of the rights sublicensed to us from the first commercial sale of FIRDAPSE\u00ae equal to 7% of net sales (as defined in the FIRDAPSE\u00ae License Agreement between BioMarin and the third-party licensor) in any calendar year for the duration of regulatory exclusivity within a territory and 3.5% for territories in any calendar year in territories without regulatory exclusivity. |\n| \u2022 | Payments due to Jacobus. In connection with our July 2022 settlement with Jacobus, we agreed to pay the following consideration to Jacobus: |\n| \u2022 | $30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022, $10 million was paid on the first anniversary of closing and the remaining $10 million will be paid on the second anniversary of closing; |\n| \u2022 | An annual royalty on Catalyst\u2019s net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst\u2019s FIRDAPSE\u00ae patents in the United States, 2.5% (with a minimum annual royalty of $5 million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and |",
            "type": "table"
        },
        {
            "id": 72,
            "context": "Index to Financial Statements\n\n| \u2022 | If Catalyst were to receive a priority review voucher for FIRDAPSE\u00ae or RUZURGI\u00ae in the future, 50% of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. |\n| \u2022 | Payments due under our asset purchase agreement for FYCOMPA\u00ae. In connection with our asset purchase agreement with Eisai Co., Ltd. (Eisai): |\n| \u2022 | We paid at closing a $160 million upfront cash payment, plus $1.6 million for reimbursement of certain prepayments. Eisai was also eligible to receive a contingent payment of $25 million if a patent term extension for FYCOMPA\u00ae was approved until June 8, 2026 by the USPTO, which request for reconsideration of the patent term extension was denied by the USPTO in June 2023; |\n| \u2022 | Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to 12% on net sales greater than $10 million and less than $100 million, 17% on net sales of greater than $100 million and less than $125 million and 22% on net sales greater than $125 million prior to the date of generic entry. Royalties equal to 6% on net sales greater than $10 million and less than $100 million, 8.5% on net sales of greater than $100 million and less than $125 million and 11% on net sales greater than $125 million after the date of generic entry. |\n| \u2022 | Concurrently with the acquisition, the parties entered into two related agreements: (i) a short-term TSA for commercial and manufacturing services (to which transition services ended on December 31, 2023) and (ii) a long-term Supply Agreement for the manufacturing of FYCOMPA\u00ae. Under the TSA, Eisai provided certain commercial and manufacturing services to the Company for a transition period following the closing of the acquisition. Further, under the Supply Agreement, Eisai will manufacture FYCOMPA\u00ae for the Company for a period of seven years (or such longer period as is set forth in the Supply Agreement) following the closing of the acquisition. |\n| \u2022 | Payments due under our license agreement for AGAMREE\u00ae. In connection with our recent acquisition from Santhera: |\n| \u2022 | At closing we paid a $75 million initial cash payment. |\n| \u2022 | In the fourth quarter of 2023, following regulatory approval of Santhera\u2019s NDA by the FDA, we paid a regulatory milestone payment of $36 million. We are also obligated to pay additional regulatory milestone payments upon regulatory approval by the FDA in the U.S. of an NDA for the product for the first, second, and third additional indications in the amounts of $50 million, $45 million, and $45 million, respectively. |\n| \u2022 | We are obligated to pay sales-based milestone payments if the applicable amount of net sales of all products in the territory in a single calendar year reach one of more of the net sales threshold levels set forth in the AGAMREE\u00ae License Agreement. |\n| \u2022 | Until January 1, 2026, we are obligated to purchase all of the requirements for product solely from Santhera, and Santhera is required to manufacture, supply, and sell product to us at an agreed upon supply price. |\n| \u2022 | Simultaneously, we made a strategic equity investment into Santhera by acquiring 1,414,688 of Santhera\u2019s post reverse-split ordinary shares (representing approximately 11.26% of Santhera\u2019s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the approximately $15.7 million USD in equity investment proceeds, inclusive of the approximately $13.5 million USD fair value of the investment in Santhera and approximately $2.2 million USD of transaction costs included in acquired in-process research and development, to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE\u00ae. |\n| \u2022 | Purchase commitment. We have entered into a purchase commitment with a contract manufacturing organization for approximately $0.5 million per year. The agreement expires in December 2024. |",
            "type": "table"
        },
        {
            "id": 73,
            "context": "Index to Financial Statements\n\n| \u2022 | Lease for office space. We operate our business in leased office space in Coral Gables, Florida. We lease approximately 10,700 square feet of office space and we pay annual rent of approximately $0.5 million. |\n| \u2022 | Whether we will be able to continue to successfully market and sell FIRDAPSE\u00ae and FYCOMPA\u00ae while maintaining full compliance with applicable federal and state laws, rules and regulations; |\n| \u2022 | Whether our estimates of the size of the market for FIRDAPSE\u00ae for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) will prove to be accurate; |\n| \u2022 | Whether our supplemental New Drug Application (sNDA) seeking to increase the maximum daily dosage of FIRDAPSE\u00ae from 80 mg to 100 mg will be approved by the U.S. Food and Drug Administration (FDA); |\n| \u2022 | Whether the daily dose of FIRDAPSE\u00ae taken by patients changes over time and affects our results of operations; |\n| \u2022 | Whether we will be able to locate LEMS patients who are undiagnosed or are misdiagnosed with other diseases; |\n| \u2022 | Whether patients will discontinue from the use of FIRDAPSE\u00ae and FYCOMPA\u00ae at rates that are higher than historically experienced or are higher than we project; |\n| \u2022 | Whether new FIRDAPSE\u00ae patients and new FYCOMPA\u00ae patients can be successfully titrated to stable therapy; |\n| \u2022 | Whether we can continue to market FIRDAPSE\u00ae and FYCOMPA\u00ae on a profitable and cash flow positive basis; |\n| \u2022 | Whether we will successfully launch AGAMREE\u00ae in the first quarter of 2024 as we currently plan; |\n| \u2022 | Whether we will be able to successfully commercialize AGAMREE\u00ae in the territory; |\n| \u2022 | Whether we will be able to demonstrate, to the satisfaction of the FDA and third-party payors, whether AGAMREE\u00ae offers advantages compared to corticosteroids or competitor\u2019s products; |\n| \u2022 | Whether the acquisition of AGAMREE\u00ae will prove to be accretive to EBITDA and EPS in 2024 and beyond; |\n| \u2022 | Whether any revenue or earnings guidance that we provide to the public market will turn out to be accurate; |\n| \u2022 | Whether payors will provide coverage and reimburse for our products at the price that we charge for our products; |\n| \u2022 | The ability of our third-party suppliers and contract manufacturers to supply sufficient product to meet our customers\u2019 needs in future periods; |",
            "type": "table"
        },
        {
            "id": 74,
            "context": "Index to Financial Statements\n\n| \u2022 | The ability of our third-party suppliers and contract manufacturers to maintain compliance with current Good Manufacturing Practices (cGMP); |\n| \u2022 | The ability of those third parties that distribute our products to maintain compliance with applicable law; |\n| \u2022 | Our ability to maintain compliance with applicable rules relating to our patient assistance programs for our products; |\n| \u2022 | Our ability to maintain compliance with the applicable rules that relate to our contributions to 501(c)(3) organizations that support patients in financial need; |\n| \u2022 | The scope of our intellectual property and the outcome of any challenges to our intellectual property, and, conversely, whether any third-party intellectual property presents unanticipated obstacles for FIRDAPSE\u00ae, FYCOMPA\u00ae, or AGAMREE\u00ae; |\n| \u2022 | Whether there will be a post-closing review by antitrust regulators of our previous acquisition transactions, and the outcome of any such reviews if they occur; |\n| \u2022 | Whether we will be able to acquire additional drug products under development, complete development required to commercialize such products, and thereafter, if such products are approved for commercialization, successfully market such products; |\n| \u2022 | Whether our patents will be sufficient to prevent generic competition for FIRDAPSE\u00ae and AGAMREE\u00ae after our orphan drug exclusivity for each product expires; |\n| \u2022 | Whether we will be successful in our litigation to enforce our patents against the Paragraph IV challengers who have filed Abbreviated New Drug Applications (ANDAs) seeking to introduce generic versions of FIRDAPSE\u00ae and FYCOMPA\u00ae; |\n| \u2022 | The impact on our profits and cash flow of adverse changes in reimbursement and coverage policies or regulations from government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators, or the impact of pricing pressures enacted by industry organizations, the federal government or the government of any state, including as a result of increased scrutiny over pharmaceutical pricing or otherwise; |\n| \u2022 | Changes in the healthcare industry and the effect of political pressure from and actions by the President, Congress and/or medical professionals seeking to reduce prescription drug costs, and changes to the healthcare industry occasioned by any future changes in laws relating to the pricing of drug products, including changes made in the Inflation Reduction Act of 2022, or changes in the healthcare industry generally; |\n| \u2022 | Whether we and Santhera Pharmaceuticals can successfully develop additional indications for AGAMREE\u00ae and obtain the ability to commercialize the product for these additional indications; |\n| \u2022 | The state of the economy generally and its impact on our business; |\n| \u2022 | The scope, rate of progress and expense of our clinical trials and studies, pre-clinical studies, proof-of-concept studies, and our other drug development activities, and whether our trials and studies will be successful; |\n| \u2022 | Our ability to complete any clinical trials and studies that we may undertake on a timely basis and within the budgets we establish for such trials and studies; |\n| \u2022 | Whether FIRDAPSE\u00ae can be successfully commercialized in Canada on a profitable basis through KYE Pharmaceuticals, our collaboration partner in Canada; |\n| \u2022 | The impact on sales of FIRDAPSE\u00ae in the United States if an amifampridine product is purchased in Canada for use in the United States; |\n| \u2022 | Whether DyDo will be able to obtain approval to commercialize FIRDAPSE\u00ae in Japan; and |\n| \u2022 | Whether our plans to expand the reach of FIRDAPSE\u00ae and AGAMREE\u00ae into other global regions will be successful. |",
            "type": "table"
        },
        {
            "id": 75,
            "context": "Index to Financial Statements\nItem\u20097A.\nQuantitative and Qualitative Disclosures About Market Risk\nMarket risk represents the risk of changes in the value of market risk-sensitive instruments caused by fluctuations in interest rates, foreign exchange rates and commodity prices. Changes in these factors could cause fluctuations in our results of operations and cash flows. Our exposure to interest rate risk is currently confined to our cash and short-term investments that are from time to time invested in highly liquid money market funds and U.S. Treasuries. The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. We do not use derivative financial instruments in our investment portfolio. Our cash and investments policy emphasizes liquidity and preservation of principal over other portfolio considerations.",
            "type": "paragraph"
        },
        {
            "id": 76,
            "context": "Item\u20098.\nFinancial Statements and Supplementary Data\nSee the list of financial statements filed with this report under Item 15 below.\n\nItem\u20099.\nChanges in and Disagreements with Accountants on Accounting and Financial Disclosure\nNone.\n\nItem\u20099A.\nControls and Procedures\nDisclosure Controls and Procedures We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. The term \u201cdisclosure controls and procedures\u201d, as defined in Rules 13a-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934 (the \u201cExchange Act\u201d), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission\u2019s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company\u2019s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.",
            "type": "paragraph"
        },
        {
            "id": 77,
            "context": "Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of December 31, 2023, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports filed or submitted by us under the Securities Exchange Act of 1934, as amended, was recorded, processed, summarized or reported within the time periods specified in the rules and regulations of the SEC, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports was accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "Management\u2019s Annual Assessment of Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our consolidated financial statements.",
            "type": "paragraph"
        },
        {
            "id": 79,
            "context": "73\nIndex to Financial Statements\nItem\u20099B.\nOther Information\nNot applicable.\nPART III\n\nItem\u200910.\nDirectors and Executive Officers of the Registrant The information required by this item will be contained in our definitive proxy statement, or Proxy Statement, to be filed with the SEC in connection with our 2024 Annual Meeting of Stockholders. Our Proxy Statement for the 2024 Annual Meeting of Stockholders is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2023 and is incorporated into this report by this reference.",
            "type": "paragraph"
        },
        {
            "id": 80,
            "context": "We have adopted a code of ethics that applies to our chief executive officer, chief financial officer, and to all of our other officers, directors, employees and agents. The code of ethics is available on our website at www.catalystpharma.com. We intend to disclose future amendments to, or waivers from, certain provisions of our code of ethics on the above website within five business days following the date of such amendment or waiver.",
            "type": "paragraph"
        },
        {
            "id": 81,
            "context": "Item\u200911.\nExecutive Compensation\nThe information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.\n\nItem\u200912.\nSecurity Ownership of Certain Beneficial Owners and Management\nThe information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.\n\nItem\u200913.\nCertain Relationships and Related Transactions\nThe information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.\n\nItem\u200914.\nPrincipal Accounting Fees and Services\nThe information required by this item will be set forth in the Proxy Statement and is incorporated into this report by this reference.\n74\nIndex to Financial Statements\nItem\u200915.\nExhibits and Financial Statement Schedules\nDocuments filed as part of this report.\nThe following financial statements of Catalyst Pharmaceuticals, Inc. and Reports of Grant Thornton LLP, independent registered public accounting firm, are included in this report:\nReports of Grant Thornton LLP, Independent Registered Public Accounting Firm.\nConsolidated Balance Sheets as of December 31, 2023 and 2022.\nConsolidated Statements of Operations and Comprehensive Income for the years ended December 31, 2023, 2022 and 2021.\nConsolidated Statements of Changes in Stockholders\u2019 Equity for the years ended December 31, 2023, 2022 and 2021.\nConsolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021.\nNotes to Consolidated Financial Statements.\nList of financial statement schedules. All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.\nList of exhibits required by Item 601 of Regulation S-K. See part (b) below.\nExhibits.\n\n| Incorporated by Reference |\n| ExhibitNumber | Description of Exhibit | Form | File Number | Date ofFiling | ExhibitNumber | FiledHerewith |\n| 2.1 | Agreement and Plan of Merger, dated August 14, 2006, between the Company and Catalyst Pharmaceutical Partners, Inc., a Florida corporation | S-1 | 333-136039 | 9/1/2006 | 10.9 |\n| 2.2 | Asset Purchase Agreement by and between Eisai Co., Ltd. and the Company, dated as of December 17, 2022 | 8-K | 001-33057 | 12/22/2022 | 2.1 |\n| 3.1 | Certificate of Incorporation | S-1 | 333-136039 | 7/25/2006 | 3.1 |\n| 3.2 | Amendment to Certificate of Incorporation | S-1 | 333-136039 | 7/25/2006 | 3.2 |\n| 3.3 | Amendment to Certificate of Incorporation | DEF 14A | 001-33057 | 3/30/2015 | Annex A |\n| 3.4 | Amendment to Certificate of Incorporation | 8-K | 001-33057 | 8/21/2020 | 3.1 |\n| 3.5 | By-Laws | S-1 | 333-136039 | 9/1/2006 | 3.3 |\n| 3.6 | Amendment to By-Laws | 8-K | 001-33057 | 11/27/2019 | 3.1 |\n| 4.1 | Specimen Stock Certificate for Common Stock | S-1 | 333-136039 | 9/1/2006 | 4.1 |\n| 4.2 | Description of the Company\u2019s Capital Stock | 10-K | 001-33057 | 3/16/2023 | 4.5 |\n| 10.1(a)+ | Offer Letter between the Company and Richard J. Daly * | X |\n| 10.1(b)+ | Offer Letter between the Company and Michael W. Kalb* | X |\n| 10.1(c)+ | Separation Agreement between the Company and Patrick J. McEnany* | X |\n| 10.1(d)+ | Separation Agreement between the Company and Alicia Grande * | X |\n| 10.2(a)+ | 2014 Stock Incentive Plan | DEF 14A | 001-33057 | 3/19/2014 | Annex A |\n| 10.2(b)+ | Amendment No. 1 to 2014 Stock Incentive Plan | DEF 14A | 001-33057 | 4/29/2016 | Annex A |\n| 10.2(c)+ | Amendment No. 2 to 2014 Stock Incentive Plan | DEF 14A | 001-33057 | 4/14/2017 | Annex A |\n| 10.3(a)+ | 2018 Stock Incentive Plan | DEF 14A | 001-33057 | 4/17/2018 | Annex A |\n| 10.3(b)+ | Amendment No. 1 to 2018 Stock Incentive Plan | DEF 14A | 001-33057 | 7/7/2020 | Annex A |\n| 10.3(c)+ | Amendment No. 2 to 2018 Stock Incentive Plan | DEF 14A | 001-33057 | 10/25/2021 | Annex A |\n| 10.3(d)+ | Amendment No. 3 to 2018 Stock Incentive Plan | DEF 14A | 001-33057 | 7/12/2023 | Annex A |\n| 10.4+ | Severance and Change in Control Plan | X |\n| 10.5(a) | Lease Agreement between the Company and 355 Alhambra Plaza, Ltd. | 10-Q | 001-33057 | 5/14/2007 | 10.1 |",
            "type": "table"
        },
        {
            "id": 82,
            "context": "75\nIndex to Financial Statements\n\n| Incorporated by Reference |\n| ExhibitNumber | Description of Exhibit | Form | File Number | Date ofFiling | ExhibitNumber | FiledHerewith |\n| 10.5(b) | First Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC | 10-Q | 001-33057 | 8/15/2011 | 10.1 |\n| 10.5(c) | Second Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC | 8-K | 001-33057 | 2/20/2014 | 10.1 |\n| 10.5(d) | Third Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC | 8-K | 001-33057 | 3/27/2015 | 10.1 |\n| 10.5(e) | Fourth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC | 8-K | 001-33057 | 8/17/2018 | 10.1 |\n| 10.5(f) | Fifth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC | 8-K | 001-33057 | 5/13/2020 | 10.1 |\n| 10.6 | License Agreement, dated as of December 13, 2011, among New York University, the Feinstein Institute for Medical Research, and the Company | 10-K | 001-33057 | 3/30/2012 | 10.15 |\n| 10.7(a) | License Agreement, dated as of October 26, 2012, between the Company and BioMarin | 8-K | 001-33057 | 10/31/2012 | 10.2 |\n| 10.7(b) | Amendment No. 1 to License Agreement, dated as of April 8, 2014, between the Company and BioMarin | 8-K | 001-33057 | 4/17/2014 | 10.1 |\n| 10.7(c) | Settlement Agreement, dated effective as of July 26, 2018, by and among (i) Aceras BioMedical, LLC, in its capacity as Stockholder Representative for the Former stockholders of Huxley Pharmaceuticals, Inc., (ii) BioMarin, and (iii) the Company | 10-Q | 001-33057 | 8/17/2018 | 10.1 |\n| 10.7(d) | Second Amendment to License Agreement, dated May 29, 2019, between the Company and BioMarin | 8-K | 001-33057 | 5/30/2019 | 10.1 |\n| 10.8 | Development, License and Commercialization Agreement, dated effective as of December 18, 2018, by and between Endo Ventures Limited and the Company | 8-K | 001-33057 | 12/26/2018 | 10.1 |\n| 10.9 | License and Supply Agreement, dated as of August 14, 2020, by and between KYE Pharmaceuticals, Inc. and the Company | 8-K | 001-33057 | 8/20/2020 | 10.1 |\n| 10.10 | License and Supply Agreement, dated as of June 28, 2021, by and between DyDo Pharma, Inc. and the Company | 8-K | 001-33057 | 6/28/2021 | 10.1 |\n| 10.11(a) | Settlement Agreement, dated July 11, 2022, by and between the Company and SERB SA, on the one hand, and Jacobus Pharmaceutical Company, Inc., PantherRx Specialty LLC, and Panther Specialty Holding Co., on the other hand | 8-K | 001-33057 | 7/12/2022 | 10.1 |\n| 10.11(b) | License and Asset Purchase Agreement, dated as of July 11, 2022, by and between Jacobus Pharmaceutical Company, Inc. and the Company | 8-K | 001-33057 | 7/12/2022 | 10.2 |\n| 10.12(a) | Transition Services Agreement between Eisai, Inc. and the Company | 8-K | 001-33057 | 12/22/2022 | 10.1 |\n| 10.12(b) | Amendment to Transition Services Agreement, dated as of July 31, 2023, made by and between the Company and Eisai | 10-Q | 001-33057 | 8/9/2023 | 10.1 |\n| 10.12(c) | Supply Agreement between Eisai Co., Ltd. and the Company | 8-K | 001-33057 | 12/22/2022 | 10.2 |\n| 10.13(a) | License and Collaboration Agreement, executed and delivered as of June 19, 2023, by and between Santhera, its wholly-owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG and the Company | 8-K | 001-33057 | 6/23/2023 | 10.1 |\n| 10.13(b) | Investment Agreement, dated as of June 19, 2023, by and between Santhera and the Company | 8-K | 001-33057 | 6/23/2023 | 10.2 |\n| 21.1 | Subsidiaries of the Registrant | 10-K | 001-33057 | 3/16/2020 | 21.1 |\n| 23.1 | Consent of Independent Registered Public Accounting Firm | X |",
            "type": "table"
        },
        {
            "id": 83,
            "context": "Index to Financial Statements\n\n| Incorporated by Reference |\n| ExhibitNumber | Description of Exhibit | Form | FileNumber | DateofFiling | ExhibitNumber | FiledHerewith |\n| 31.1 | Section 302 CEO Certification | X |\n| 31.2 | Section 302 CFO Certification | X |\n| 32.1 | Section 906 CEO Certification | X |\n| 32.2 | Section 906 CFO Certification | X |\n| 97.1 | Clawback Policy | X |\n| 101.INS | XBRL Instance Document |\n| 101.SCH | XBRL Taxonomy Extension Schema |\n| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase |\n| 101.DEF | XBRL Taxonomy Extension Definition Linkbase |\n| 101.LAB | XBRL Taxonomy Extension Label Linkbase |\n| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase |\n| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |\n| * | Certain identified information has been excluded from these exhibits because it is both (i) not material, and (ii) would likely cause competitive harm to the Company if publicly disclosed. |\n| + | Management contract or compensatory plan. |",
            "type": "table"
        },
        {
            "id": 84,
            "context": "Index to Financial Statements\n\n| CATALYST PHARMACEUTICALS, INC. |\n| By: | /s/ Richard J. Daly |\n| Richard J. Daly, |\n| President and CEO |\n| Signature | Title | Date |\n| /s/ Richard J. Daly Richard J. Daly | President and Chief Executive Officer (Principal Executive Officer) | February 28, 2024 |\n| /s/ Michael W. Kalb Michael W. Kalb | Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | February 28, 2024 |\n| /s/ Patrick J. McEnany | Chairman of the Board of Directors | February 28, 2024 |\n| Patrick J. McEnany |\n| /s/ Charles B. O\u2019Keeffe | Director | February 28, 2024 |\n| Charles B. O\u2019Keeffe |\n| /s/ David S. Tierney, M.D. | Director | February 28, 2024 |\n| David S. Tierney, M.D. |\n| /s/ Donald A. Denkhaus | Director | February 28, 2024 |\n| Donald A. Denkhaus |\n| /s/ Molly Harper | Director | February 28, 2024 |\n| Molly Harper |\n| /s/ Tamar Thompson | Director | February 28, 2024 |\n| Tamar Thompson |",
            "type": "table"
        },
        {
            "id": 85,
            "context": "Index to Financial Statements\nhttp://fasb.org/us-gaap/2023#LiabilitiesCurrent http://fasb.org/us-gaap/2023#LiabilitiesCurrent 6 years P5Y P5Y P3Y\n\n| Reports of Independent Registered Public Accounting Firm (PCAOB ID Number 248 ) | F-2 |\n| Consolidated Balance Sheets | F-4 |\n| Consolidated Statements of Operations and Comprehensive Income | F-5 |\n| Consolidated Statements of Changes in Stockholders\u2019 Equity | F-6 |\n| Consolidated Statements of Cash Flows | F-7 |\n| Notes to Consolidated Financial Statements | F-8 |",
            "type": "table"
        },
        {
            "id": 86,
            "context": "| December 31, 2023 | December 31, 2022 |\n| ASSETS |\n| Current Assets: |\n| Cash and cash equivalents | $ | 137,636 | $ | 298,395 |\n| Accounts receivable, net | 53,514 | 10,439 |\n| Inventory | 15,644 | 6,805 |\n| Prepaid expenses and other current assets | 12,535 | 5,167 |\n| Total current assets | 219,329 | 320,806 |\n| Operating lease right-of-use asset | 2,508 | 2,770 |\n| Property and equipment, net | 1,195 | 847 |\n| License and acquired intangibles, net | 194,049 | 32,471 |\n| Deferred tax assets, net | 36,544 | 18,736 |\n| Investment in equity securities | 16,489 | \u2014 |\n| Total assets | $ | 470,114 | $ | 375,630 |\n| LIABILITIES AND STOCKHOLDERS\u2019 EQUITY |\n| Current Liabilities: |\n| Accounts payable | $ | 14,795 | $ | 3,975 |\n| Accrued expenses and other liabilities | 61,268 | 53,613 |\n| Total current liabilities | 76,063 | 57,588 |\n| Operating lease liability, net of current portion | 3,188 | 3,557 |\n| Other non-current liabilities | 2,982 | 14,064 |\n| Total liabilities | 82,233 | 75,209 |\n| Commitments and contingencies (Note 12) |\n| Stockholders\u2019 Equity: |\n| Preferred stock, $ 0.001 par value, 5,000,000 shares authorized: no ne issued and outstanding at December 31, 2023 and 2022 | \u2014 | \u2014 |\n| Common stock, $ 0.001 par value, 200,000,000 shares authorized; 107,121,549 shares and 105,263,031 shares issued and outstanding at December 31, 2023 and 2022, respectively | 107 | 105 |\n| Additional paid-in capital | 266,488 | 250,430 |\n| Retained earnings | 121,272 | 49,862 |\n| Accumulated other comprehensive income (Note 4) | 14 | 24 |\n| Total stockholders\u2019 equity | 387,881 | 300,421 |\n| Total liabilities and stockholders\u2019 equity | $ | 470,114 | $ | 375,630 |",
            "type": "table"
        },
        {
            "id": 87,
            "context": "| Year Ended December 31, |\n| 2023 | 2022 | 2021 |\n| Revenues: |\n| Product revenue, net | $ | 396,502 | $ | 213,938 | $ | 137,997 |\n| License and other revenue | 1,702 | 265 | 2,836 |\n| Total revenues | 398,204 | 214,203 | 140,833 |\n| Operating costs and expenses: |\n| Cost of sales (a) | 51,967 | 34,393 | 21,884 |\n| Research and development | 93,150 | 19,789 | 16,936 |\n| Selling, general and administrative (a) | 133,710 | 57,085 | 49,628 |\n| Amortization of intangible assets | 32,565 | 1,098 | \u2014 |\n| Total operating costs and expenses | 311,392 | 112,365 | 88,448 |\n| Operating income | 86,812 | 101,838 | 52,385 |\n| Other income, net | 7,699 | 2,881 | 282 |\n| Net income before income taxes | 94,511 | 104,719 | 52,667 |\n| Income tax provision | 23,101 | 21,640 | 13,185 |\n| Net income | $ | 71,410 | $ | 83,079 | $ | 39,482 |\n| Net income per share: |\n| Basic | $ | 0.67 | $ | 0.80 | $ | 0.38 |\n| Diluted | $ | 0.63 | $ | 0.75 | $ | 0.37 |\n| Weighted average shares outstanding: |\n| Basic | 106,279,736 | 103,374,606 | 103,379,349 |\n| Diluted | 113,753,154 | 111,375,631 | 107,795,585 |\n| Net income | $ | 71,410 | $ | 83,079 | $ | 39,482 |\n| Other comprehensive income (Note 4): |\n| Unrealized gain (loss) on available-for-sale securities, net of tax of $ 4 , ($ 54 ) and $ 46 , respectively | ( 10 | ) | 172 | ( 179 | ) |\n| Comprehensive income | $ | 71,400 | $ | 83,251 | $ | 39,303 |\n| (a) | exclusive of amortization of intangible assets |",
            "type": "table"
        },
        {
            "id": 88,
            "context": "| PreferredStock | Common Stock | AdditionalPaid-inCapital | RetainedEarnings(AccumulatedDeficit) | AccumulatedOtherComprehensiveGain (Loss) | Total |\n| Shares | Amount |\n| Balance at December 31, 2020 | $ | \u2014 | 103,782 | $ | 104 | $ | 223,168 | $ | ( 53,705 | ) | $ | 31 | $ | 169,598 |\n| Stock-based compensation | \u2014 | \u2014 | \u2014 | 6,073 | \u2014 | \u2014 | 6,073 |\n| Exercise of stock options for common stock | \u2014 | 1,328 | 1 | 4,098 | \u2014 | \u2014 | 4,099 |\n| Issuance of common stock upon vesting of restricted stock units, net | \u2014 | 91 | \u2014 | ( 153 | ) | \u2014 | \u2014 | ( 153 | ) |\n| Repurchase of common stock | \u2014 | ( 2,208 | ) | ( 2 | ) | \u2014 | ( 12,087 | ) | \u2014 | ( 12,089 | ) |\n| Other comprehensive gain (loss) | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | ( 179 | ) | ( 179 | ) |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | 39,482 | \u2014 | 39,482 |\n| Balance at December 31, 2021 | \u2014 | 102,993 | 103 | 233,186 | ( 26,310 | ) | ( 148 | ) | 206,831 |\n| Stock-based compensation | \u2014 | \u2014 | \u2014 | 7,907 | \u2014 | \u2014 | 7,907 |\n| Exercise of stock options for common stock | \u2014 | 3,172 | 2 | 9,567 | \u2014 | \u2014 | 9,569 |\n| Issuance of common stock upon vesting of restricted stock units, net | \u2014 | 98 | \u2014 | ( 230 | ) | \u2014 | \u2014 | ( 230 | ) |\n| Repurchase of common stock | \u2014 | ( 1,000 | ) | \u2014 | \u2014 | ( 6,907 | ) | \u2014 | ( 6,907 | ) |\n| Other comprehensive gain (loss) | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | 172 | 172 |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | 83,079 | \u2014 | 83,079 |\n| Balance at December 31, 2022 | \u2014 | 105,263 | 105 | 250,430 | 49,862 | 24 | 300,421 |\n| Stock-based compensation | \u2014 | \u2014 | \u2014 | 14,250 | \u2014 | \u2014 | 14,250 |\n| Exercise of stock options for common stock | \u2014 | 1,652 | 2 | 2,790 | \u2014 | \u2014 | 2,792 |\n| Issuance of common stock upon vesting of restricted stock units, net | \u2014 | 207 | \u2014 | ( 982 | ) | \u2014 | \u2014 | ( 982 | ) |\n| Other comprehensive gain (loss) | \u2014 | \u2014 | \u2014 | \u2014 | \u2014 | ( 10 | ) | ( 10 | ) |\n| Net income | \u2014 | \u2014 | \u2014 | \u2014 | 71,410 | \u2014 | 71,410 |\n| Balance at December 31, 2023 | $ | \u2014 | 107,122 | $ | 107 | $ | 266,488 | $ | 121,272 | $ | 14 | $ | 387,881 |",
            "type": "table"
        },
        {
            "id": 89,
            "context": "| Year Ended December 31, |\n| 2023 | 2022 | 2021 |\n| Operating Activities: |\n| Net income | $ | 71,410 | $ | 83,079 | $ | 39,482 |\n| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |\n| Depreciation | 316 | 141 | 192 |\n| Stock-based compensation | 14,250 | 7,907 | 6,073 |\n| Amortization of intangible assets | 32,565 | 1,098 | \u2014 |\n| Deferred taxes | ( 17,818 | ) | 4,937 | 9,316 |\n| Accretion of discount | 1,320 | 17 | ( 5 | ) |\n| Reduction in the carrying amount of right-of-use asset | 262 | 247 | 292 |\n| Realized loss on sale of available-for-sale securities | \u2014 | 762 | \u2014 |\n| Acquired research and development inventory expensed from asset acquisition | \u2014 | 4,130 | \u2014 |\n| Acquired inventory samples expensed from asset acquisition | 130 | \u2014 | \u2014 |\n| Acquired in-process research and development | 81,513 | \u2014 | \u2014 |\n| Change in fair value of equity securities | ( 3,024 | ) | \u2014 | \u2014 |\n| (Increase) decrease in: |\n| Accounts receivable, net | ( 43,075 | ) | ( 3,820 | ) | ( 632 | ) |\n| Inventory | ( 4,739 | ) | 1,065 | ( 3,219 | ) |\n| Prepaid expenses and other current assets | ( 5,792 | ) | ( 807 | ) | 3,977 |\n| Increase (decrease) in: |\n| Accounts payable | 10,820 | 1,207 | ( 1,488 | ) |\n| Accrued expenses and other liabilities | 5,800 | 16,391 | 5,520 |\n| Operating lease liability | ( 338 | ) | ( 307 | ) | 864 |\n| Net cash provided by (used in) operating activities | 143,600 | 116,047 | 60,372 |\n| Investing Activities: |\n| Purchases of property and equipment | ( 231 | ) | ( 29 | ) | ( 1,021 | ) |\n| Purchases of investments | \u2014 | \u2014 | ( 10,000 | ) |\n| Proceeds from sale of available-for-sale securities | \u2014 | 19,238 | \u2014 |\n| Payments in connection with asset acquisitions | ( 198,293 | ) | ( 10,000 | ) | \u2014 |\n| Acquisition of in-process research and development | ( 81,513 | ) | \u2014 | \u2014 |\n| Purchase of equity securities | ( 13,465 | ) | \u2014 | \u2014 |\n| Net cash provided by (used in) investing activities | ( 293,502 | ) | 9,209 | ( 11,021 | ) |\n| Financing Activities: |\n| Payment of employee withholding tax related to stock-based compensation | ( 982 | ) | ( 230 | ) | ( 153 | ) |\n| Proceeds from exercise of stock options | 2,792 | 9,569 | 4,099 |\n| Repurchase of common stock | \u2014 | ( 6,907 | ) | ( 12,089 | ) |\n| Payment of liabilities arising from asset acquisition | ( 12,667 | ) | ( 738 | ) | \u2014 |\n| Net cash provided by (used in) financing activities | ( 10,857 | ) | 1,694 | ( 8,143 | ) |\n| Net increase (decrease) in cash and cash equivalents | ( 160,759 | ) | 126,950 | 41,208 |\n| Cash and cash equivalents \u2013 beginning of period | 298,395 | 171,445 | 130,237 |\n| Cash and cash equivalents \u2013 end of period | $ | 137,636 | $ | 298,395 | $ | 171,445 |\n| Supplemental disclosures of cash flow information: |\n| Cash paid for income taxes | $ | 50,458 | $ | 7,667 | $ | 3,000 |\n| Cash paid for interest | $ | 705 | $ | \u2014 | $ | \u2014 |\n| Non-cash investing and financing activities: |\n| Operating lease liabilities arising from obtaining right-of-use assets | $ | \u2014 | $ | \u2014 | $ | 3,309 |\n| Liabilities arising from asset acquisition | $ | 1,915 | $ | 27,699 | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 90,
            "context": "| 1. | Organization and Description of Business. |\n| 2. | Basis of Presentation and Significant Accounting Policies. |\n| a. | PRINCIPLES OF CONSOLIDATION. The consolidated financial statements include the Company\u2019s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017. |\n| b. | USE OF ESTIMATES. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. |\n| c. | CASH AND CASH EQUIVALENTS. The Company considers all highly liquid instruments, purchased with an original maturity of three months or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has substantially all its cash and cash equivalents deposited with one financial institution. These amounts exceed federally insured limits. |\n| d. | INVESTMENTS. The Company invests in high credit-quality instruments in order to obtain higher yields on its cash available for investments. At December 31, 2023, investments consisted of U.S. Treasuries and an investment in equity securities. At December 31, 2022, investments consisted of U.S. Treasuries. Such investments are not insured by the Federal Deposit Insurance Corporation. |\n| e. | ACCOUNTS RECEIVABLE, NET. Accounts receivable is recorded net of customer allowance for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. At December 31, 2023 and December 31, 2022, the Company determined that an allowance for expected credit losses was not required. No accounts were written off during the periods presented. |",
            "type": "table"
        },
        {
            "id": 91,
            "context": "| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| f. | INVENTORY. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, work-in-process and finished goods. Costs to be capitalized as inventories primarily include third-party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. |\n| g. | PREPAID EXPENSES AND OTHER CURRENT ASSETS. Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid co-pay assistance program, amounts due from collaborative and license arrangements and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company\u2019s product development activities, including contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing consists of advances for the Company\u2019s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. |\n| h. | PROPERTY AND EQUIPMENT, NET. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from three to five years for computer equipment and software, from five to seven years for furniture and equipment, and from five to ten years for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred. |\n| i. | BUSINESS COMBINATIONS AND ASSET ACQUISITIONS. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. |\n| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| j. | INTANGIBLE ASSETS, NET. Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. |\n| k. | FAIR VALUE OF FINANCIAL INSTRUMENTS. The Company\u2019s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and accrued expenses and other liabilities. At December 31, 2023 and December 31, 2022, the fair value of these instruments approximated their carrying value. |\n| l. | FAIR VALUE MEASUREMENTS. Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity\u2019s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). |\n| Fair Value Measurements at Reporting Date Using (in thousands) |\n| Balances as ofDecember 31,2023 | Quoted Prices inActive Markets forIdenticalAssets/Liabilities(Level 1) | Significant OtherObservable Inputs(Level 2) | SignificantUnobservable Inputs(Level 3) |\n| Cash and cash equivalents: |\n| Money market funds | $ | 18,256 | $ | 18,256 | $ | \u2014 | $ | \u2014 |\n| U.S. Treasuries | $ | 94,523 | $ | 94,523 | $ | \u2014 | $ | \u2014 |\n| Investment in equity securities: |\n| Equity securities | $ | 16,489 | $ | 16,489 | $ | \u2014 | $ | \u2014 |\n| Balances as ofDecember 31,2022 | Quoted Prices inActive Markets forIdenticalAssets/Liabilities(Level 1) | Significant OtherObservable Inputs(Level 2) | SignificantUnobservable Inputs(Level 3) |\n| Cash and cash equivalents: |\n| Money market funds | $ | 168,853 | $ | 168,853 | $ | \u2014 | $ | \u2014 |\n| U.S. Treasuries | $ | 105,442 | $ | 105,442 | $ | \u2014 | $ | \u2014 |",
            "type": "table"
        },
        {
            "id": 92,
            "context": "| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| m. | OPERATING LEASES. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company\u2019s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company\u2019s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and non-lease components, which are accounted for separately. |\n| n. | SHARE REPURCHASES. In March 2021, the Company\u2019s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $ 40 million of the Company\u2019s common stock. |\n| o. | REVENUE RECOGNITION. |\n| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| For the Years Ended December 31, |\n| 2023 | 2022 | 2021 |\n| FIRDAPSE\u00ae | $ | 258,426 | $ | 213,938 | $ | 137,997 |\n| FYCOMPA\u00ae | 138,076 | \u2014 | \u2014 |\n| Total product revenue, net | $ | 396,502 | $ | 213,938 | $ | 137,997 |",
            "type": "table"
        },
        {
            "id": 93,
            "context": "| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| p. | RESEARCH AND DEVELOPMENT. Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research related services for the Company. |\n| q. | ADVERTISING EXPENSE. Advertising costs are expensed as incurred. The Company incurred approximately $ 9.1 million, $ 3.3 million and $ 2.9 million in advertising costs during the years ended December 31, 2023, 2022 and 2021, respectively, which are included in selling, general and administrative expenses in the Company\u2019s consolidated statements of operations and comprehensive income. |\n| r. | STOCK-BASED COMPENSATION. The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to three years . Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. |\n| s. | CONCENTRATION OF RISK. The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. |\n| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| t. | ROYALTIES. Royalties incurred in connection with the Company\u2019s license agreement for FIRDAPSE\u00ae, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. |\n| u. | INCOME TAXES. The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. |\n| v. | COMPREHENSIVE INCOME. U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders\u2019 equity. The Company\u2019s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2023, 2022 and 2021, and is comprised of net unrealized gains (losses) on the Company\u2019s available-for-sale securities. |\n| w. | NET INCOME PER COMMON SHARE. Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. |\n| For the Years Ended December 31, |\n| 2023 | 2022 | 2021 |\n| Basic weighted average common shares outstanding | 106,279,736 | 103,374,606 | 103,379,349 |\n| Effect of dilutive securities | 7,473,418 | 8,001,025 | 4,416,236 |\n| Diluted weighted average common shares outstanding | 113,753,154 | 111,375,631 | 107,795,585 |\n| x. | SEGMENT INFORMATION. Management has determined that the Company operates in one reportable segment, which is the development and commercialization of drug products. |\n| y. | RECLASSIFICATIONS. Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. |\n| z. | RECENTLY ISSUED ACCOUNTING STANDARDS. The Company did not adopt any accounting standards during the year ended December 31, 2023. |",
            "type": "table"
        },
        {
            "id": 94,
            "context": "| 2. | Basis of Presentation and Significant Accounting Policies (continued). |\n| 3. | Investments. |\n| Estimated Fair Value | Gross Unrealized Gains | Gross Unrealized Losses | Amortized Cost |\n| At December 31, 2023: |\n| U.S. Treasuries - Cash equivalents | $ | 94,523 | $ | 18 | $ | \u2014 | $ | 94,505 |\n| Total | $ | 94,523 | $ | 18 | $ | \u2014 | $ | 94,505 |\n| At December 31, 2022: |\n| U.S. Treasuries - Cash equivalents | $ | 105,442 | $ | 32 | $ | \u2014 | $ | 105,410 |\n| Total | $ | 105,442 | $ | 32 | $ | \u2014 | $ | 105,410 |\n| 2023 |\n| Due in one year or less | $ | 94,523 |\n| For the Years Ended December 31, |\n| 2023 | 2022 | 2021 |\n| Equity securities: |\n| Net gains (losses) recognized during the period on equity securities | $ | 3,024 | $ | \u2014 | $ | \u2014 |\n| Unrealized net gains (losses) recognized during the period on equity securities still held at the reporting date | $ | 3,024 | $ | \u2014 | $ | \u2014 |\n| 4. | Accumulated Other Comprehensive Income (loss). |\n| Total Accumulated Other Comprehensive Income (Loss) |\n| Balance at December 31, 2021 | $ | ( 148 | ) |\n| Other comprehensive gain (loss) before reclassifications | ( 590 | ) |\n| Amount reclassified from accumulated other comprehensive income (loss) | 762 |\n| Net current period other comprehensive gain | 172 |\n| Balance at December 31, 2022 | $ | 24 |\n| Other comprehensive gain (loss) before reclassifications | ( 10 | ) |\n| Net current period other comprehensive gain | ( 10 | ) |\n| Balance at December 31, 2023 | $ | 14 |\n| 5. | Inventory. |\n| December 31, 2023 | December 31, 2022 |\n| Raw materials | $ | 1,910 | $ | \u2014 |\n| Work-in-process | 4,573 | 5,543 |\n| Finished goods | 9,161 | 1,262 |\n| Total inventory | $ | 15,644 | $ | 6,805 |\n| 6. | Prepaid Expenses and Other Current Assets. |\n| December 31, 2023 | December 31, 2022 |\n| Prepaid manufacturing costs | $ | 2,005 | $ | 1,147 |\n| Prepaid tax | 1,238 | 44 |\n| Prepaid insurance | 1,332 | 1,224 |\n| Prepaid subscriptions fees | 1,299 | 808 |\n| Prepaid research fees | 1,500 | 178 |\n| Prepaid commercialization expenses | 3,038 | 592 |\n| Due from collaborative and licensing arrangements | 138 | 354 |\n| Prepaid conference and travel expenses | 771 | 234 |\n| Prepaid co-pay assistance program | 863 | 97 |\n| Other | 351 | 489 |\n| Total prepaid expenses and other current assets | $ | 12,535 | $ | 5,167 |",
            "type": "table"
        },
        {
            "id": 95,
            "context": "| 7. | Operating Leases. |\n| For the Years EndedDecember 31, |\n| 2023 | 2022 |\n| Operating lease cost | $ | 431 | $ | 431 |\n| For the Years EndedDecember 31, |\n| 2023 | 2022 |\n| Cash paid for amounts included in the measurement of lease liabilities: |\n| Operating cash flows | $ | 506 | $ | 492 |\n| Right-of-use assets obtained in exchange for lease obligations: |\n| Operating lease | $ | 89 | $ | 89 |\n| December 31, 2023 | December 31, 2022 |\n| Operating lease right-of-use assets | $ | 2,508 | $ | 2,770 |\n| Other current liabilities | $ | 369 | $ | 337 |\n| Operating lease liabilities, net of current portion | 3,188 | 3,557 |\n| Total operating lease liabilities | $ | 3,557 | $ | 3,894 |\n| 2024 | $ | 522 |\n| 2025 | 537 |\n| 2026 | 553 |\n| 2027 | 570 |\n| 2028 | 587 |\n| Thereafter | 1,440 |\n| Total lease payments | 4,209 |\n| Less: imputed interest | ( 652 | ) |\n| Total | $ | 3,557 |\n| 8. | Property and Equipment, Net. |\n| December 31, 2023 | December 31, 2022 |\n| Furniture and equipment | $ | 494 | $ | 273 |\n| Leasehold improvements | 991 | 980 |\n| Software | 433 | \u2014 |\n| Less: Accumulated depreciation | ( 723 | ) | ( 406 | ) |\n| Total property and equipment, net | $ | 1,195 | $ | 847 |\n| 9. | License and Acquired Intangibles, Net. |\n| Gross Carrying Value | Accumulated Amortization | Net Carrying Value |\n| Intangible assets: |\n| License and acquired intangibles for RUZURGI\u00ae | $ | 33,569 | $ | 3,418 | $ | 30,151 |\n| License and acquired intangibles for FYCOMPA\u00ae | 158,143 | 29,673 | 128,470 |\n| License and acquired intangibles for AGAMREE\u00ae | 36,000 | 572 | 35,428 |\n| Total | $ | 227,712 | $ | 33,663 | $ | 194,049 |\n| Gross Carrying Value | Accumulated Amortization | Net Carrying Value |\n| Intangible assets: |\n| License and acquired intangibles for RUZURGI\u00ae | $ | 33,569 | $ | 1,098 | $ | 32,471 |\n| Total | $ | 33,569 | $ | 1,098 | $ | 32,471 |",
            "type": "table"
        },
        {
            "id": 96,
            "context": "| 9. | License and Acquired Intangibles, Net (continued). |\n| 2024 | $ | 37,378 |\n| 2025 | 37,378 |\n| 2026 | 37,378 |\n| 2027 | 37,378 |\n| 2028 | 7,705 |\n| Thereafter | 36,832 |\n| Total | $ | 194,049 |\n| 10. | Accrued Expenses and Other Liabilities. |\n| 2023 | 2022 |\n| Accrued preclinical and clinical trial expenses | $ | 1,015 | $ | 479 |\n| Accrued professional fees | 4,730 | 1,619 |\n| Accrued compensation and benefits | 8,883 | 5,132 |\n| Accrued license fees | 24,437 | 20,444 |\n| Accrued purchases | 192 | 154 |\n| Operating lease liability | 369 | 337 |\n| Accrued variable consideration | 6,877 | 3,381 |\n| Accrued income tax | 729 | 8,702 |\n| Due to licensor | 12,540 | 13,127 |\n| Accrued interest payable | 1,031 | \u2014 |\n| Other | 465 | 238 |\n| Current accrued expenses and other liabilities | 61,268 | 53,613 |\n| Lease liability \u2013 non-current | 3,188 | 3,557 |\n| Due to licensor \u2013 non-current | 2,497 | 14,064 |\n| Other \u2013 non-current | 485 | \u2014 |\n| Non-current accrued expenses and other liabilities | 6,170 | 17,621 |\n| Total accrued expenses and other liabilities | $ | 67,438 | $ | 71,234 |\n| 11. | Collaborative and Licensing Arrangements. |\n| 11. | Collaborative and Licensing Arrangements (continued). |",
            "type": "table"
        },
        {
            "id": 97,
            "context": "| 11. | Collaborative and Licensing Arrangements (continued). |\n| 12. | Commitments and Contingencies. |\n| 12. | Commitments and Contingencies (continued). |\n| \u2022 | $ 30 million of cash, of which $ 10 million was paid at the closing of the settlement on July 11, 2022, $ 10 million was paid on the first anniversary of closing, and the remaining $ 10 million will be paid on the second anniversary of closing; |\n| \u2022 | An annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5 % (with a minimum annual royalty of $ 3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of the Company\u2019s FIRDAPSE\u00ae patents in the United States, 2.5 % (with a minimum annual royalty of $ 5 million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and |\n| \u2022 | If the Company were to receive a priority review voucher for FIRDAPSE\u00ae or RUZURGI\u00ae in the future, 50 % of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. |",
            "type": "table"
        },
        {
            "id": 98,
            "context": "| 12. | Commitments and Contingencies (continued). |\n| 13. | Agreements. |\n| a. | LICENSE AGREEMENT FOR FIRDAPSE\u00ae. On October 26, 2012 , the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to FIRDAPSE\u00ae. Under the license agreement, the Company pays: (i) royalties to the licensor for seven years from the first commercial sale of FIRDAPSE\u00ae equal to 7 % of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $ 100 million, and 10 % of net sales in North America in any calendar year in excess of $100 million; and (ii) royalties to the third-party licensor of the rights sublicensed to the Company for seven years from the first commercial sale of FIRDAPSE\u00ae equal to 7 % of net sales (as defined in the license agreement between BioMarin and the third-party licensor) in any calendar year for the duration of any regulatory exclusivity within a territory and 3.5 % for territories in any calendar year in territories without regulatory exclusivity. |\n| 13. | Agreements (continued). |\n| b. | LICENSE AGREEMENT FOR RUZURGI\u00ae. On July 11, 2022 (the Effective Date), the Company entered into an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI\u00ae in the United States and Mexico. |\n| License and acquired intangibles | $ | 33,569 |\n| Acquired research and development inventory expensed from asset acquisition | 4,130 |\n| Total purchase price | $ | 37,699 |",
            "type": "table"
        },
        {
            "id": 99,
            "context": "| 13. | Agreements (continued). |\n| c. | ACQUISITION OF U.S. RIGHTS FOR FYCOMPA\u00ae. On January 24, 2023 , the Company acquired the U.S. Rights for FYCOMPA\u00ae (perampanel) CIII a commercial stage epilepsy asset, from Eisai Co., Ltd. (Eisai). The aggregate consideration for the acquisition was $ 164.2 \u00a0million in cash, including the reimbursement of certain liabilities and the payment of transaction costs. |\n| Base cash payment | $ | 160,000 |\n| Cash paid for pro-rated prepaid expenses | 1,576 |\n| Reimbursement on base purchase price(i) | ( 3,238 | ) |\n| Transaction costs(ii) | 5,870 |\n| Total purchase consideration | $ | 164,208 |\n| (i) | Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. |\n| (ii) | As of December 31, 2023, the full $ 5.9 million has been paid in cash. |\n| Inventory | $ | 4,100 |\n| Prepaid expenses and other current assets (samples) | 130 |\n| Prepaid commercialization expenses | 1,576 |\n| Property and equipment, net | 433 |\n| License and acquired intangibles for FYCOMPA\u00ae | 158,143 |\n| Accrued preclinical and clinical trial expenses | ( 174 | ) |\n| Total purchase consideration | $ | 164,208 |\n| 13. | Agreements (continued). |\n| d. | LICENSE AGREEMENT FOR AGAMREE\u00ae (VAMOROLONE). |\n| Initial cash payment | $ | 75,000 |\n| Investment in Santhera | 13,465 |\n| Transaction costs | 6,513 |\n| Total purchase consideration | $ | 94,978 |\n| License and acquired intangibles for AGAMREE\u00ae\u00a0(vamorolone) (IPR&D) | $ | 81,513 |\n| Investment in Santhera(i) | 13,465 |\n| Total purchase consideration | $ | 94,978 |\n| (i) | The fair value of the investment in Santhera was determined based on the closing market price (CHF 8.25 ) of Santhera shares and the exchange rate ( 1.1537 ) of CHF to USD on the date the shares were transferred, July 19, 2023. |",
            "type": "table"
        },
        {
            "id": 100,
            "context": "| 13. | Agreements (continued). |\n| e. | AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES. The Company has entered into agreements with contract manufacturers for the manufacture of commercial drug and drug and study placebo for the Company\u2019s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company\u2019s trials and studies and with various entities for laboratories and other testing related to the Company\u2019s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. |\n| 14. | Income Taxes. |\n| 2023 | 2022 | 2021 |\n| Current - Federal | $ | 34,975 | $ | 12,858 | $ | 2,455 |\n| Current - State | 5,931 | 3,877 | 1,414 |\n| Deferred - Federal | ( 16,093 | ) | 4,739 | 8,620 |\n| Deferred - State | ( 1,712 | ) | 166 | 696 |\n| $ | 23,101 | $ | 21,640 | $ | 13,185 |\n| 2023 | 2022 | 2021 |\n| Statutory rate | 21.0 | % | 21.0 | % | 21.0 | % |\n| State tax | 3.1 | % | 3.1 | % | 3.4 | % |\n| Executive compensation limitation | 2.6 | % | 3.6 | % | 1.1 | % |\n| Tax credit | \u2014 | ( 1.9 | )% | ( 0.6 | )% |\n| Stock compensation windfall | ( 4.4 | )% | ( 5.6 | )% | ( 0.6 | )% |\n| Other | 2.1 | % | 0.5 | % | 0.7 | % |\n| 24.4 | % | 20.7 | % | 25.0 | % |\n| 2023 | 2022 |\n| Deferred tax assets: |\n| Start-up costs | $ | \u2014 | $ | 9,771 |\n| Deferred compensation | 6,473 | 4,706 |\n| Inventory | 448 | 296 |\n| Intangible assets | 24,847 | 52 |\n| Accrued expenses | 788 | \u2014 |\n| Operating lease liability | 854 | 953 |\n| Capitalized research | 4,927 | 4,255 |\n| Total deferred tax assets | 38,337 | 20,033 |\n| Deferred tax liabilities: |\n| Prepaid expenses | ( 1,023 | ) | ( 481 | ) |\n| Right-of use asset | ( 759 | ) | ( 860 | ) |\n| Other | ( 11 | ) | 44 |\n| Total deferred tax liabilities | ( 1,793 | ) | ( 1,297 | ) |\n| Deferred tax assets, net | $ | 36,544 | $ | 18,736 |\n| 14. | Income Taxes (continued). |\n| 15. | Stockholders\u2019 Equity. |",
            "type": "table"
        },
        {
            "id": 101,
            "context": "| 16. | Stock Compensation. |\n| 2023 | 2022 | 2021 |\n| Research and development | $ | 1,481 | $ | 1,729 | $ | 1,611 |\n| Selling, general and administrative | 12,769 | 6,178 | 4,462 |\n| Total stock-based compensation | $ | 14,250 | $ | 7,907 | $ | 6,073 |\n| 16. | Stock Compensation (continued). |\n| Number ofOptions | WeightedAverageExercise Price | WeightedAverageRemainingContractual Term(in years) | AggregateIntrinsic Value(in thousands) |\n| Outstanding at beginning of year | 12,309,108 | $ | 4.93 |\n| Granted | 3,598,535 | 14.62 |\n| Exercised or released | ( 1,651,345 | ) | 1.69 |\n| Forfeited or cancelled | ( 78,810 | ) | 11.83 |\n| Expired | \u2014 | \u2014 |\n| Outstanding at end of year | 14,177,488 | $ | 7.73 | 4.05 | $ | 130,966 |\n| Exercisable at end of year | 8,891,904 | $ | 4.45 | 2.78 | $ | 110,488 |\n| 2023 | 2022 | 2021 |\n| Weighted\u2013average fair value of granted stock options | $ | 8.66 | $ | 8.52 | $ | 3.24 |\n| Total fair value of vested stock options (in thousands) | $ | 8,278 | $ | 6,096 | $ | 6,421 |\n| Total intrinsic value of exercised stock options (in thousands) | $ | 22,265 | $ | 31,881 | $ | 3,623 |",
            "type": "table"
        },
        {
            "id": 102,
            "context": "| 16. | Stock Compensation (continued). |\n| 2023 | 2022 | 2021 |\n| Risk free interest rate | 3.55 % to 4.92 % | 1.27 % to 4.07 % | 0.34 % to 1.18 % |\n| Expected term | 4.5 to 5.2 years | 4.5 years | 4.5 to 4.8 years |\n| Expected volatility | 68.0 % to 71.0 % | 68.4 % to 69.5 % | 68.6 % to 72.8 % |\n| Expected dividend yield | \u2014 % | \u2014 % | \u2014 % |\n| Expected forfeiture rate | \u2014 % | \u2014 % | \u2014 % |\n| Number ofRestrictedStock Units | Weighted AverageGrant Date FairValue |\n| Nonvested balance at beginning of year | 752,500 | $ | 11.46 |\n| Granted | 370,117 | 13.67 |\n| Vested | ( 268,158 | ) | 11.25 |\n| Forfeited | \u2014 | \u2014 |\n| Nonvested balance at end of year | 854,459 | $ | 12.48 |\n| 17. | Benefit Plan. |\n| 18. | Subsequent Events. |",
            "type": "table"
        }
    ],
    "html_tables": [
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"text-decoration:underline\">Continue to commercialize FIRDAPSE</span><span style=\"text-decoration:underline\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span><span style=\"text-decoration:underline\"> for the treatment of LEMS and improve disease awareness</span>. We are currently commercializing FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the United States and through a sublicense to KYE Pharmaceuticals in Canada. We are working to expand awareness of the disease, including to physicians treating LEMS patients who have small-cell lung cancer, and helping health care providers and their patients understand the benefits of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. A cornerstone of our U.S. strategy is our continuing development of Catalyst Pathways<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>, our personalized treatment support program, and our development of the patient assistance programs that are required to further our goal that no LEMS patient be denied access to FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> for financial reasons within existing legal restrictions. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"text-decoration:underline\">Continue to commercialize FYCOMPA</span><span style=\"text-decoration:underline\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span>. In the first quarter of 2023, we acquired the U.S. rights to the epilepsy drug FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. We are currently successfully distributing and marketing FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. We believe that having a second marketed product adds substantially to our business franchise. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"text-decoration:underline\">Successfully launch AGAMREE</span><span style=\"text-decoration:underline\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span><span style=\"text-decoration:underline\"> in the United States</span>. In the third quarter of 2023, we acquired an exclusive license from Santhera Pharmaceuticals. Under the AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> License Agreement, we obtained an exclusive North America license for AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> for the treatment of DMD and as a treatment for other diseases. We also made a strategic investment into Santhera, the funds of which will be used to further the development of the product. We believe that this transaction not only added a third product to our portfolio, but also leverages the sales infrastructure that we have developed to market FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. We currently plan to launch this product before the end of the first quarter of 2024. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">$30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022 and $10 million was paid on the first anniversary of the closing of the settlement. We will be obligated to pay the remaining balance on the second anniversary of closing; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">An annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst\u2019s FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup><sup style=\"font-size:75%; vertical-align:top\"> </sup>patents in the United States, 2.5% (with a minimum annual royalty of $5 million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">If Catalyst were to receive a priority review voucher for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> or RUZURGI<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the future, 50% of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\"><span style=\"font-weight:bold\">Motor:</span> A simple focal seizure with motor symptoms will affect muscle activity, causing jerking movements of a foot, the face, an arm or another part of the body. Physicians can diagnose which side of the brain is affected by observing which side of the body experiences symptoms, since the left brain controls the right side of the body and the right brain controls the left. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\"><span style=\"font-weight:bold\">Sensory:</span> A simple focal seizure may cause sensory symptoms affecting the senses, such as: hearing problems, hallucinations and olfactory or other distortions. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\"><span style=\"font-weight:bold\">Autonomic:</span> A simple focal seizure with autonomic symptoms affects the part of the brain responsible for involuntary functions. These seizures may cause changes in blood pressure, heart rhythm, or bowel or bladder function. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:2%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\"><span style=\"font-weight:bold\">Psychic:</span> Some simple focal seizures strike parts of the brain that trigger emotions or memories of previous experiences, causing feelings of fear, anxiety, or d\u00e9j\u00e0 vu (the illusory feeling that something has been experienced before). </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td style=\"width:78%\"></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td style=\"width:12%\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom;white-space:nowrap\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman\">U.S. Patent No.</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center\">Indication</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center\">Expiration Date</p></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">10,857,161</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><span style=\"white-space:nowrap\">Non-hormonal</span> steroid modulators of <span style=\"white-space:nowrap\">NF-kB</span> for treatment of disease</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">May 28, 2029</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">8,334,279</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><span style=\"white-space:nowrap\">Non-hormonal</span> steroid modulators of <span style=\"white-space:nowrap\">NF-.kappa.B</span> for treatment of disease</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">May 28, 2029</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">11,471,471</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">Aqueous oral pharmaceutical suspension compositions</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">March 17, 2040</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">11,382,922</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">Aqueous oral pharmaceutical suspension compositions</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">July 16, 2040</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">11,690,853</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><span style=\"white-space:nowrap\">Non-hormonal</span> steroid modulators of <span style=\"white-space:nowrap\">NF-</span><span style=\"FONT-FAMILY:SYMBOL\">k</span><span style=\"FONT-FAMILY:SYMBOL\">b</span> for treatment of disease</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">March 7, 2033</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">11,833,159</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><span style=\"white-space:nowrap\">Non-hormonal</span> steroid modulators of <span style=\"white-space:nowrap\">NF-</span><span style=\"FONT-FAMILY:SYMBOL\">k</span><span style=\"FONT-FAMILY:SYMBOL\">b</span> for treatment of disease</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">May 28, 2029</td></tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Progressive muscle weakness and atrophy that begins in the legs and pelvis, occurring less severely in the arms, neck, and other areas of the body. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Calf muscle hypertrophy (increase in muscle size). </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Difficulty climbing up stairs. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Difficulty walking that gets worse over time. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Frequent falls. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Waddling gait (walk). </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Toe walking. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Fatigue. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Cardiomyopathy. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Breathing difficulties and shortness of breath. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Cognitive impairment and learning difficulty. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Delayed speech and language development. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Developmental delay. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Scoliosis. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Short stature. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">our ability to complete clinical development and obtain regulatory approvals for our drug candidates; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the demonstrated efficacy, safety and reliability of our drug candidates; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the timing and scope of regulatory approvals; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">product acceptance by physicians and other health care providers; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the willingness of payors to cover and reimburse for our product; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">protection of our proprietary rights and the level of generic competition; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the speed at which we develop drug candidates; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">our ability to supply commercial quantities of a product to the market; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">our ability to obtain reimbursement from private and/or public insurance entities for product use in approved indications; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">our ability to recruit and retain skilled employees; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the availability of capital resources to fund our development and commercialization activities, including the availability of funding from the federal government. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">submission of an investigational new drug application (IND) which must become effective before human clinical trials may begin and which must include approval by an institutional review board, or IRB, at each clinical site before the trials are initiated; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use conducted in compliance with federal regulations and good clinical practice (GCP), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">submission to, and acceptance by, the FDA of an NDA; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice (cGMP) regulations to assure that the facilities, methods and controls are adequate to preserve the drug\u2019s identity, strength, quality and purity; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">potential FDA audit of the <span style=\"white-space:nowrap\">non-clinical</span> and clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">FDA review and approval of the NDA. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Phase 1 clinical trials involve the initial introduction of the drug into human subjects. These studies are designed to determine the safety of usually single doses of the compound and determine any dose limiting intolerance, as well as evidence of the metabolism and pharmacokinetics of the drug in humans. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Phase 2 clinical trials usually involve studies in a limited patient population to evaluate the safety and efficacy of the drug for specific, targeted indications, to determine dosage tolerance and optimal dosage, and to identify possible adverse effects and safety risks. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">In Phase 3, if a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 (or occasionally Phase 1) studies, the Phase 3 studies will be conducted to further confirm clinical efficacy, optimal dosage and safety within an expanded population which may involve geographically diverse clinical trial sites. Generally, but not always, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Phase 4 clinical trials are studies required of or agreed to by a sponsor that are conducted after the FDA has approved a product for marketing. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials where necessary could result in withdrawal of approval for products approved under accelerated approval regulations. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">public transparency on qualifying prices of newly launched drugs, price increases and/or discounting to better inform purchasers; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">additional controls on government-funded reimbursement for drugs; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">controls on healthcare providers; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">reform of drug importation laws; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">entering into contractual agreements with payors; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">expansion of use of managed-care systems in which healthcare providers contract to provide comprehensive healthcare for a fixed cost per person. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the <span style=\"white-space:nowrap\">non-clinical</span> and clinical data necessary for approval is as efficient as possible; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">taking steps to ensure that the design of the clinical trials is as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the cross-discipline members of the review team (i.e., clinical, pharmacology-toxicology, chemistry, manufacturing and control (CMC), compliance) for coordinated internal interactions and communications with the sponsor through the review division\u2019s Regulatory Health Project Manager; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our success depends on the successful commercialization of our products. To the extent that our drug products are not commercially successful, our business, financial condition and results of operations will be materially harmed. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our drug products may fail to receive the degree of market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would negatively impact our business. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our strategy of seeking to acquire or <span style=\"white-space:nowrap\">in-license</span> innovative technical platforms or earlier stage drug development programs outside of the neuromuscular disease space may not be successful. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our business may require additional capital. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Because the target patient populations for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> are small, we must achieve significant market share and obtain relatively high <span style=\"white-space:nowrap\">per-patient</span> prices for our products to achieve meaningful gross margins. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Because of risks associated with taking FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>, potential patients may be reluctant to start treatment with FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> or may discontinue use. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Failure can occur at any stage of our drug development efforts. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We rely on third parties to conduct our <span style=\"white-space:nowrap\">pre-clinical</span> studies and clinical studies and trials, and if they do not perform their obligations to us we may not be able to obtain approval for additional indications. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We will need to continue to develop and maintain distribution and production capabilities or relationships to be successful. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We could be impacted by the viability of our suppliers. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We may encounter difficulties in managing our growth, which would adversely affect our results of operations. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Pressure on drug product third-party payor coverage, reimbursement and pricing may impair our ability to be reimbursed at prices or on terms sufficient to provide a viable financial outcome. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our internal computer systems, or those of our contract research organizations and other key vendors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our employees, sales agents and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">The regulatory approval process is lengthy, and we may not be able to obtain all of the regulatory approvals required to manufacture and commercialize our drug products in which we are licensed to them. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">If our <span style=\"white-space:nowrap\">pre-clinical</span> studies or our clinical studies and trials are unsuccessful or significantly delayed, our ability to commercialize our products will be impaired. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We may face significant delays in our clinical studies and trials due to an inability to recruit patients for our clinical studies and trials or to retain patients in the clinical studies and trials we may perform. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">If our third-party suppliers or contract manufacturers do not maintain appropriate standards of manufacturing in accordance with cGMP and other manufacturing regulations, our development and commercialization activities could suffer significant interruptions or delays. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our drug products are subject to continuing regulatory review. If we fail to comply with continuing United States and applicable foreign regulations, we could lose those approvals, and our business would be severely harmed. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Enacted and future legislation or judicial action may increase the difficulty and cost for us to market our approved products or commercialize any other drug candidates we may acquire or license and affect the prices we may obtain. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">If we fail to obtain or subsequently maintain orphan drug exclusivity or regulatory exclusivity for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and any other orphan drug candidates we may acquire or license, our competitors may sell products to treat the same conditions at greatly reduced prices, and our revenues would be significantly adversely affected. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Changes to the ODA or successful legal challenges to the FDA\u2019s interpretation of the ODA may affect our ability to obtain or subsequently maintain orphan drug exclusivity or may affect the scope orphan drug exclusivity for our products. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our operations and relationships with healthcare providers, healthcare organizations, customers and third-party payors are subject to applicable anti-bribery, anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, enforcement actions, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Whether we will be successful in our litigation to enforce our patents against Paragraph IV challengers who have filed relating to FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">There is a risk that our patents may not protect our products from generic competition. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Our success will depend significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">successfully establishing and maintaining effective sales, marketing, and distribution systems in jurisdictions in which our drug products are approved for sale; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">successfully establishing and maintaining commercial third-party manufacturers and having adequate commercial quantities of our drug products manufactured at acceptable cost and quality levels, including maintaining current good manufacturing practice (cGMP) and quality systems regulation standards required by various regulatory agencies; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">broad acceptance of our drug products by physicians, patients and the healthcare community; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the acceptance of pricing and placement of our drug products on payors\u2019 formularies and the associated tiers; </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">effectively competing with other approved or used medicines and future compounds in development; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">continued demonstration of safety and efficacy of our drug products in comparison to competing products; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">obtaining, maintaining, enforcing, and defending intellectual property rights and claims. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the efficacy and potential advantages compared to alternative treatments, including the convenience and ease, or duration of administration; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the prevalence and severity of any side effects; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the acceptability of the price of our drug products relative to other treatments; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the content of the approved product labels and our ability to make compelling product claims; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the effectiveness and adequacy of our and our collaboration partner\u2019s sales and marketing efforts; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the patients\u2019 <span style=\"white-space:nowrap\"><span style=\"white-space:nowrap\">out-of-pocket</span></span> costs in relation to alternative treatments; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the breadth and cost of distribution support; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the effectiveness of our patient assistance and support programs; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the availability of third-party payor coverage and adequate reimbursement; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">any restrictions on the use of our drug products together with other medications. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">exposure to known and unknown liabilities, including possible intellectual property infringement claims, violations of laws, tax liabilities and commercial disputes; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">higher than expected acquisition and integration costs; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">difficulty in combining the operations and personnel of any acquired businesses with our operations and personnel; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">inability to maintain uniform standards, controls, procedures and policies; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">restructuring charges related to eliminating redundancies or disposing of assets as part of any such combination; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">large write-offs and difficulties in assessing the relative percentages of <span style=\"white-space:nowrap\">in-process</span> research and development expense that can be immediately written off as compared to the amount that must be amortized over the appropriate life of the asset; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">increased amortization expenses or, in the event that we write down the value of acquired assets, impairment losses; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">potential failure of the due diligence process to identify significant problems, liabilities or other shortcomings or challenges of an acquired or licensed product candidate or technology, including problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, revenue recognition or other accounting practices, partner disputes or issues and other legal and financial contingencies and known and unknown liabilities; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">entry into therapeutic modalities, indications or markets in which we have no or limited direct prior development or commercial experience and where competitors in such markets have stronger market positions. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">regulators or Institutional Review Boards (IRBs) may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">conditions may be imposed upon us by the FDA regarding the scope or design of our clinical trials, or we may be required to resubmit our clinical trial protocols to IRBs for review due to changes in the regulatory environment; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the number of subjects required for our clinical trials may be larger, patient enrollment may take longer, or patients may drop out of our clinical trials at a higher rate than we anticipate; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">we may have to suspend or terminate one or more of our clinical trials if we, regulators, or IRBs determine that the participants are being subjected to unreasonable health risks; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">our third-party contractors, clinical investigators or contractual collaborators may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the FDA may not accept clinical data from trials that are conducted at clinical sites in countries where the standard of care is potentially different from the United States; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">our tests may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional testing; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the costs of our <span style=\"white-space:nowrap\">pre-clinical</span> and/or clinical trials may be greater than we anticipate. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">reliance on the third-party for regulatory compliance and quality assurance; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">reliance on the continued financial viability of the third parties; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">limitations on supply availability resulting from capacity and scheduling constraints of the third parties; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">impact on our reputation in the marketplace if manufacturers of our products fail to meet the demands of our customers; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the possible breach of the manufacturing agreement by the third-party because of factors beyond our control; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the possible termination or nonrenewal of the agreement by the third-party, based on its own business priorities, at a time that is costly or inconvenient for us. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the federal criminal and civil false claims and civil monetary penalties laws, including the federal False Claims Act, which can be imposed through civil whistleblower or qui tam actions against individuals or entities, prohibits, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including <span style=\"white-space:nowrap\">off-label</span> promotion, may also violate false claims laws. Moreover, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">HIPAA, which imposes criminal and civil liability, prohibits, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">HIPAA, as amended by HITECH, which impose obligations on certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as their business associates that perform certain services involving the storage, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of covered drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children\u2019s Health Insurance Program, with certain exceptions, to report annually to CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced care practice nurses and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members, with the information made publicly available on a searchable website; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <span style=\"white-space:nowrap\">non-governmental</span> third-party payors, including private insurers; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">certain state and local laws that, among other things, require pharmaceutical companies to comply with the pharmaceutical industry\u2019s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures; require manufacturers to report price increases that exceed a statutory threshold, as well as information on the reasons for the price increase; require manufacturers to report the introduction into the market of costly drugs; require the registration of pharmaceutical sales representatives; and govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">developments concerning our clinical studies and trials and our <span style=\"white-space:nowrap\">pre-clinical</span> studies; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">status of regulatory requirements for approval of our drug candidates; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">adverse publicity regarding the pricing our drug products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">announcements of product development successes and failures by us or our competitors; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">new products introduced or announced by us or our competitors; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">adverse changes in the abilities of our third-party manufacturers to provide drug or product in a timely manner or to meet FDA requirements; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">challenges to our intellectual property which could affect our products, such as the currently pending litigation involving Paragraph IV challenges to FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in reimbursement levels; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in financial estimates by securities analysts; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">actual or unanticipated variations in operating results; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in laws regarding FDA approval; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">expiration or termination of licenses (particularly our FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> License Agreement), research contracts, or other collaboration agreements; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">conditions or trends in the regulatory climate and the biotechnology and pharmaceutical industries; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">intellectual property, product liability or other litigation against us; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in the market valuations of similar companies; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in pharmaceutical company regulations or reimbursements for pharmaceutical products as a result of healthcare reform or other legislation; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">changes in economic conditions; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">sales of shares of our common stock, particularly sales by our officers, directors and significant stockholders, or the perception that such sales may occur. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the ability of our Board of Directors to issue preferred stock with voting or other rights or preferences; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">limitations on the ability of stockholders to amend our charter documents, including stockholder supermajority voting requirements; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">the inability of stockholders to act by written consent or to call special meetings; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">requirements that special meetings of our stockholders may only be called by the Board of Directors; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td align=\"left\" style=\"width:4%;vertical-align:top\">\u2022</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">advance notice procedures our stockholders must comply with in order to nominate candidates for election to our Board of Directors or to place stockholders\u2019 proposals on the agenda for consideration at meetings of stockholders. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td style=\"width:64%\"></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/18</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/19</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/20</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/21</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/22</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">12/23</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold\">Catalyst Pharmaceuticals, Inc.</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">100.00</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">195.31</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">173.96</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">352.60</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">968.75</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">875.52</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold\">NASDAQ Composite</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">100.00</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">136.69</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">198.10</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">242.03</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">163.28</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">236.17</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold\">Russell MicroCap</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">100.00</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">122.43</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">148.10</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">176.73</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">137.93</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">150.80</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold\">NASDAQ Biotechnology</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">100.00</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">125.11</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">158.17</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">158.20</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">142.19</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">148.72</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:45%\"></td> <td style=\"vertical-align:bottom;width:11%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:11%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:11%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"10\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Equity Compensation Plan Information</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom;white-space:nowrap\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold\">Plan Category</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Number of securities to<br/>be issued upon exercise<br/>of outstanding options,<br/>warrants, and rights</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Weighted-average<br/>exercise price of<br/>outstanding options,<br/>warrants, and rights</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Number of securities<br/>remaining available<br/>for equity<br/>compensation plans</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Equity compensation plans approved by security holders <sup style=\"font-size:75%; vertical-align:top\">(1)</sup></p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">14,177,488</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">7.73</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">1,801,949</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><sup style=\"font-size:75%; vertical-align:top\">(2)</sup>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Equity compensation plans not approved by security holders</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold\">Total</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">14,177,488</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">$</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">7.73</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">1,801,949</span></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><span style=\"font-weight:bold\">\u00a0</span></td></tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td align=\"left\" style=\"width:4%;vertical-align:top\"><sup style=\"font-size:75%; vertical-align:top\">(1)</sup>\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Includes our 2014 Stock Incentive Plan and our 2018 Stock Incentive Plan </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td align=\"left\" style=\"width:4%;vertical-align:top\"><sup style=\"font-size:75%; vertical-align:top\">(2)</sup>\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Remaining shares are only under our 2018 Stock Incentive Plan </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto\"> <tr> <td style=\"width:68%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"6\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">For the year ended December 31,</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"6\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Change</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2023</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2022</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap\"><span style=\"font-weight:bold\">$</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">%</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Research and development expenses</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">10,156</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">18,060</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">(7,904</td> <td style=\"white-space:nowrap;vertical-align:bottom\">)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">(43.8</td> <td style=\"white-space:nowrap;vertical-align:bottom\">)</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Acquired in-process research and development</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">81,513</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">81,513</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Employee stock-based compensation</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">1,481</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">1,729</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">(248</td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">(14.3</td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Total research and development expenses</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">93,150</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">19,789</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">73,361</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">370.7</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto\"> <tr> <td style=\"width:68%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"6\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">For the year ended December 31,</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"6\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">Change</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2023</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2022</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap\"><span style=\"font-weight:bold\">$</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">%</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Selling</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">86,689</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">29,469</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">57,220</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">194.2</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">General and administrative</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">34,252</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">21,438</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">12,814</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">59.8</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Employee stock-based compensation</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">12,769</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">6,178</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">6,591</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">106.7</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Total selling, general and administrative expenses</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">133,710</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">57,085</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">76,625</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">134.2</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td></tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto\"> <tr> <td style=\"width:76%\"></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"6\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">For the year ended December 31,</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2023</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"><span style=\"font-weight:bold\">2022</span></td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Interest income (expense), net</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">4,675</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">3,550</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Dividend income</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">93</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Realized gains (losses) from the sale of <span style=\"white-space:nowrap\"><span style=\"white-space:nowrap\">available-for-sale</span></span> securities</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">(762</td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Net gains (losses) recognized during the period on equity securities</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">3,024</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000\">\u00a0</p></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Total other income, net</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">7,699</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td align=\"right\" style=\"white-space:nowrap;vertical-align:bottom\">2,881</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td style=\"vertical-align:bottom\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000\">\u00a0</p></td> <td>\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the cost of diligence in seeking potential acquisitions and of the completion of such acquisitions, if any future acquisitions occur; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">future clinical trial results; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the scope, rate of progress and cost of our clinical trials and other product development activities; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the cost and timing of regulatory approvals; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the amount of net revenues that we report from sales of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>, FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup><sup style=\"font-size:75%; vertical-align:top\"> </sup>and AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the effect of competition and market developments; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">the extent to which we acquire or invest in other products. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Payments due under our license agreement for FIRDAPSE</span><span style=\"font-style:italic\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span><span style=\"font-style:italic\">. </span>We currently pay the following royalties under our license agreement: </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Royalties to our licensor for seven years from the first commercial sale of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> equal to 7% of net sales (as defined in the FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> License Agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Royalties to the third-party licensor of the rights sublicensed to us from the first commercial sale of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> equal to 7% of net sales (as defined in the FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> License Agreement between BioMarin and the third-party licensor) in any calendar year for the duration of regulatory exclusivity within a territory and 3.5% for territories in any calendar year in territories without regulatory exclusivity. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Payments due to Jacobus. </span>In connection with our July 2022 settlement with Jacobus, we agreed to pay the following consideration to Jacobus: </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">$30 million of cash, of which $10 million was paid at the closing of the settlement on July 11, 2022, $10 million was paid on the first anniversary of closing and the remaining $10 million will be paid on the second anniversary of closing; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">An annual royalty on Catalyst\u2019s net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025, 1.5% (with a minimum annual royalty of $3.0 million per year), and (b) for calendar years 2026 through the expiration of the last to expire of Catalyst\u2019s FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> patents in the United States, 2.5% (with a minimum annual royalty of $5 million per year); <span style=\"font-style:italic\">provided, however</span>, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">If Catalyst were to receive a priority review voucher for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> or RUZURGI<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the future, 50% of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Payments due under our asset purchase agreement for FYCOMPA</span><span style=\"font-style:italic\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span><span style=\"font-style:italic\">. </span>In connection with our asset purchase agreement with Eisai Co., Ltd. (Eisai): </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">We paid at closing a $160 million upfront cash payment, plus $1.6 million for reimbursement of certain prepayments. Eisai was also eligible to receive a contingent payment of $25 million if a patent term extension for FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> was approved until June 8, 2026 by the USPTO, which request for reconsideration of the patent term extension was denied by the USPTO in June 2023; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Royalties commencing on loss of exclusivity for each calendar year during the royalty term equal to 12% on net sales greater than $10 million and less than $100 million, 17% on net sales of greater than $100 million and less than $125 million and 22% on net sales greater than $125 million prior to the date of generic entry. Royalties equal to 6% on net sales greater than $10 million and less than $100 million, 8.5% on net sales of greater than $100 million and less than $125 million and 11% on net sales greater than $125 million after the date of generic entry. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Concurrently with the acquisition, the parties entered into two related agreements: (i) a short-term TSA for commercial and manufacturing services (to which transition services ended on December 31, 2023) and (ii) a long-term Supply Agreement for the manufacturing of FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. Under the TSA, Eisai provided certain commercial and manufacturing services to the Company for a transition period following the closing of the acquisition. Further, under the Supply Agreement, Eisai will manufacture FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> for the Company for a period of seven years (or such longer period as is set forth in the Supply Agreement) following the closing of the acquisition. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Payments due under our license agreement for AGAMREE</span><span style=\"font-style:italic\"><sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup></span><span style=\"font-style:italic\">. </span>In connection with our recent acquisition from Santhera: </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">At closing we paid a $75 million initial cash payment. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">In the fourth quarter of 2023, following regulatory approval of Santhera\u2019s NDA by the FDA, we paid a regulatory milestone payment of $36 million. We are also obligated to pay additional regulatory milestone payments upon regulatory approval by the FDA in the U.S. of an NDA for the product for the first, second, and third additional indications in the amounts of $50 million, $45 million, and $45 million, respectively. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">We are obligated to pay sales-based milestone payments if the applicable amount of net sales of all products in the territory in a single calendar year reach one of more of the net sales threshold levels set forth in the AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> License Agreement. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Until January 1, 2026, we are obligated to purchase all of the requirements for product solely from Santhera, and Santhera is required to manufacture, supply, and sell product to us at an agreed upon supply price. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:14%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:2%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Simultaneously, we made a strategic equity investment into Santhera by acquiring 1,414,688 of Santhera\u2019s post reverse-split ordinary shares (representing approximately 11.26% of Santhera\u2019s outstanding ordinary shares following the transaction) at an investment price of CHF 9.477 per share (corresponding to a mutually agreed volume-weighted average price prior to signing), with the approximately $15.7 million USD in equity investment proceeds, inclusive of the approximately $13.5 million USD fair value of the investment in Santhera and approximately $2.2 million USD of transaction costs included in acquired in-process research and development, to be used by Santhera for Phase IV studies in DMD and further development of additional indications for AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Purchase commitment</span>. We have entered into a purchase commitment with a contract manufacturing organization for approximately $0.5 million per year. The agreement expires in December 2024. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:10%\">\u00a0</td> <td align=\"left\" style=\"width:2%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\"><span style=\"font-style:italic\">Lease for office space</span>. We operate our business in leased office space in Coral Gables, Florida. We lease approximately 10,700 square feet of office space and we pay annual rent of approximately $0.5 million. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be able to continue to successfully market and sell FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> while maintaining full compliance with applicable federal and state laws, rules and regulations; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether our estimates of the size of the market for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) will prove to be accurate; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether our supplemental New Drug Application (sNDA) seeking to increase the maximum daily dosage of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> from 80 mg to 100 mg will be approved by the U.S. Food and Drug Administration (FDA); </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether the daily dose of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> taken by patients changes over time and affects our results of operations; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be able to locate LEMS patients who are undiagnosed or are misdiagnosed with other diseases; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether patients will discontinue from the use of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> at rates that are higher than historically experienced or are higher than we project; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether new FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> patients and new FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> patients can be successfully titrated to stable therapy; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we can continue to market FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> on a profitable and cash flow positive basis; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will successfully launch AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the first quarter of 2024 as we currently plan; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be able to successfully commercialize AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the territory; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be able to demonstrate, to the satisfaction of the FDA and third-party payors, whether AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> offers advantages compared to corticosteroids or competitor\u2019s products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether the acquisition of AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> will prove to be accretive to EBITDA and EPS in 2024 and beyond; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether any revenue or earnings guidance that we provide to the public market will turn out to be accurate; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether payors will provide coverage and reimburse for our products at the price that we charge for our products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The ability of our third-party suppliers and contract manufacturers to supply sufficient product to meet our customers\u2019 needs in future periods; </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The ability of our third-party suppliers and contract manufacturers to maintain compliance with current Good Manufacturing Practices (cGMP); </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The ability of those third parties that distribute our products to maintain compliance with applicable law; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Our ability to maintain compliance with applicable rules relating to our patient assistance programs for our products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Our ability to maintain compliance with the applicable rules that relate to our contributions to 501(c)(3) organizations that support patients in financial need; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The scope of our intellectual property and the outcome of any challenges to our intellectual property, and, conversely, whether any third-party intellectual property presents unanticipated obstacles for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>, FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>, or AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether there will be a post-closing review by antitrust regulators of our previous acquisition transactions, and the outcome of any such reviews if they occur; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be able to acquire additional drug products under development, complete development required to commercialize such products, and thereafter, if such products are approved for commercialization, successfully market such products; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether our patents will be sufficient to prevent generic competition for FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> after our orphan drug exclusivity for each product expires; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we will be successful in our litigation to enforce our patents against the Paragraph IV challengers who have filed Abbreviated New Drug Applications (ANDAs) seeking to introduce generic versions of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and FYCOMPA<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup>; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The impact on our profits and cash flow of adverse changes in reimbursement and coverage policies or regulations from government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators, or the impact of pricing pressures enacted by industry organizations, the federal government or the government of any state, including as a result of increased scrutiny over pharmaceutical pricing or otherwise; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Changes in the healthcare industry and the effect of political pressure from and actions by the President, Congress and/or medical professionals seeking to reduce prescription drug costs, and changes to the healthcare industry occasioned by any future changes in laws relating to the pricing of drug products, including changes made in the Inflation Reduction Act of 2022, or changes in the healthcare industry generally; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether we and Santhera Pharmaceuticals can successfully develop additional indications for AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and obtain the ability to commercialize the product for these additional indications; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The state of the economy generally and its impact on our business; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The scope, rate of progress and expense of our clinical trials and studies, <span style=\"white-space:nowrap\">pre-clinical</span> studies, <span style=\"white-space:nowrap\"><span style=\"white-space:nowrap\">proof-of-concept</span></span> studies, and our other drug development activities, and whether our trials and studies will be successful; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Our ability to complete any clinical trials and studies that we may undertake on a timely basis and within the budgets we establish for such trials and studies; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> can be successfully commercialized in Canada on a profitable basis through KYE Pharmaceuticals, our collaboration partner in Canada; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">The impact on sales of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in the United States if an amifampridine product is purchased in Canada for use in the United States; </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether DyDo will be able to obtain approval to commercialize FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> in Japan; and </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:5%\">\u00a0</td> <td align=\"left\" style=\"width:3%;vertical-align:top\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left\">Whether our plans to expand the reach of FIRDAPSE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> and AGAMREE<sup style=\"font-size:75%; vertical-align:top\">\u00ae</sup> into other global regions will be successful. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td style=\"width:54%\"></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"7\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Incorporated by Reference</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom;white-space:nowrap\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman\">Exhibit<br/>Number</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center\">Description of Exhibit</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Form</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">File Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Date of<br/>Filing</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Exhibit<br/>Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Filed<br/>Herewith</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">2.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm\">Agreement and Plan of Merger, dated August<span style=\"text-decoration:underline\"></span> 14, 2006, between the</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm\">Company and Catalyst Pharmaceutical Partners, Inc., a Florida</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406008469/g02464a1exv10w9.htm\">corporation</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">S-1</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">333-136039</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">9/1/2006</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.9</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">2.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex21.htm\">Asset Purchase Agreement by and between Eisai Co., Ltd. and the Company, dated as of December<span style=\"text-decoration:underline\"></span> 17, 2022</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">12/22/2022</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">2.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w1.htm\">Certificate of Incorporation</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">S-1</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">333-136039</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/25/2006</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w2.htm\">Amendment to Certificate of Incorporation</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">S-1</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">333-136039</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/25/2006</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.3</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312515111873/d862051ddef14a.htm#tx862051_19\">Amendment to Certificate of Incorporation</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/30/2015</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.4</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520227098/d67771dex31.htm\">Amendment to Certificate of Incorporation </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/21/2020</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.5</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406006906/g02464exv3w3.htm\"><span style=\"white-space:nowrap\">By-Laws</span></a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">S-1</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">333-136039</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">9/1/2006</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3.3</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">3.6</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312519302591/d841417dex31.htm\">Amendment to <span style=\"white-space:nowrap\">By-Laws</span></a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">11/27/2019</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">4.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014406009063/g02464a2exv4w1.htm\">Specimen Stock Certificate for Common Stock</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">S-1</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">333-136039</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">9/1/2006</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">4.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312522077228/d159262dex45.htm\">Description of the Company\u2019s Capital Stock </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/16/2023</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4.5</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.1(a)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101a.htm\">Offer Letter between the Company and Richard J. Daly</a> *</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.1(b)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101b.htm\">Offer Letter between the Company and Michael W. Kalb* </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.1(c)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101c.htm\">Separation Agreement between the Company and Patrick J. McEnany* </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.1(d)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex101d.htm\">Separation Agreement between the Company and Alicia Grande </a>*</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.2(a)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312514104689/d660291ddef14a.htm\">2014 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/19/2014</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.2(b)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312516569377/d81688ddef14a.htm#toc81688_19\">Amendment No.<span style=\"text-decoration:underline\"></span> 1 to 2014 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4/29/2016</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.2(c)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312517124737/d302409ddef14a.htm#toc302409_19\">Amendment No.<span style=\"text-decoration:underline\"></span> 2 to 2014 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4/14/2017</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.3(a)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518119932/d558293ddef14a.htm#toc558293_20\">2018 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4/17/2018</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.3(b)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520188818/d932120ddef14a.htm#tx932120_22\">Amendment No.<span style=\"text-decoration:underline\"></span> 1 to 2018 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/7/2020</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.3(c)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312521308040/d249150ddef14a.htm#tx249150_20\">Amendment No.<span style=\"text-decoration:underline\"></span> 2 to 2018 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10/25/2021</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.3(d)+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312523185962/d500830ddef14a.htm#toc500830_23\">Amendment No.<span style=\"text-decoration:underline\"></span> 3 to 2018 Stock Incentive Plan</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">DEF 14A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/12/2023</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">Annex A</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.4+</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex104.htm\">Severance and Change in Control Plan </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(a)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000095014407004805/g07390exv10w1.htm\">Lease Agreement between the Company and 355 Alhambra Plaza, Ltd. </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-Q</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">5/14/2007</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td style=\"width:60%\"></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"7\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Incorporated by Reference</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom;white-space:nowrap\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman\">Exhibit<br/>Number</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center\">Description of Exhibit</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Form</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">File Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Date of<br/>Filing</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Exhibit<br/>Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Filed<br/>Herewith</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(b)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312511223174/dex101.htm\">First Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-Q</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/15/2011</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(c)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312514060790/d678177dex101.htm\">Second Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">2/20/2014</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(d)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312515109517/d897752dex101.htm\">Third Amendment to Lease Agreement between the Company and CPT 355 Alhambra Circle, LLC</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/27/2015</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(e)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518251807/d610816dex101.htm\">Fourth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/17/2018</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.5(f)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520141636/d931443dex101.htm\">Fifth Amendment to Lease Agreement between the Company and PRII 355 Alhambra Circle, LLC</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">5/13/2020</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.6</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm\">License Agreement, dated as of December<span style=\"text-decoration:underline\"></span> 13, 2011, among New York</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm\">University, the Feinstein Institute for Medical Research, and the</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312512143728/d258031dex1015.htm\">Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/30/2012</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.15</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.7(a)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312512442533/d429885dex102.htm\">License Agreement, dated as of October 26, 2012, between the Company and BioMarin </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10/31/2012</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.7(b)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312514147816/d712457dex101.htm\">Amendment No.<span style=\"text-decoration:underline\"></span> 1 to License Agreement, dated as of April<span style=\"text-decoration:underline\"></span> 8, 2014,</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312514147816/d712457dex101.htm\">between the Company and BioMarin</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">4/17/2014</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.7(c)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm\">Settlement Agreement, dated effective as of July<span style=\"text-decoration:underline\"></span> 26, 2018, by and</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm\">among (i)<span style=\"text-decoration:underline\"></span> Aceras BioMedical, LLC, in its capacity as Stockholder</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm\">Representative for the Former stockholders of Huxley</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/d557514dex101.htm\">Pharmaceuticals, Inc., (ii) BioMarin, and (iii)<span style=\"text-decoration:underline\"></span> the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-Q</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/17/2018</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.7(d)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/d755191dex101.htm\">Second Amendment to License Agreement, dated May<span style=\"text-decoration:underline\"></span> 29, 2019,</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/d755191dex101.htm\">between the Company and BioMarin</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">5/30/2019</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.8</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312518358175/d666131dex101.htm\">Development, License and Commercialization Agreement, dated effective as of December 18, 2018, by and between Endo Ventures Limited and the Company </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">12/26/2018</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.9</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/d811529dex101.htm\">License and Supply Agreement, dated as of August<span style=\"text-decoration:underline\"></span> 14, 2020, by and</a> <a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/d811529dex101.htm\">between KYE Pharmaceuticals, Inc. and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/20/2020</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.10</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312521204754/d187873dex101.htm\">License and Supply Agreement, dated as of June<span style=\"text-decoration:underline\"></span> 28, 2021, by and between DyDo Pharma, Inc. and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">6/28/2021</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.11(a)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312522191772/d329751dex101.htm\">Settlement Agreement, dated July<span style=\"text-decoration:underline\"></span> 11, 2022, by and between the Company and SERB SA, on the one hand, and Jacobus Pharmaceutical Company, Inc., PantherRx Specialty LLC, and Panther Specialty Holding Co., on the other hand</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/12/2022</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.11(b)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312522191772/d329751dex102.htm\">License and Asset Purchase Agreement, dated as of July<span style=\"text-decoration:underline\"></span> 11, 2022, by and between Jacobus Pharmaceutical Company, Inc. and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">7/12/2022</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.12(a)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex101.htm\">Transition Services Agreement between Eisai, Inc. and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">12/22/2022</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.12(b)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312523207344/d524408dex101.htm\">Amendment to Transition Services Agreement, dated as of July<span style=\"text-decoration:underline\"></span> 31, 2023, made by and between the Company and Eisai</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-Q</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">8/9/2023</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.12(c)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312522311070/d432372dex102.htm\">Supply Agreement between Eisai Co., Ltd. and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">12/22/2022</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.13(a)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312523173863/d499888dex101.htm\">License and Collaboration Agreement, executed and delivered as of June<span style=\"text-decoration:underline\"></span> 19, 2023, by and between Santhera, its wholly-owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">6/23/2023</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">10.13(b)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/0001369568/000119312523173863/d499888dex102.htm\">Investment Agreement, dated as of June<span style=\"text-decoration:underline\"></span> 19, 2023, by and between Santhera and the Company</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">8-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">6/23/2023</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">10.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">21.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"http://www.sec.gov/Archives/edgar/data/1369568/000119312520075048/d838851dex211.htm\">Subsidiaries of the Registrant</a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">10-K</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"white-space:nowrap\">001-33057</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">3/16/2020</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">21.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">23.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex231.htm\">Consent of Independent Registered Public Accounting Firm </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td style=\"width:66%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" colspan=\"7\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Incorporated by Reference</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align:bottom;white-space:nowrap\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman\">Exhibit<br/>Number</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\"> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center\">Description of Exhibit</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Form</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">File<br/>Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Date<br/>of<br/>Filing</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Exhibit<br/>Number</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom\">Filed<br/>Herewith</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">31.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex311.htm\">Section<span style=\"text-decoration:underline\"></span> 302 CEO Certification </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">31.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex312.htm\">Section<span style=\"text-decoration:underline\"></span> 302 CFO Certification </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">32.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex321.htm\">Section<span style=\"text-decoration:underline\"></span> 906 CEO Certification </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">32.2</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex322.htm\">Section<span style=\"text-decoration:underline\"></span> 906 CFO Certification </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">97.1</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"><a href=\"https://www.sec.gov/Archives/edgar/data/1369568/000119312524050908/d723690dex971.htm\">Clawback Policy </a></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\">X</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.INS</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Instance Document</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.SCH</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Taxonomy Extension Schema</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.CAL</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Taxonomy Extension Calculation Linkbase</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.DEF</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Taxonomy Extension Definition Linkbase</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.LAB</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Taxonomy Extension Label Linkbase</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">101.PRE</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">XBRL Taxonomy Extension Presentation Linkbase</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td> <td colspan=\"2\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top;white-space:nowrap\">104</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td></tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td align=\"left\" style=\"width:4%;vertical-align:top\">*</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Certain identified information has been excluded from these exhibits because it is both (i) not material, and (ii) would likely cause competitive harm to the Company if publicly disclosed. </p></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td align=\"left\" style=\"width:4%;vertical-align:top\">+</td> <td align=\"left\" style=\"vertical-align:top\"> <p style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\">Management contract or compensatory plan. </p></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto\"> <tr> <td style=\"width:7%\"></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td style=\"width:92%\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td colspan=\"3\" style=\"vertical-align:top\"><span style=\"font-weight:bold\">CATALYST PHARMACEUTICALS, INC.</span></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">By:</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Richard J. Daly</p></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">Richard J. Daly,</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\">President and CEO</td></tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0\"> <tr> <td style=\"width:38%\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"width:44%\"></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td style=\"width:16%\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"font-weight:bold\">Signature</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"font-weight:bold\">Title</span></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:bottom\"><span style=\"font-weight:bold\">Date</span></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Richard J. Daly</p> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman\">Richard J. Daly</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center\">President and Chief</p> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center\">Executive Officer (Principal Executive Officer)</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Michael W. Kalb</p> <p style=\"margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman\">Michael W. Kalb</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Patrick J. McEnany</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Chairman of the Board of Directors</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">Patrick J. McEnany</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Charles B. O\u2019Keeffe</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Director</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">Charles B. O\u2019Keeffe</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ David S. Tierney, M.D.</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Director</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">David S. Tierney, M.D.</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Donald A. Denkhaus</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Director</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">Donald A. Denkhaus</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Molly Harper</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Director</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">Molly Harper</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td> <td colspan=\"2\" style=\"height:12pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <p style=\"margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman\">/s/ Tamar Thompson</p></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">Director</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td align=\"center\" style=\"vertical-align:top\">February 28, 2024</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\">Tamar Thompson</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:top\"></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td style=\"width:96%\"></td> <td style=\"vertical-align:bottom;width:1%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_1\">Reports of Independent Registered Public Accounting Firm (PCAOB ID Number  248 <span style=\"text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;\">)</span> </a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-2</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"4\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_2\">Consolidated Balance Sheets</a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-4</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"4\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_3\">Consolidated Statements of Operations and Comprehensive Income</a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-5</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"4\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_4\">Consolidated Statements of Changes in Stockholders\u2019 Equity</a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-6</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"4\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_5\">Consolidated Statements of Cash Flows</a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-7</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1pt\"> <td style=\"height:6pt\"></td> <td colspan=\"4\" style=\"height:6pt\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><a href=\"#fin723690_6\">Notes to Consolidated Financial Statements</a></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">F-8</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td style=\"width:82%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31,</div></div><br/> <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31,</div></div><br/> <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">ASSETS</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Current Assets:</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash and cash equivalents</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 137,636 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 298,395 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accounts receivable, net</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 53,514 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 10,439 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Inventory</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 15,644 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,805 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid expenses and other current assets</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,535 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,167 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total current assets</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 219,329 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 320,806 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">right-of-use</div></div> asset</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,508 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,770 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Property and equipment, net</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,195 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 847 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>License and acquired intangibles, net</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 194,049 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 32,471 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred tax assets, net</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 36,544 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 18,736 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Investment in equity securities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 16,489 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total assets</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 470,114 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 375,630 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">LIABILITIES AND STOCKHOLDERS\u2019 EQUITY</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Current Liabilities:</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accounts payable</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,795 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,975 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued expenses and other liabilities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 61,268 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 53,613 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total current liabilities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 76,063 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 57,588 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease liability, net of current portion</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,188 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,557 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">non-current</div> liabilities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,982 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,064 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total liabilities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 82,233 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 75,209 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Commitments and contingencies (Note 12)</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"> </td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"> </td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Stockholders\u2019 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">E</div>quity:</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Preferred stock, $  0.001   par value,   5,000,000   shares authorized:     no    ne issued and outstanding at December 31, 2023 and 2022</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Common stock, $  0.001   par value,   200,000,000   shares authorized;   107,121,549   shares and   105,263,031   shares issued and outstanding at December 31, 2023 and 2022, respectively</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 107 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 105 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Additional <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">paid-in</div> capital</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 266,488 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 250,430 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Retained earnings</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 121,272 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 49,862 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accumulated other comprehensive income (Note 4)</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 24 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total stockholders\u2019 equity</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 387,881 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 300,421 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total liabilities and stockholders\u2019 equity</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 470,114 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 375,630 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 67%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"10\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Year Ended December 31,</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr> <td style=\"width:67%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Revenues:</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Product revenue, net</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 396,502 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 213,938 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 137,997 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>License and other revenue</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 1,702 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 265 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 2,836 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total revenues</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 398,204 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 214,203 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 140,833 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating costs and expenses:</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cost of sales (a)</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 51,967 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 34,393 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 21,884 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Research and development</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 93,150 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 19,789 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 16,936 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Selling, general and administrative (a)</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 133,710 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 57,085 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 49,628 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Amortization of intangible assets</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 32,565 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 1,098 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; width: 8%; padding: 0pt 1pt 0pt 0pt; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> \u2014 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total operating costs and expenses</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 311,392 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 112,365 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 88,448 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating income</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 86,812 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 101,838 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 52,385 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other income, net</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 7,699 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 2,881 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 282 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income before income taxes</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 94,511 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 104,719 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 52,667 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Income tax provision</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 23,101 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 21,640 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 13,185 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 71,410 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 83,079 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 39,482 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income per share:</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Basic</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 0.67 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 0.80 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 0.38 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Diluted</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 0.63 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 0.75 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 0.37 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Weighted average shares outstanding:</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Basic</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 106,279,736 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 103,374,606 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 103,379,349 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Diluted</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 113,753,154 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 111,375,631 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 107,795,585 </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"padding: 0px; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>\u2003</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>\u2003</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>\u2003</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 71,410 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 83,079 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 39,482 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255); padding: 0px;;background-color:rgb(204, 238, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive income (Note 4):</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255); padding: 0px;;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Unrealized gain (loss) on <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">available-for-sale</div></div> securities, net of tax of $ 4 , ($ 54 ) and $ 46 , respectively</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 10 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 172 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 179 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">)<div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Comprehensive income</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 71,400 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 83,251 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"> 39,303 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\">\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\">(a)</td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'>exclusive of amortization of intangible assets </div> </td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 47%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" rowspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Preferred<br/>Stock</div></div></div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"6\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Common Stock</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" rowspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Additional<br/><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Paid-in</div><br/>Capital</div></div></div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" rowspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Retained<br/>Earnings<br/>(Accumulated<br/>Deficit)</div></div></div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" rowspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Accumulated<br/>Other<br/>Comprehensive<br/>Gain (Loss)</div></div></div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" rowspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Total</div></div></div></td> <td rowspan=\"2\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Shares</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Amount</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2020</div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 103,782 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 104 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 223,168 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 53,705 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 31 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 169,598 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">Stock-based compensation<br/></div></div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 6,073 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 6,073 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Exercise of stock options for common stock</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 1,328 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 1 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 4,098 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 4,099 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Issuance of common stock upon vesting of restricted stock units, net</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 91 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 153 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 153 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style=\" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman\">Repurchase of common stock</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 2,208 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 2 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 12,087 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 12,089 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive gain (loss)</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 179 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 179 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 39,482 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 39,482 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2021</div></div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 102,993 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 103 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 233,186 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 26,310 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 148 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 206,831 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">Stock-based compensation<br/></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 7,907 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 7,907 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Exercise of stock options for common stock</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 3,172 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 2 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 9,567 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 9,569 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Issuance of common stock upon vesting of restricted stock units, net</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 98 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 230 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 230 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Repurchase of common stock</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 1,000 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 6,907 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 6,907 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive gain (loss)</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 172 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 172 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 83,079 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 83,079 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2022</div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 105,263 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 105 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 250,430 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 49,862 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 24 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 300,421 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">Stock-based compensation<br/></div></div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 14,250 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 14,250 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Exercise of stock options for common stock</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 1,652 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 2 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 2,790 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 2,792 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Issuance of common stock upon vesting of restricted stock units, net</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 207 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 982 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">( 982 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive gain (loss)</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 10 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">( 10 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">) </td></tr> <tr style='break-inside: avoid; font-family: \"Times New Roman\"; font-size: 10pt;'> <td style=\"vertical-align: top; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 71,410 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;;background-color:rgba(255, 255, 255, 0);\"> 71,410 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2023</div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\">\u2014\u2002</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 107,122 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 107 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 266,488 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 121,272 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 14 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">$</td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"> 387,881 </td> <td style=\"white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"background-color: rgba(255, 255, 255, 0);;background-color:rgba(255, 255, 255, 0);\">\u00a0</td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto\"> <tr> <td style=\"width:76%\"></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Year Ended December 31,</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Operating Activities:</div></div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net income</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 71,410 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 83,079 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 39,482 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Depreciation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 316 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 141 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 192 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Stock-based compensation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,250 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 7,907 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,073 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Amortization of intangible assets</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 32,565 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,098 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred taxes</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 17,818 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,937 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 9,316 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accretion of discount</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,320 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 17 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 5 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Reduction in the carrying amount of <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">right-of-use</div></div> asset</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 262 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 247 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 292 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Realized loss on sale of <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">available-for-sale</div></div> securities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 762 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Acquired research and development inventory expensed from asset acquisition</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,130 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Acquired inventory samples expensed from asset acquisition</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 130 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Acquired <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">in-process</div> research and development</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 81,513 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Change in fair value of equity securities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 3,024 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>(Increase) decrease in:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accounts receivable, net</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 43,075 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 3,820 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 632 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Inventory</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 4,739 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,065 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 3,219 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid expenses and other current assets</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 5,792 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 807 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,977 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Increase (decrease) in:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accounts payable</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 10,820 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,207 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,488 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued expenses and other liabilities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,800 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 16,391 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,520 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease liability</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 338 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 307 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 864 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net cash provided by (used in) operating activities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 143,600 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 116,047 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 60,372 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Investing</div></div> <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Activities</div></div>:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Purchases of property and equipment</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 231 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 29 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,021 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Purchases of investments</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 10,000 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Proceeds from sale of <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">available-for-sale</div></div> securities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 19,238 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Payments in connection with asset acquisitions</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 198,293 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 10,000 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Acquisition of <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">in-process</div> research and development</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 81,513 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Purchase of equity securities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 13,465 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net cash provided by (used in) investing activities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 293,502 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 9,209 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 11,021 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Financing Activities:</div></div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Payment of employee withholding tax related to stock-based compensation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 982 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 230 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 153 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Proceeds from exercise of stock options</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,792 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 9,569 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,099 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Repurchase of common stock</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 6,907 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 12,089 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Payment of liabilities arising from asset acquisition</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 12,667 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 738 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net cash provided by (used in) financing activities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 10,857 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,694 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 8,143 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net increase (decrease) in cash and cash equivalents</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 160,759 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 126,950 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 41,208 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash and cash equivalents \u2013 beginning of period</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 298,395 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 171,445 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 130,237 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash and cash equivalents \u2013 end of period</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 137,636 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 298,395 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 171,445 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Supplemental disclosures of cash flow information:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash paid for income taxes</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 50,458 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 7,667 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,000 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash paid for interest</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 705 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Non-cash</div> investing and financing activities:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease liabilities arising from obtaining <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">right-of-use</div></div> assets</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,309 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Liabilities arising from asset acquisition</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,915 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 27,699 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">\u2014\u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr style=\"page-break-inside: avoid;\"> <td style=\"width: 4%; vertical-align: top;;text-align:left;\"><div style=\"display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">1.</div></div></div></td> <td style=\"vertical-align: top;;text-align:left;\"><div style='text-align: left; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;'><div style=\"display:inline;\"><div style=\"font-weight:bold;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Organization and Description of Business. </div></div></div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">a.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">PRINCIPLES OF CONSOLIDATION.</div></div> The consolidated financial statements include the Company\u2019s accounts and those of its wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd. (Catalyst Ireland). All intercompany accounts and transactions have been eliminated in consolidation. Catalyst Ireland was organized in 2017. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">b.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">USE OF ESTIMATES.</div></div> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">c.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">CASH AND CASH EQUIVALENTS.</div></div> The Company considers all highly liquid instruments, purchased with an original maturity of  three months  or less, to be cash equivalents. Cash equivalents consist mainly of money market funds and U.S. Treasuries. The Company has substantially all its cash and cash equivalents deposited with one financial institution. These amounts exceed federally insured limits. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">d.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;;text-indent: 0px;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">INVESTMENTS.</div></div> <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">The Company invests in high credit-quality instruments in order to obtain higher yields on its cash available for investments. At December 31, 2023, investments consisted of U.S. Treasuries and an investment in equity securities. At December 31, 2022, investments consisted of U.S. Treasuries. Such investments are not insured by the Federal Deposit Insurance Corporation. <br/></div> </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">e.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">ACCOUNTS RECEIVABLE, NET.</div></div> Accounts receivable is recorded net of customer allowance for distribution fees, trade discounts, prompt payment discounts, chargebacks and expected credit losses. Allowances for distribution fees, trade discounts, prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for expected credit losses based on existing contractual payment terms, actual payment patterns of its customers, current and future economic and market conditions and individual customer circumstances. At December 31, 2023 and December 31, 2022, the Company determined that an allowance for expected credit losses was not required. No accounts were written off during the periods presented. </div></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"font-weight:bold;display:inline;\">f.</div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left\"><div style=\"font-weight:bold;display:inline;\">INVENTORY</div>. Inventories are stated at the lower of cost or net realizable value. Inventories consist of raw materials, <div style=\"white-space:nowrap;display:inline;\"><div style=\"white-space:nowrap;display:inline;\">work-in-process</div></div> and finished goods. Costs to be capitalized as inventories primarily include third-party manufacturing costs and other overhead costs. Cost is determined using a standard cost method, which approximates actual cost, and assumes a <div style=\"white-space:nowrap;display:inline;\">first-in,</div> first out (FIFO) flow of goods. If information becomes available that suggests that inventories may not be realizable, the Company may be required to expense a portion or all of the previously capitalized inventories. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">g.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">PREPAID EXPENSES AND OTHER CURRENT ASSETS.</div></div> Prepaid expenses and other current assets consist primarily of prepaid manufacturing, prepaid tax, prepaid insurance, prepaid subscription fees, prepaid research fees, prepaid commercialization expenses, prepaid <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">co-pay</div> assistance program, amounts due from collaborative and license arrangements and prepaid conference and travel expenses. Prepaid research fees consist of advances for the Company\u2019s product development activities, including contracts for <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">pre-clinical</div> studies, clinical trials and studies, regulatory affairs and consulting. Prepaid manufacturing consists of advances for the Company\u2019s drug manufacturing activities. Such advances are recorded as expense as the related goods are received or the related services are performed. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">h.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">PROPERTY AND EQUIPMENT,</div></div> <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">NET.</div></div> Property and equipment are recorded at cost less accumulated depreciation. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Leasehold improvements are amortized on a straight-line basis over the term of the lease or the estimated life of the improvement, whichever is shorter. Useful lives generally range from <div style=\"-sec-ix-hidden:hidden102502906;display:inline;\">three </div>to  five years  for computer equipment and software, from <div style=\"-sec-ix-hidden:hidden102502903;display:inline;\">five </div>to  seven years  for furniture and equipment, and from <div style=\"-sec-ix-hidden:hidden102502904;display:inline;\">five </div>to  ten years  for leasehold improvements. Expenditures for repairs and maintenance are charged to expenses as incurred. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">i</div></div>.</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">BUSINESS COMBINATIONS AND ASSET ACQUISITIONS</div></div>. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be an asset acquisition, the Company accounts for the transaction under ASC <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">805-50,</div> which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">j.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">INTANGIBLE ASSETS, NET.</div></div> Identifiable intangible assets with a finite life are comprised of licensed rights and other acquired intangible assets and are amortized on a straight-line basis over the respective estimated useful life. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">k.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">FAIR VALUE OF FINANCIAL INSTRUMENTS.</div></div> The Company\u2019s financial instruments consist of cash and cash equivalents, investments, accounts receivable, accounts payable, and accrued expenses and other liabilities. At December 31, 2023 and December 31, 2022, the fair value of these instruments approximated their carrying value. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">l.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">FAIR VALUE MEASUREMENTS.</div></div> Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity\u2019s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px currentColor; border-image: none; width: 90%; font-family: Times New Roman; font-size: 10pt; margin-left: auto; border-collapse: collapse;\"> <tr> <td style=\"width: 44%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"14\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Fair Value Measurements at Reporting Date Using (in thousands)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Balances as of<br/>December 31,<br/>2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Quoted Prices in<br/>Active Markets for<br/>Identical<br/>Assets/Liabilities<br/>(Level 1)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Significant Other<br/>Observable Inputs<br/>(Level 2)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Significant<br/>Unobservable Inputs<br/>(Level 3)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style:italic;display:inline;\">Cash and cash equivalents:</div></div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Money market funds</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 18,256 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 18,256 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>U.S. Treasuries</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 94,523 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 94,523 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style:italic;display:inline;\">Investment in equity securities:</div></div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Equity securities</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 16,489 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 16,489 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px currentColor; border-image: none; width: 90%; font-family: Times New Roman; font-size: 10pt; margin-left: auto; border-collapse: collapse;\"> <tr> <td style=\"width: 42%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 10%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Balances as of<br/>December 31,<br/>2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Quoted Prices in<br/>Active Markets for<br/>Identical<br/>Assets/Liabilities<br/>(Level 1)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Significant Other<br/>Observable Inputs<br/>(Level 2)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Significant<br/>Unobservable Inputs<br/>(Level 3)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style:italic;display:inline;\">Cash and cash equivalents:</div></div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Money market funds</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 168,853 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 168,853 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>U.S. Treasuries</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 105,442 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 105,442 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u2014\u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">m.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">OPERATING LEASES. </div></div>The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">right-of-use</div></div> (ROU) assets, other current liabilities, and operating lease liabilities on its consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As the Company\u2019s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company\u2019s lease term includes options to extend or terminate the lease, however, these options are not considered in the lease term as the Company is not reasonably certain that it will exercise these options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company has a lease agreement with lease and <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">non-lease</div> components, which are accounted for separately. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">n.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">SHARE REPURCHASES.</div></div> In March 2021, the Company\u2019s Board of Directors approved a share repurchase program that authorizes the repurchase of up to $ 40  million of the Company\u2019s common stock. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr style=\"page-break-inside: avoid;\"> <td style=\"width: 4%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"width: 5%; vertical-align: top;;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">o.</div></div></div></td> <td style=\"vertical-align: top;;text-align:left;\"> <div style='text-align: left; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>REVENUE RECOGNITION. </div></div></div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 1%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 1%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 71%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td rowspan=\"6\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">\u2009\u2007</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"10\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">For the Years Ended December 31,</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>FIRDAPSE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div></div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 258,426 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 213,938 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 137,997 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>FYCOMPA<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div></div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 138,076 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> \u2014 \u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> \u2014 \u2002</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Total product revenue, net</div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 396,502 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 213,938 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 137,997 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Basis of Presentation and Significant Accounting Policies (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">p.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">RESEARCH AND DEVELOPMENT.</div></div> Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform research related services for the Company. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">q.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">ADVERTISING EXPENSE. </div></div>Advertising costs are expensed as incurred. The <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">C</div>ompany incurred approximately $ 9.1  million, $ 3.3  million and $ 2.9  million in advertising costs during the years ended December 31, 2023, 2022 and 2021, respectively, which are included in selling, general and administrative expenses in the Company\u2019s consolidated statements of operations and comprehensive income. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">r.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">STOCK-BASED COMPENSATION. </div></div>The Company recognizes expense in the consolidated statements of operations and comprehensive income for the grant date fair value of all stock-based payments to employees, directors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach, and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally one to  three years . Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">s.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">CONCENTRATION OF RISK. </div></div>The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents, investments and accounts receivable, net. The Company places its cash and cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border: 0px currentcolor; width: 100%; font-family: \"Times New Roman\"; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside: avoid;\"> <td style=\"width: 4%; vertical-align: top;;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></div></td> <td style=\"vertical-align: top;;text-align:left;\"> <div style='text-align: left; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Basis of Presentation and Significant Accounting Policies (continued). </div></div></div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">t.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">ROYALTIES.</div></div> Royalties incurred in connection with the Company\u2019s license agreement for FIRDAPSE\u00ae, as disclosed in Note 13 (Agreements), are expensed to cost of sales as revenue from product sales is recognized. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">u.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">INCOME TAXES.</div></div> The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">v.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">COMPREHENSIVE INCOME.</div></div> U.S. GAAP requires that all components of comprehensive income be reported in the financial statements in the period in which they are recognized. Comprehensive income is net income, plus certain other items that are recorded directly into stockholders\u2019 equity. The Company\u2019s comprehensive income is shown on the consolidated statements of operations and comprehensive income for the years ended December 31, 2023, 2022 and 2021, and is comprised of net unrealized gains (losses) on the Company\u2019s <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">available-for-sale</div></div> securities. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">w.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">NET INCOME PER COMMON SHARE.</div></div> Basic net income per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. With regard to common stock subject to vesting requirements, the calculation includes only the vested portion of such stock and units. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: \"Times New Roman\"; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;'> <tr> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 1%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 63%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td rowspan=\"7\" style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"10\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">For the Years Ended December 31,</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Basic weighted average common shares outstanding</div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 106,279,736 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 103,374,606 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 103,379,349 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Effect of dilutive securities</div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 7,473,418 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 8,001,025 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 4,416,236 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: top;\"> <div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Diluted weighted average common shares outstanding</div></div></div> </td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 113,753,154 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 111,375,631 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 107,795,585 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td style=\"vertical-align: bottom;\"> <div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div> </td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">x.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">SEGMENT INFORMATION.</div></div> Management has determined that the Company operates in  one  reportable segment, which is the development and commercialization of drug products. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">y.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">RECLASSIFICATIONS.</div></div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">z.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">RECENTLY ISSUED ACCOUNTING STANDARDS. </div></div>The Company did not adopt any <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">accounting </div>standards during the year ended December 31, 2023. </div> </td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; font-size: 10pt; border: 0px; width: 816px;\"> <tr style=\"break-inside: avoid;\"> <td style=\"width: 32.625px; vertical-align: top;;text-align:left;\"><div style=\"display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2.</div></div></div></td> <td style=\"vertical-align: top;;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"display:inline;\"><div style=\"font-weight:bold;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Basis of Presentation and Significant Accounting Policies (continued).</div></div></div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"font-weight:bold;display:inline;\">3.</div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style=\" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left\">Investments. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto\"> <tr> <td style=\"width:63%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Estimated<br/> Fair Value</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Gross<br/> Unrealized<br/> Gains</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Gross<br/> Unrealized<br/> Losses</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Amortized<br/> Cost</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">At December 31, 2023:</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>U.S. Treasuries - Cash equivalents</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,523 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 18 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,505 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,523 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 18 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,505 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">At December 31, 2022:</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>U.S. Treasuries - Cash equivalents</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 105,442 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 32 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 105,410 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 105,442 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 32 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 105,410 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:68%;border:0;margin:0 auto\"> <tr> <td style=\"width:88%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Due in one year or less</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,523 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:80%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"10\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">For the Years Ended<br/> December 31,</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Equity securities:</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net gains (losses) recognized during the period on equity securities</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,024 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Unrealized net gains (losses) recognized during the period on equity securities still held at the reporting date</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,024 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">4.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Accumulated Other Comprehensive Income (loss). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto\"> <tr> <td style=\"width:77%\"></td> <td style=\"vertical-align:bottom;width:18%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Total Accumulated<br/> Other Comprehensive<br/> Income (Loss)</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2021</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 148 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive gain (loss) before reclassifications</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 590 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Amount reclassified from accumulated other comprehensive income (loss)</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 762 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net current period other comprehensive gain</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 172 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2022</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 24 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other comprehensive gain (loss) before reclassifications</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 10 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Net current period other comprehensive gain</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 10 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Balance at December 31, 2023</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; padding-bottom: 1.25pt;\"></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"margin-top: 0px; margin-bottom: 0px; font-size: 0pt; line-height: 0pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"margin-top: 0px; margin-bottom: 0px; font-size: 0pt; line-height: 0pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">5.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Inventory. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 65%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 12%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 12%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Raw materials</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 1,910 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> \u2014 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Work-in-process</div></div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 4,573 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 5,543 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Finished goods</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 9,161 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 1,262 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Total inventory</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 15,644 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap;;text-align:right;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 6,805 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">6.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Prepaid Expenses and Other Current Assets. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto\"> <tr> <td style=\"width:65%\"></td> <td style=\"vertical-align:bottom;width:12%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:12%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid manufacturing costs</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,005 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,147 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid tax</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,238 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 44 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid insurance</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,332 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,224 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid subscriptions fees</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,299 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 808 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid research fees</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,500 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 178 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid commercialization expenses</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,038 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 592 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Due from collaborative and licensing arrangements</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 138 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 354 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid conference and travel expenses</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 771 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 234 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">co-pay</div> assistance program</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 863 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 97 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 351 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 489 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total prepaid expenses and other current assets</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,535 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,167 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">7.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Operating Leases. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 8pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;\"> <tr> <td style=\"width: 84%;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></div></td></tr> <tr style=\"font-size: 8pt; break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"6\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">For the Years Ended<br/>December 31,</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td></tr> <tr style=\"font-size: 8pt; break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Operating lease cost</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 431 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 431 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 10pt; border-collapse: collapse; text-indent: 0px; border-spacing: 0px;\"> <tr> <td style=\"width: 84%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 5%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-size: 8pt; break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"6\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">For the Years Ended<br/>December 31,</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 8pt; break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Cash paid for amounts included in the measurement of lease liabilities:</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Operating cash flows</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 506 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 492 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\">\u00a0</td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">Right-of-use</div></div> assets obtained in exchange for lease obligations:</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Operating lease</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 89 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 89 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\">\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;\"> <tr> <td style=\"width:64%\"></td> <td style=\"vertical-align:bottom;width:13%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:13%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"break-inside: avoid; font-size: 8pt;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Operating lease <div style=\"text-wrap: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">right-of-use</div></div> assets</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 2,508 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 2,770 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style=\"-sec-ix-hidden:hidden102502897;display:inline;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Other</div></div><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> </div><div style=\"-sec-ix-hidden:hidden102502898;display:inline;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>current liabilities</div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 369 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 337 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Operating lease liabilities, net of current portion</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,188 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,557 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Total operating lease liabilities</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,557 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,894 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; padding-bottom: 1.25pt;\"></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></div></td> <td style=\"line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></div></td> <td style=\"line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;\"> <tr> <td style=\"width:90%\"></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>2024</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 522 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>2025</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 537 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>2026</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 553 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>2027</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 570 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>2028</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 587 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Thereafter</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 1,440 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Total lease payments</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 4,209 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Less: imputed interest</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>( 652 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>) </div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Total</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,557 </div></td> <td style=\"text-wrap: nowrap; vertical-align: bottom;\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; padding-bottom: 1.25pt;\"></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; line-height: 0pt; font-size: 0pt; border-bottom: 2.5pt double black;\"><div style=\"font-size: 0pt; line-height: 0pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"line-height: 0pt; font-size: 0pt; padding-bottom: 1.25pt;\"><div style=\"font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"line-height: 0pt; letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">8.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Property and Equipment, Net. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 76%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 64%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 14%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 13%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">December 31, 2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Furniture and equipment</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div>\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 494 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div>\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 273 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style='font-family: \"Times New Roman\"; font-size: 10pt; break-inside: avoid;'> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Leasehold improvements</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 991 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 980 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Software</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 433 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> \u2014 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style='font-family: \"Times New Roman\"; font-size: 10pt; break-inside: avoid;'> <td style=\"vertical-align: top; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Less: Accumulated depreciation</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">( 723 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">) </div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">( 406 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">) </div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;\"> <td style=\"vertical-align: top; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style='font-family: \"Times New Roman\"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;'>Total property and equipment, net</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 1,195 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">$</div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> 847 </div></td> <td style=\"vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;background-color:rgb(204, 238, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr> <tr style=\"font-size: 1px;\"> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"vertical-align: bottom; background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></div></div></td> <td style=\"background-color: rgb(255, 255, 255);;background-color:rgb(255, 255, 255);\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">9.</div></div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"font-weight:bold;display:inline;\">License and Acquired Intangibles, Net. </div></div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; font-size: 10pt; width: 84%; border: 0px; margin: 0px auto; border-spacing: 0px;\"> <tr> <td style=\"width:59%\"></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"break-inside: avoid; font-size: 8pt;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Gross Carrying<br/> Value</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Accumulated<br/> Amortization</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Net Carrying Value</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style:italic;display:inline;\">Intangible assets:</div></div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align: top;\"><div style=\"text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>License and acquired intangibles for RUZURGI<div style=\"font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;\">\u00ae</div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 33,569 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 3,418 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 30,151 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align: top;\"><div style=\"text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>License and acquired intangibles for FYCOMPA<div style=\"font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;\">\u00ae</div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 158,143 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 29,673 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 128,470 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align: top;\"><div style=\"text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>License and acquired intangibles for AGAMREE<div style=\"font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;\">\u00ae</div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 36,000 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 572 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 35,428 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Total</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 227,712 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 33,663 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 194,049 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse: collapse; font-size: 10pt; width: 84%; border: 0px; margin: 0px auto; border-spacing: 0px;\"> <tr> <td style=\"width:59%\"></td> <td style=\"vertical-align:bottom;width:8%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:8%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:8%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"break-inside: avoid; font-size: 8pt;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Gross Carrying<br/> Value</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Accumulated<br/> Amortization</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Net Carrying Value</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-style:italic;display:inline;\">Intangible assets:</div></div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt;\"> <td style=\"vertical-align: top;\"><div style=\"text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>License and acquired intangibles for RUZURGI<div style=\"font-size: 75%; vertical-align: top; letter-spacing: 0px; top: 0px;;display:inline;\">\u00ae</div></div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 33,569 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 1,098 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 32,471 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);\"> <td style=\"vertical-align:top\"><div style=\"margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; line-height: normal;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>Total</div></div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 33,569 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 1,098 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>$</div></td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'> 32,471 </div></td> <td style=\"white-space:nowrap;vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td style=\"vertical-align:bottom\"><div style=\"border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;\"><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></div></td> <td><div style='font-family: \"Times New Roman\", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;'>\u00a0</div></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">9.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">License and Acquired Intangibles, Net (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto\"> <tr> <td style=\"width:87%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>2024</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 37,378 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>2025</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 37,378 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>2026</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 37,378 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>2027</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 37,378 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>2028</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 7,705 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Thereafter</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 36,832 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 194,049 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align: bottom; padding-bottom: 1.25pt;\"></td> <td style=\"vertical-align: bottom; padding-bottom: 1.25pt;\">\u00a0</td> <td style=\"vertical-align: bottom; border-bottom: 2.5pt double black;\"> <div style=\"margin-top: 0px; margin-bottom: 0px; line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align: bottom; border-bottom: 2.5pt double black;\"> <div style=\"margin-top: 0px; margin-bottom: 0px; line-height: normal;\">\u00a0</div> </td> <td style=\"padding-bottom: 1.25pt;\">\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">10.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Accrued Expenses and Other Liabilities. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto\"> <tr> <td style=\"width:80%\"></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued preclinical and clinical trial expenses</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,015 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 479 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued professional fees</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,730 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,619 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued compensation and benefits</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8,883 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,132 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued license fees</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 24,437 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 20,444 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued purchases</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 192 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 154 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease liability</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 369 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 337 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued variable consideration</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,877 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,381 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued income tax</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 729 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8,702 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Due to licensor</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,540 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 13,127 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued interest payable</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,031 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt;;text-align:right;\"> \u2014 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 465 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 238 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Current accrued expenses and other liabilities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 61,268 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 53,613 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Lease liability \u2013 <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">non-current</div></div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,188 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,557 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Due to licensor \u2013 <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">non-current</div></div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,497 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,064 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other \u2013 <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">non-current</div></div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 485 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; width: 5%; padding: 0pt;;text-align:right;\"> \u2014 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Non-current</div> accrued expenses and other liabilities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,170 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 17,621 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total accrued expenses and other liabilities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 67,438 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 71,234 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">11.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Collaborative and Licensing Arrangements. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">11.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Collaborative and Licensing Arrangements (continued). </div></div> </td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">11.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Collaborative and Licensing Arrangements (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">12.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Commitments and Contingencies. </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">12.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Commitments and Contingencies (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width: 10%;\">\u00a0</td> <td style=\"width: 2%; vertical-align: top;;text-align:left;\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-family: \"Times New Roman\"; font-size: 10pt; text-align: left; line-height: normal;'>$ 30  million of cash, of which $ 10  million was paid at the closing of the settlement on July 11, 2022, $ 10  million was paid on the first anniversary of closing<div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">,</div> and the remaining $ 10  million will be paid on the second anniversary of closing; </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width: 10%;\">\u00a0</td> <td style=\"width: 2%; vertical-align: top;;text-align:left;\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-family: \"Times New Roman\"; font-size: 10pt; text-align: left; line-height: normal;'>An annual royalty on our net sales (as defined in the License and Asset Purchase Agreement between Catalyst and Jacobus) of amifampridine products in the United States equal to: (a) for calendar years 2022 through 2025,  1.5 % (with a minimum annual royalty of $ 3.0  million per year), and (b) for calendar years 2026 through the expiration of the last to expire of the Company\u2019s FIRDAPSE\u00ae patents in the United States,  2.5 % (with a minimum annual royalty of $ 5  million per year); provided, however, that the royalty rate may be reduced and the minimum annual royalty may be eliminated under certain circumstances; and </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width: 10%;\">\u00a0</td> <td style=\"width: 2%; vertical-align: top;;text-align:left;\">\u2022</td> <td style=\"width:1%;vertical-align:top\">\u00a0</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-family: \"Times New Roman\"; font-size: 10pt; text-align: left; line-height: normal;'>If the Company were to receive a priority review voucher for FIRDAPSE\u00ae or RUZURGI\u00ae in the future,  50 % of the consideration paid by a third-party to acquire that voucher will be paid to Jacobus. </div></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">12.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Commitments and Contingencies (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">13.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Agreements. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr style=\"page-break-inside: avoid;\"> <td style=\"vertical-align: top; line-height: 0pt; font-size: 0pt;;text-align:left;\"> <div style='text-align: left; font-family: \"Times New Roman\"; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;'></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">a.</div></div></td> <td style=\"vertical-align: top;;text-align:left;\"> <div style='text-align: left; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">LICENSE AGREEMENT FOR FIRDAPSE</div></div><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\"><div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div></div></div>. On  October 26, 2012 , the Company entered into a license agreement with BioMarin Pharmaceutical, Inc. (BioMarin) for the North American rights to FIRDAPSE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div>. Under the license agreement, the Company pays: (i) royalties to the licensor for seven years from the first commercial sale of FIRDAPSE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div> equal to  7 % of net sales (as defined in the license agreement) in North America for any calendar year for sales up to $ 100  million, and  10 % of net sales in North America in any calendar year in excess of $100 million; and (ii) royalties to the third-party licensor of the rights sublicensed to the Company for  seven years  from the first commercial sale of FIRDAPSE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div> equal to  7 % of net sales (as defined in the license agreement between BioMarin and the third-party licensor) in any calendar year for the duration of any regulatory exclusivity within a territory and  3.5 % for territories in any calendar year in territories without regulatory exclusivity. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">13.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Agreements (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">b.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">LICENSE AGREEMENT FOR RUZURGI</div></div><div style=\"font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px\">\u00ae</div></div>. On <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"> July 11, 2022 </div> (the Effective Date), the Company entered into an exclusive license agreement with Jacobus Pharmaceutical Company, Inc. (Jacobus), for the rights to develop and commercialize RUZURGI<div style=\"font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px\">\u00ae</div></div> in the United States and Mexico. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto;text-indent: 0px;\"> <tr> <td style=\"width:88%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>License and acquired intangibles</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 33,569 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Acquired research and development inventory expensed from asset acquisition</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,130 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total purchase price</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 37,699 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">13.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Agreements (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">c.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; text-indent: 0px; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">ACQUISITION OF U.S. RIGHTS FOR FYCOMPA</div></div><div style=\"font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px\">\u00ae</div></div><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">. </div></div>On  January 24, 2023 , the Company acquired the U.S. Rights for FYCOMPA<div style=\"font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-size: 7.5pt; line-height: 7.5pt;;display:inline;vertical-align: super;;font-size:8.3px\">\u00ae</div></div> (perampanel) CIII a commercial stage epilepsy asset, from Eisai Co., Ltd. (Eisai). The aggregate consideration for the acquisition was $ 164.2 \u00a0<div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">million in cash, including the reimbursement of certain liabilities and the payment of transaction costs.</div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;'> <tr> <td style=\"width:87%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Base cash payment</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 160,000 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Cash paid for <div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">pro-rated</div> prepaid expenses</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,576 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Reimbursement on base purchase price<div style=\"font-size:75%; vertical-align:top;display:inline;;font-size:8.3px\">(i)</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 3,238 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Transaction costs<div style=\"font-size:75%; vertical-align:top;display:inline;;font-size:8.3px\">(ii)</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,870 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total purchase consideration</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 164,208 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td style=\"width:4%;vertical-align:top;text-align:left;\">(i)</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'>Recorded in prepaid expenses and other current assets in the accompanying consolidated balance sheet as of the acquisition date and reimbursement was fully applied as of June 30, 2023. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:9%\">\u00a0</td> <td style=\"width:4%;vertical-align:top;text-align:left;\">(ii)</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'>As of December 31, 2023<div style=\"display:inline;\">,</div> the full $ 5.9  million has been paid in cash. </div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; text-indent: 0px; border-spacing: 0px;'> <tr> <td style=\"width:87%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Inventory</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,100 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid expenses and other current assets (samples)</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 130 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid commercialization expenses</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,576 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Property and equipment, net</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 433 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'>License and acquired intangibles for FYCOMPA<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 158,143 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued preclinical and clinical trial expenses</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 174 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total purchase consideration</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 164,208 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">13.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Agreements (continued). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">d.</div></div></td> <td style=\"vertical-align: top;;text-align:left;\"><div style='text-align: left; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">LICENSE AGREEMENT FOR AGAMREE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div> (VAMOROLONE). </div></div></td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;'> <tr> <td style=\"width:88%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Initial cash payment</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 75,000 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Investment in Santhera</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 13,465 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Transaction costs</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,513 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total purchase consideration</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,978 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; width: 68%; border: 0px; margin: 0px auto; border-spacing: 0px;'> <tr> <td style=\"width:88%\"></td> <td style=\"vertical-align:bottom;width:5%\"></td> <td></td> <td></td> <td></td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align: top;\"><div style='text-indent: -1em; font-family: \"Times New Roman\"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;'>License and acquired intangibles for AGAMREE<div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00ae</div><div style=\"font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px\">\u00a0</div>(vamorolone) (IPR&amp;D)</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 81,513 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Investment in Santhera<div style=\"font-size:75%; vertical-align:top;display:inline;;font-size:8.3px\">(i)</div></div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 13,465 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"><div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total purchase consideration</div></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 94,978 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td></tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td style=\"vertical-align:bottom\"><div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div></td> <td>\u00a0</td></tr></table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width: 9%; vertical-align: top;;text-align:left;\"><div style=\"line-height: normal; margin-bottom: 0px; margin-top: 0px;\">\u00a0</div></td> <td style=\"width: 4%; vertical-align: top;;text-align:left;\">(i)</td> <td style=\"vertical-align:top;text-align:left;\"><div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'>The fair value of the investment in Santhera was determined based on the closing market price (CHF  8.25 ) of Santhera shares and the exchange rate ( 1.1537 ) of CHF to USD on the date the shares were transferred, July 19, 2023. </div></td></tr></table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">13.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Agreements (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%\">\u00a0</td> <td style=\"width:5%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">e.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">AGREEMENTS FOR DRUG MANUFACTURING, DEVELOPMENT, PRECLINICAL AND CLINICAL STUDIES.</div></div> The Company has entered into agreements with contract manufacturers for the manufacture of commercial drug and drug and study placebo for the Company\u2019s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company\u2019s trials and studies and with various entities for laboratories and other testing related to the Company\u2019s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. </div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">14.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Income Taxes. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:71%\"></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Current - Federal</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 34,975 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,858 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2,455 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Current - State</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 5,931 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,877 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,414 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred - Federal</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 16,093 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,739 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8,620 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred - State</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,712 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 166 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 696 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 23,101 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 21,640 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 13,185 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:84%\"></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Statutory rate</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 21.0 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 21.0 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 21.0 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>State tax</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.1 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.1 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.4 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Executive compensation limitation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2.6 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.6 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1.1 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Tax credit</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1.9 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 0.6 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)% </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Stock compensation windfall</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 4.4 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 5.6 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 0.6 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">)% </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2.1 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 0.5 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 0.7 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 24.4 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 20.7 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 25.0 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">% </td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto\"> <tr> <td style=\"width:79%\"></td> <td style=\"vertical-align:bottom;width:4%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred tax assets:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Start-up</div> costs</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 9,771 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred compensation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,473 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,706 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Inventory</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 448 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 296 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Intangible assets</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 24,847 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 52 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Accrued expenses</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 788 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Operating lease liability</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 854 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 953 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Capitalized research</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,927 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,255 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total deferred tax assets</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 38,337 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 20,033 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred tax liabilities:</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Prepaid expenses</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,023 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 481 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'><div style=\"white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;\">Right-of</div> use asset</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 759 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 860 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Other</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 11 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 44 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total deferred tax liabilities</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,793 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,297 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Deferred tax assets, net</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 36,544 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 18,736 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">14.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Income Taxes (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%;text-indent: 0px;\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">15.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Stockholders\u2019 Equity. </div></div> </td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">16.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Stock Compensation. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:75%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Research and development</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,481 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,729 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1,611 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Selling, general and administrative</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,769 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,178 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4,462 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total stock-based compensation</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,250 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 7,907 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,073 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">16.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Stock Compensation (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 92%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 52%;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 7%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 6%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 7%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td style=\"width: 7%; vertical-align: bottom;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> <td><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"></div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Number of<br/>Options</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Weighted<br/>Average<br/>Exercise Price</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Weighted<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Aggregate<br/>Intrinsic Value<br/>(in thousands)</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">\u00a0</div></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Outstanding at beginning of year</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12,309,108 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.93 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"></td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Granted</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,598,535 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14.62 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Exercised or released</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 1,651,345 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1.69 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Forfeited or cancelled</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 78,810 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 11.83 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Expired</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;;text-align:right;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\"></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Outstanding at end of year</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 14,177,488 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 7.73 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.05 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 130,966 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Exercisable at end of year</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8,891,904 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.45 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 2.78 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 110,488 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto\"> <tr> <td style=\"width:74%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Weighted\u2013average fair value of granted stock options</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8.66 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8.52 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.24 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total fair value of vested stock options (in thousands)</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 8,278 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,096 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 6,421 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Total intrinsic value of exercised stock options (in thousands)</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 22,265 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 31,881 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3,623 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">16.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Stock Compensation (continued). </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style=\"margin: 0px auto; border: 0px currentColor; border-image: none; width: 84%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;;text-indent: 0px;\"> <tr> <td style=\"width: 52%;\"><div style=\"display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td style=\"width: 2%; vertical-align: bottom;\"><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> <td><div style=\"display:inline;\"></div></td> </tr> <tr style=\"font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2023</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2022</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;\"><div style=\"display:inline;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">2021</div></div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\"><div style=\"display:inline;\">\u00a0</div></td> </tr> <tr> <td style=\"width:56%\"></td> <td style=\"vertical-align:bottom;width:3%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:2%\"></td> <td></td> <td></td> <td style=\"line-height: 0pt; font-size: 0pt;\"> <div style=\"font-size: 0pt; line-height: 0pt;\"><div style=\"font-size:0pt;;display:inline;\">\u00a0</div></div> </td> <td></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Risk free interest rate</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 3.55 % to  4.92 %</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 1.27 % to  4.07 %</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\"> <div style=\"margin-bottom: 0px; margin-top: 0px;\">\u00a0</div> </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 0.34 % to  1.18 %</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Expected term</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.5  to  5.2  years</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.5  years</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\"> <div style=\"margin-bottom: 0px; margin-top: 0px;\">\u00a0</div> </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 4.5  to  4.8  years</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Expected volatility</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 68.0 % to  71.0 %</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 68.4 % to  69.5 %</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\"> <div style=\"margin-bottom: 0px; margin-top: 0px;\">\u00a0</div> </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 68.6 % to  72.8 %</td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Expected dividend yield</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\"> <div style=\"margin-bottom: 0px; margin-top: 0px;\">\u00a0</div> </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Expected forfeiture rate</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\"> <div style=\"margin-bottom: 0px; margin-top: 0px;\">\u00a0</div> </td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;\"> \u2014 <div style=\"letter-spacing: 0px; top: 0px;;display:inline;\">%</div></td> <td style=\"white-space: nowrap; vertical-align: bottom; padding: 0px;\">\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; width: 76%; border: 0px; margin: 0px auto; border-spacing: 0px;'> <tr> <td style=\"width:71%\"></td> <td style=\"vertical-align:bottom;width:8%\"></td> <td></td> <td></td> <td></td> <td style=\"vertical-align:bottom;width:7%\"></td> <td></td> <td></td> <td></td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\"> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Number of<br/>Restricted<br/>Stock Units</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> <td colspan=\"2\" style=\"vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">Weighted Average<br/>Grant Date Fair<br/>Value</div></div></td> <td style=\"vertical-align: bottom; padding-bottom: 0.5pt;\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Nonvested balance at beginning of year</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 752,500 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 11.46 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Granted</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 370,117 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 13.67 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Vested</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\">( 268,158 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">) </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 11.25 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Forfeited</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> \u2014 \u2002</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> <tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff\"> <td style=\"vertical-align:top\"> <div style='margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: \"Times New Roman\"; line-height: normal;'>Nonvested balance at end of year</div> </td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 854,459 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"white-space:nowrap;vertical-align:bottom\">$</td> <td style=\"white-space:nowrap;vertical-align:bottom;text-align:right;\"> 12.48 </td> <td style=\"white-space:nowrap;vertical-align:bottom\">\u00a0</td> </tr> <tr style=\"font-size:1px\"> <td style=\"vertical-align:bottom\"></td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> <td style=\"vertical-align:bottom\">\u00a0</td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td style=\"vertical-align:bottom\"> <div style=\"margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;\">\u00a0</div> </td> <td>\u00a0</td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">17.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Benefit Plan. </div></div> </td> </tr> </table><table cellpadding=\"0\" cellspacing=\"0\" style='border-collapse: collapse; font-family: \"Times New Roman\"; font-size: 10pt; border: 0px; width: 100%; border-spacing: 0px;'> <tr style=\"page-break-inside:avoid\"> <td style=\"width:4%;vertical-align:top;text-align:left;\"><div style=\"letter-spacing: 0px; top: 0px;;display:inline;\"><div style=\"font-weight:bold;display:inline;\">18.</div></div></td> <td style=\"vertical-align:top;text-align:left;\"> <div style='margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: \"Times New Roman\"; text-align: left; line-height: normal;'><div style=\"font-weight:bold;display:inline;\">Subsequent Events. </div></div> </td> </tr> </table>"
    ]
}